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Abstract
Background The diagnosis of sepsis is challenging because the infection can be
caused by more than 50 species of pathogens that might exist in the bloodstream
in very low concentrations, e.g., less than 1 colony-forming unit/ml. As a result,
among the current sepsis diagnostic methods there is an unsatisfactory trade-off
between the assay time and the specificity of the derived diagnostic information.
Although the present qPCR-based test is more specific than biomarker detection
and faster than culturing, its 6 ∼ 10 hr turnaround remains suboptimal relative to
the 7.6%/hr rapid deterioration of the survival rate, and the 3 hr hands-on time is
labor-intensive. To address these issues, this work aims to utilize the advances in
microfluidic technologies to expedite and automate the “nucleic acid purification -
qPCR sequence detection” workflow.
Methods and Results This task is evaluated to be best approached by combining
immiscible phase filtration (IPF) and digital microfluidic droplet actuation (DM) on
a fluidic device. In IPF, as nucleic acid-bound magnetic beads are transported from
an aqueous phase to an immiscible phase, the carryover of aqueous contaminants is
minimized by the high interfacial tension. Thus, unlike a conventional bead-based
assay, the necessary degree of purification can be attained in a few wash steps. After
IPF reduces the sample volume from a milliliter-sized lysate to a microliter-sized
eluent, DM can be used to automatically prepare the PCR mixture. This begins
with compartmenting the eluent in accordance with the desired number of multiplex
iv
qPCR reactions, and then transporting droplets of the PCR reagents to mix with the
eluent droplets. Under the outlined approach, the IPF - DM integration should lead
to a notably reduced turnaround and a hands-free “lysate-to-answer” operation.
As the first step towards such a diagnostic device, the primary objective of this
thesis is to verify the feasibility of the IPF - DM integration. This is achieved in
four phases. First, the suitable assays, fluidic device, and auxiliary systems are de-
veloped. Second, the extent of purification obtained per IPF wash, and hence the
number of washes needed for uninhibited qPCR, are estimated via off-chip UV ab-
sorbance measurement and on-chip qPCR. Third, the performance of on-chip qPCR,
particularly the copy number - threshold cycle correlation, is characterized. Lastly,
the above developments accumulate to an experiment that includes the following
on-chip steps: DNA purification by IPF, PCR mixture preparation via DM, and tar-
get quantification using qPCR - thereby demonstrating the core procedures in the
proposed approach.
Conclusions It is proposed to expedite and automate qPCR-based multiplex sparse
pathogen detection by combining IPF and DM on a fluidic device. As a start, this
work demonstrated the feasibility of the IPF - DM integration. However, a more
thermally robust device structure will be needed for later quantitative investigations,
e.g., improving the bead - buffer mixing. Importantly, evidences indicate that future
iterations of the IPF - DM fluidic device could reduce the sample-to-answer time by
75% to 1.5 hr and decrease the hands-on time by 90% to approximately 20 min.
v
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1Introduction
This thesis represents the initial development of a fluidic device designed to reduce
the sample-to-answer time of multiplex sparse pathogen detection, particularly in
the case of sepsis diagnosis.
Septic shock is a severe form of bloodstream infection. Its diagnosis is challenging
in part for two reasons. First, the infection could be caused by more than 50 species
of pathogens [1]. Second, the pathogens may exist in the bloodstream in very low
concentrations, e.g., less than 1 colony-forming unit/ml blood [2]. Consequently,
depending on the method it might be necessary to analyze 3 ∼ 20 ml of blood [2, 3].
In turn, these difficulties of identifying the pathogens translate to inadequate and
delayed treatments. The median time to receive an effective antimicrobial therapy is
6 hr after hypotension onset. By then, the survival rate has dropped at an average
of 7.6%/hr to 42% [4].
Importantly, among the current sepsis diagnostic methods there exists a trade-off
between the assay time and the specificity of the derived diagnostic information. Sit-
uated between the two extremes (blood culture and biomarker detection) is pathogen
DNA quantification. For instance, the qPCR-based SeptiFast test measures the DNA
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of 25 pathogens with a turnaround of 6 ∼ 10 hr [5], which includes a lengthy hands-on
time of 3 hr [6]. Such timescale remains unsatisfactory relative to the aforementioned
rapid decrease in the survival rate.
Therefore, this work aims to take advantage of the advances in microfluidic tech-
nologies to expedite and automate the detection of sparse pathogens in a large-volume
biofluid. Specifically, this improvement is evaluated to be best approached by com-
bining immiscible phase filtration and digital microfluidic droplet actuation to en-
hance nucleic acid purification and qPCR sequence detection, respectively. Thus, the
primary objective herein is to demonstrate the feasibility of the proposed integration.
This thesis details the developments en route to this main objective. It is struc-
tured as follows:
Chapter 2 The motivations and the objectives of this research are further elaborated.
Chapter 3 The three technologies that are tightly related to this work will be re-
viewed: qPCR sequence detection, digital microfluidic droplet actuation, and immis-
cible phase filtration.
Chapter 4 This chapter examines how the two microfluidic technologies could be
combined to enable a short sample-to-answer time and a high degree of automation.
Chapter 5 The developments that lead to the experiments in Ch. 6 are discussed,
including the evaluation of the three assays, the improvements applied to the fluidic
device, and the construction of the auxiliary systems needed for qPCR execution.
2
Chapter 6 This chapter presents the results from the wet experiments. Based on
the experimental method, the chapter is divided into three parts:
– In Sec. 6.1, the effectiveness of on-chip purification is assessed by off-chip mea-
surements.
– In contrast, in Sec. 6.2, on-chip purification is followed by on-chip qPCR,
thereby demonstrating the feasibility of the IPF - DM integration.
– The performance of on-chip qPCR is discussed in Sec. 6.3.
Chapter 7 The key results are recited in the last chapter of this thesis.
Appendix A The experimental methods used in Ch. 6 are detailed.
Appendix B The initial dye-based evaluation of IPF is summarized.
3
2Background and Motivation
Taking septic shock as an example disease, this chapter will first examine the chal-
lenges of multiplex sparse pathogen detection and the importance of having a short
assay time and an automated workflow. Then, the other backdrop of this work,
augment a fluidic device with cyberphysical control to enhance the execution of a
bioassay, would be overviewed. Finally, the objectives of this investigation will be
specified in the last section of the chapter.
2.1 Challenges of Sepsis Diagnosis
Septic shock is a severe form of bloodstream infection. It has an overall mortality
rate of 56% [4]. Further, since the increase in invasive medical procedures inevitably
exacerbates the likelihood of hospital-acquired infections, the incidence of septic
shock has been climbing and amounts to 10% of all admissions to the intensive
care unit [7].
The diagnosis of severe sepsis and septic shock are challenging in part for two
reasons. First, the infection can be caused by more than 50 species of pathogens
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that include Gram positive bacteria 47%, Gram negative bacteria 62%, and fungi
19% (based on the patients who had positive cultures [1, 7].) Second, the pathogens
might exist in the bloodstream in very low concentrations, e.g., less than 1 colony-
forming unit/ml blood [2]. Consequently, depending on the method it might be
necessary to analyze 3 ∼ 20 ml of blood [2, 3]. As indicated by the two problems,
definitive pathogen identification involves the multiplex detection of sparse pathogens
from a large-volume biofluid.
In turn, the difficulties of identifying the pathogens translate to inadequate and
delayed treatments. As can be seen in Fig. 2.1, the median time to receive an effective
antimicrobial therapy is 6 hr after hypotension onset. By then, the survival rate has
dropped at an average of 7.6%/hr to 42% [4].
Figure 2.1: Septic shock survival rate vs. time from hypotension onset [4].
The gold standard of sepsis diagnostic methods is the blood culture. It indicates
the species, concentrations, and antibiotic resistance of viable pathogens. However,
definitive pathogen identification takes at least 24 ∼ 48 hr on automated systems -
far longer than the aforementioned 6 hr timescale [6, 8].
In contrast, biomarker-based methods generally have a shorter assay time but
provide relatively unspecific data. For example, by measuring the protein procal-
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citonin in plasma, the VIDAS BRAHMS PCT test shows the severity of bacterial
infection in 20 min [9]. Still, these biomarkers are common to many inflammation
types and can be found in simple infections [8].
In terms of the assay time and the usefulness of the derived diagnostic informa-
tion, the molecular diagnostic approach that uses qPCR or microarray to quantify
the DNA of 25 ∼ 50 pathogens [3, 10] is situated between culturing and biomarker
detection. Molecular diagnostic tests generate the same types of information as the
blood culture, albeit in most cases without the specificity to viable pathogens. Ad-
ditionally, a significant drawback is the considerable hands-on time. For example,
the qPCR-based SeptiFast test has an average turnaround of 6 hr, which includes a
hands-on time of 3 hr [6]. Also, as a related issue, the delay caused by the operator
has been observed to further prolong the assay time to 10 hr [5].
In summary, certain approaches to sepsis diagnosis involve the multiplex detection
of sparse pathogens from a large-volume biofluid. Culturing is indispensable but
is growth rate-limited. In relation to the rapid deterioration of survival rate in
severe sepsis and septic shock, it remains to be seen to what extent the DNA-based
diagnostic methods could be expedited and automated by the advances in fluidic
technologies.
2.2 Cyberphysical System
A cyberphysical system is a system that involves computational entities interacting
with the physical world via interrelated sensors and actuators. An example is an
autonomous car that uses lidar mapping to stay on the road and preemptively diverts
from the planned route based on the real-time traffic data.
Recently, digital microfluidic devices (DM) have become sufficiently sophisticated
to be considered as basic cyberphysical systems. For instance, a PID controller can
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utilize the feedback from on-chip capacitive sensors to rapidly modulate the voltage
applied to the DM electrodes involved in the generation of droplets. The volume
variation of the droplets produced by this system can be controlled within ± 1%
[11]. Another demonstration tapped a commercial thin film transistor technology to
expand the impedance sensing capability to all DM electrodes. Hence, the position
and volume of all droplets on the fluidic device can be simultaneously monitored [12].
This ability can then be used to validate the droplet operations in a bioassay and
automatically react to a failed step, e.g., undo an uneven splitting of a microdrop
into two droplets.
However, since the implementation of a fluidic device can be highly application-
driven, an “electronics-first” approach may be less adaptable. In contrast, this work
represents the initial phase of a larger project that attempts to construct a cy-
berphysical system that enhances the execution of real-world bioassays. This goal
is thought to be best achieved via the co-development of the fluidic device, con-
trol algorithms, and sensors, e.g., on-chip photodetector, capacitive droplet position
sensor. (Algorithm: Chakrabarty group, photodetector: Jokerst group, capacitive
sensor: Chakrabarty/Fair group.)
Below are two examples of what could be implemented in this cyberphysical
system:
• Dynamically instantiated error recovery: As illustrated in Fig. 2.2, the droplets
could be rerouted to bypass a failed DM electrode. The preliminary demon-
stration of this capability is summarized in [13].
• Dynamic adaptation to intermediate qPCR results: For instance, as soon as the
qPCR detection of S. aureus shows positive amplification, the qPCR detection
of methicillin-resistant S. aureus could be initiated without waiting for the
preset number of thermocycles to finish.
7
It can be seen that these features would be required for mission-critical applica-
tions that demand the fastest sample-to-answer time, e.g., sepsis diagnosis.
DM	  electrode
shortest	  path reroute
droplet	  and
path	  of	  transporta2on
DM	  electrode	  (failed)
Figure 2.2: Reroute a droplet to bypass a failed DM electrode.
2.3 Motivation
The discussion in Sec. 2.1 indicates that among the current sepsis diagnostic tests
there is an inevitable tradeoff between the sample-to-answer time and the useful-
ness of the generated diagnostic information. However, this tradeoff is costly given
the rapid deterioration of survival rate in severe sepsis and septic shock. Located
somewhat in the middle of the two extremes is combining nucleic acid purification
and qPCR sequence detection to quantify the pathogen DNA. Still, a step-by-step
evaluation of the workflow of the commercial SeptiFast test shows that there is a
considerable room for improvement in its assay time and hands-on time.
The example of sepsis diagnosis further exposed an ironic deficiency in contempo-
rary lab-on-a-chip research: the majority of demonstrations are focused on enhancing
a particular procedure but without regard to its parent multistep workflow. Thus,
the claimed advances would be immaterial in practice if the approach is incompatible
with the intended upstream and downstream processes, e.g., in terms of flow rate,
8
sample volume, and analyte concentration.
In light of the above issues, this work will attempt to demonstrate a key concept
that could lead to a sepsis diagnostic device with a short sample-to-answer time
and a high degree of automation. Importantly, rather than electing to optimize a
particular process, fluidic technologies would be applied to expedite and automate
the entire workflow. To this end, the five objectives of this investigation are specified
below:
• Identify a compatible set of fluidic technologies that can be combined to ex-
pedite and automate nucleic acid purification and qPCR sequence detection.
Importantly, although a full-fledged diagnostic device is beyond the scope of
this project, the employed approach nonetheless should be scalable to meet the
demands of sepsis diagnosis, i.e., sample volume and the number of multiplex
qPCR reactions. – Ch. 4
• Uphold the feasibility of the proposed integration of fluidic technologies by
performing basic purification and qPCR tasks on the developed device. – Ch. 6
• Construct the auxiliary systems necessary for the operation of the fluidic device,
i.e., temperature control and fluorescence sensing systems. This task should
not be overlooked because commercial solutions can be cost prohibitive or
incompatible with the custom fluidic device. – Ch. 5
• Characterize the performance and identify the deficiencies of the initial fluidic
devices. The information can then be used to facilitate the subsequent design
revisions. – Ch. 6
• As the initial phase of a larger project that seeks to evolve the fluidic device
into a cyberphysical system, provisions will be made in the designs of the device
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and the assays to prepare for the later incorporation of additional sensors, e.g.,
the thin-film photodetector sketched in Fig. 2.3. – Ch. 5
Considering the steps involved, an aggressive yet achievable target might be im-
proving from the present 6 hr / 3 hr assay time/operator time to better than 1 hr /
0.3 hr. Such improvement may double the survival rate of septic shock from 42% to
80% [4]. This work then represents the first step towards this long-term goal.
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3Technology Overview
This chapter will overview the three technologies that are tightly related to this
work. First, because of its relevance to all aspects of the project, a longer section
is dedicated to quantitative polymerase chain reaction (qPCR.) Then, the review on
digital microfluidic droplet actuation (DM) will focus on the realizable fluidic oper-
ations. Lastly, the discussion on immiscible phase filtration (IPF) will emphasize its
workflow and a qualitative evaluation of the main factors that affect the effectiveness
of purification.
3.1 qPCR Sequence Detection
3.1.1 PCR Theory
Polymerase chain reaction (PCR) is a biochemical method that exponentially am-
plifies the amount of a DNA template. As illustrated in Fig. 3.1, a basic PCR
cycle consists of three steps: (1) Denaturation: at elevated temperature the hydro-
gen bonds between complementary bases are broken, unwinding a double-stranded
DNA to two strands. (2) Annealing: the temperature is lowered to allow for the
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hybridization of a primer to its target sequence at the 3’ end of each strand. (3)
Extension: using dNTPs as building blocks, the hybridized primer is extended by a
DNA polymerase to become a complement of the original strand.
Since a replicate of the dsDNA template is formed from each of the two initial
strands, after the first cycle there are now two templates. Then, the cycle is repeated.
Assuming 100% amplification efficiency, the amount of a template would be doubled
each cycle (Eq. 3.1.)
Cn = Ci(1 + E)
n (3.1)
(Ci, Cn: initial copy number and copy number at cycle n, E: amplification efficiency.)
In practice, exponential amplification cannot be sustained indefinitely. For in-
stance, in Fig. 3.2 it can be seen that there are only approximately 35 cycles in the
exponential phase. This is in part due to the exhaustion of dNTPs, and the thermal
degradation of the polymerase (Taq polymerase, a DNA polymerase frequently used
in PCR, has a half-life of 45 min at 95 ◦C [14].) Afterwards, as the accumulation
of nonspecific amplicons promotes further generation of nonspecific amplicons (that
is, PCR products), a negative feedback cycle is formed that rapidly terminates the
chain reaction. Eventually, PCR is ceased because of the aforementioned reasons.
3.1.2 Quantitative PCR
After PCR, the products are traditionally examined by gel electrophoresis [16]. How-
ever, due to its inadequate detection limit and dynamic range, gel electrophoresis is
unsuitable for quantifying the final amplicon concentration. This issue is exacerbated
by the fact that gel electrophoresis might be incapable of discriminating specific am-
plicons from nonspecific ones. As a consequence, under this approach it is difficult to
infer the initial template concentration. Further, as a separate step performed after
PCR, gel electrophoresis adds to the already lengthy sample preparation and PCR
time.
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Figure 3.1: Exponential amplification of DNA template [15]. Left: the first PCR
cycle. Right: products of the fourth cycle.
To address the above drawbacks, quantitative PCR (qPCR) is developed. In
qPCR, via the use of fluorogenic probes or intercalating dyes, PCR progress can be
monitored by a photodetector in real-time. Hence, initial template concentration is
correlated with threshold cycle Ct, the number of PCR cycles to reach a threshold
fluorescence intensity. Lower Ct implies higher initial concentration. Also, absolute
initial template concentration can be estimated from a Ct - log(Ci) standard curve
(Fig. 3.2.)
Notably, threshold intensity should be sufficiently low such that it can be reached
while an amplification is still in the exponential phase. Thus, in contrast to end-point
measurements such as gel electrophoresis, Ct and the subsequent estimation of initial
template concentration would not be distorted by nonspecific amplicons generated
after the exponential phase.
In addition to initial template concentration, the other information that can be
extracted from a standard curve is amplification efficiency. Specifically, via Eq. 3.2
amplification efficiency can be calculated from the slope of the standard curve. As
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Figure 3.2: qPCR of a 160 bp target. Left: amplification plot. ∆Rn is obtained by
(reporter dye fluorescence / reference dye fluorescence) - baseline. Right: standard
curve with E = 94%.
defined in Eq. 3.1, an ideal efficiency of 100% suggests that the amount of amplicons is
doubled per PCR cycle. In reality, a well-designed and executed PCR reaction should
achieve better than 90%. Moreover, because amplification efficiency is affected by
all aspects of PCR, when fine-tuning a new PCR reaction a satisfactory efficiency
could be seen as a telltale sign of an optimized chemistry. Similarly, amplification
efficiency might be used as a debugging tool. As an example, for a routine PCR
reaction, the deviation of amplification efficiency from typical values (overly low or
abnormal, e.g. higher than 110%) may indicate the presence of PCR inhibitors in
reaction mixtures.
E = 10
−1
slope − 1 (3.2)
(E: amplification efficiency, slope: slope of the standard curve.)
Regarding the generation of fluorescence in qPCR, a frequently used mechanism
is TaqMan chemistry (Fig 3.3.) In principle, a basic PCR can be converted to a
TaqMan-based qPCR by adding an appropriate TaqMan probe. TaqMan probe is a
type of fluorogenic probe that consists of three components: A < 30 nt nucleotide
complementary to a region of the amplicon, a fluorophore attached to the 5’ end of
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Figure 3.3: TaqMan-based qPCR. During extension, a DNA polymerase extends
the primer. When the enzyme reaches the probe, due to its 5’ → 3’ exonuclease
activity the fluorophore is cleaved from the probe [17].
the nucleotide, and a quencher attached to the 3’ end of the nucleotide. Prior to
PCR, fluorescence emitted by the fluorophore is quenched via fluorescence resonance
energy transfer by the quencher. During annealing, a probe hybridizes to its target
sequence on a ssDNA. Then, in the extension step of PCR, the probe is digested
by the DNA polymerase as it extends the primer. Accordingly, the fluorophore is
irreversibly cleaved from the quencher, and the fluorescence is unquenched. In other
words, each duplication of a dsDNA template would generate two amplicons and
unquench one fluorophore. Therefore, the amount of amplicons accumulated in a
reaction mixture is proportional to fluorescence intensity.
The above discussion highlights three features of probe-based qPCR. First, a
set of two sequence-specific primers can be designed to selectively amplify a target.
Second, extra specificity is introduced by the sequence-specific probe. Because fluo-
rescence can only be generated by the amplification of targets, but not by unintended
amplifications, e.g. due to mispriming. Third, initial target concentration can be
determined from the threshold cycle. Because of these attributes, probe-based qPCR
is an attractive method for quantifying sparse targets that are buried in high levels
of background nucleic acids.
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Importantly, multiplex detection can be attained by running multiple assays (an
assay includes a set of two primers and a corresponding probe) concurrently in the
same reaction mixture. One of the prerequisites for multiplexing is that each target
should be represented by a fluorophore that is spectrally distinct from the fluo-
rophores associated with other targets. Meanwhile, a photodetector needs to be able
to suppress the excitation light and resolve the emission contributed by each type
of the fluorophore. Consequently, the degree of multiplexing is limited by the avail-
ability of suitable fluorophores and optical filtering. Commercial qPCR instruments
are typically equipped with sufficient fluorescence channels to support the sensing of
three to six targets.
3.1.3 Specificity Improvement
Hot start is a technique that substantially improves the specificity of amplification.
Essentially, it is devised to prevent the amplification of misprimed ssDNA and primer
dimer during PCR preparation and while a reaction mixture is being heated up
from room temperature to the first denaturation step. This type of nonspecific
amplification is attributed to two undesirable effects. First, at low temperature
(compared to the melting temperatures of primers), the annealing of primers suffers
from poor stringency, and primer dimer is relatively stable. Secondly, Taq polymerase
- a frequently employed DNA polymerase - is somewhat active at room temperature:
0.25 nt/s extension rate [18]. Together, the two effects would produce nonspecific
amplicons even before the first PCR cycle, and these nonspecific amplicons might be
further replicated by PCR. In turn, the specificity of amplification is compromised.
As the name implies, hot start PCR is initiated by a high-temperature step that
activates the DNA polymerase. Otherwise, prior to the thermal activation the DNA
polymerase has no enzymatic activity at ambient temperature. This temporary en-
zyme inactivation can be achieved by, for example, binding or blocking the active
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Table 3.1: Thermocycling profile of TaqMan Fast Advanced Master Mix [19].
Temp. (◦C) Duration (s) Step
50 120 UNG incubation
95 20 Polymerase activation
95 1 Denature
60 20 Anneal/extend, fluorescence measurement
domain of DNA polymerase with antibody or oligonucleotide. During PCR prepa-
ration, because DNA polymerase is inactive, misprimed ssDNA and primer dimer
cannot be amplified. Later, DNA polymerase is activated, but at proper annealing
and extension temperatures the probability of mispriming and the stability of primer
dimer are greatly diminished.
Therefore, hot start minimizes the introduction of “noise” to a sample. In turn,
less “noise” is likely to be amplified by PCR, thereby enhancing the specificity of
amplification. In the context of qPCR, hot start decreases the presence of potentially
amplifiable false positives in a sample, resulting in a more accurate quantification of
targets.
3.1.4 qPCR in Practice
A baseline qPCR protocol is listed in Table 3.1. This two-temperature protocol as-
sumes that the melting temperatures of primers are designed to be approximately
60 ◦C. Thus, instead of involving a dedicated 72 ◦C extension step, annealing, exten-
sion, and fluorescence measurement are combined into one 60 ◦C step, resulting in
significantly reduced PCR run time. Although functioning at a reduced extension
rate, 20 s anneal/extend at > 24 nt/s is sufficient for extending a typical < 150 bp
qPCR amplicon (> 60 nt/s at 70 ◦C [18].)
A qPCR reaction mixture is assembled from three components: sample, assay,
and master mix. A master mix contains DNA polymerase, dNTPs, Mg2+, K+, pH
17
buffer, and other additives. In particular, the master mixes intended for Applied
Biosystems’s qPCR instruments generally contain the passive reference dye ROX.
The dye does not participate in PCR. Rather, it is used to detect non-PCR-originated
fluctuations in the fluorescence signal, e.g. due to well-to-well volume variations.
Importantly, the concentration of PCR inhibitors in a sample should be kept
low. Otherwise, targets might be undetected due to failed PCR, leading to false
negatives. For instance, whereas hemoglobin concentration in blood is on the order
of 100 mg/ml, PCR has been shown to be completely inhibited at 1 mg/ml [20].
Because multiple assays can be employed to detect more than one target in a
sample, internal positive control DNA (IPC DNA) and its corresponding assay are
frequently used to assist the identification of false negatives. Briefly, prior to PCR
a low concentration of IPC DNA is added to a sample. Later, if IPC is undetected,
or is detected with a significantly delayed threshold cycle, then the extent of PCR
inhibition should be evaluated before true negative can be declared.
Similarly, a no template control (NTC) should be performed alongside a sample.
NTC is prepared by adding water - instead of sample - to a reaction mixture. If
a target is detected in NTC, the PCR reagents could be contaminated with the
target. Accordingly, positive detection in samples may in fact be false positives.
Alternatively, NTC might be inadvertently contaminated during PCR preparation,
for instance via aerosols generated by pipetting [21].
Nevertheless, depending on the target of interest, amplified NTC could be un-
avoidable. For example, since the recombinant Taq polymerase is manufactured by
inserting the DNA polymerase gene of T. aquaticus into an E. coli host [22], per
unit enzyme it can contain 102 to 105 genome equivalents of bacterial DNA [23].
Thus, qPCR-based E. coli detection is usually encumbered by high background and
unsatisfactory detection limit, e.g. 2500 CFU/ml [24]. Even if Taq polymerase is
further purified to reduce the bacterial DNA introduced from the host, a “clear”
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NTC is still difficult to obtain [23].
3.2 Digital Microfluidic Droplet Actuation
Three topics will be overviewed in this section: the theory behind DM actuation, the
structure of a DM-based device, and the fluidic operations that can be executed on
the device. In particular, the discussion will focus on the aspects that are directly
relevant to this work. More comprehensive reviews can be found in [25] and [26].
3.2.1 Theory
Digital microfluidic droplet actuation (DM) is a liquid handling technology that is
used to control the motion of conductive droplets on an electrode array (Fig. 3.4),
primarily for lab-on-a-chip purposes. Instead of a pump, the actuation force orig-
inates from the bias applied between the DM electrode and the ground plane, as
sketched in Fig. 3.5.
Figure 3.4: Layout of a DM device, top-down view.
At low frequency (below ∼ 10 kHz [25]), the applied voltage results in an elec-
trostatic pressure that pulls the liquid - fluid interface in the proximity of the triple
19
DM	  electrode
ground	  electrode
aqueous
droplet
air,
oil
bo5om	  plate	  substrate
top	  plate	  substrate
ga
sk
et
dielectrichydrophobic	  coa:ng
hydrophobic	  coa:ng
H
L
Figure 3.5: Structure of a typical DM device, side view.
phase line (specifically, the interface within a distance of order d from the triple
phase line [27]) in the direction of the outward (droplet) surface normal (Fig. 3.6.)
After integrating the electrostatic pressure over the droplet surface, the horizontal
component (i.e., parallel with the substrate) of the obtained electromechanical force
under relevant conditions amounts to 10s of µN [25], which is sufficient to overcome
the frictional and viscous dissipation terms (former: contact line friction; latter: the
flow in the droplet and in the filler medium) and pull the liquid - fluid interface (thus,
the droplet) towards the energized DM electrode, e.g., Fig. 3.7.
This driving force scales in the same way as the energy stored in the dielectric:
εrV
2/d. (εr, d: relative permittivity and thickness of the dielectric; V: applied volt-
age.) Hence, the applied voltage can be utilized to increase the droplet transportation
speed. In practice, the actuation force is observed to fall from the V2 dependency
well before the dielectric reaches its breakdown field strength. The exact causes of
the saturation are not currently well understood [25].
Further, by affecting the Laplace pressure, another consequence of the electro-
static pressure is a reduced apparent contact angle θa. Fig. 3.6 illustrates this
electrowetting-on-dielectric effect, θy = θa(0) > θa(V). However, it is important to
note that the reduced apparent contact angle does not imply the liquid - solid in-
terfacial tension is lowered by the voltage. Indeed, the same local contact angle
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θy (again, within a distance of order d from the triple phase line) as governed by
Young’s equation is observed with or without the bias [28].
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d
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Figure 3.6: Electrowetting-on-dielectric. Solid / dotted curve: Liquid - fluid inter-
face with / without an applied voltage. Arrow: Electric field. d is typically on the
order of 1 µm. Also, note that to transport the droplet via the electromechanical
force towards the right, the depicted DM electrode would be the one that is adjacent
to the electrode where the droplet currently resides on, see Fig. 3.7.
3.2.2 Device Structure
Fig. 3.5 illustrates the structure of a baseline DM device. Also, Fig. 5.6 shows the
materials and the layer thicknesses employed by the main fluidic device in this work.
The aspect ratio L / H strongly depends on the targeted application and the
available fabrication tools. Ratios between 4 ∼ 25 have been used [29, 30]. (L: DM
electrode pitch; H: gasket thickness.) For a given droplet volume, a higher aspect
ratio permits a larger portion of the liquid - fluid interface to be influenced by the
electromechanical force. Hence, a higher ratio to certain extent could benefit DM
actuation, especially for steps such as generating and splitting a droplet [31].
Regarding the largest droplet that might be reliably transported using DM ac-
tuation, with L = 2.7 mm (capillary length of water) and H = 300 µm or 675 µm
(limited by the thickest SU-8 gasket that can be fabricated with reasonable through-
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put or the lowest reported aspect ratio, respectively) the volume would approximate
pi(L/2)2H = 2 ∼ 4 µl.
In comparison, the main device in this work has L / H = 700 / 120 µm and a
unit droplet volume of 46 nl. (For the structure shown in Fig. 2.3, the light tracing
simulation conducted by the Jokerst group suggests that a suitable balance between
the droplet’s exposure to the excitation light and the probability of the resulting
fluorescence reaching the photodetector may be obtained with L / H = 700 / 160
µm. However, to improve the fabrication throughput, the current gasket is laser-
patterned from 120 µm-thick SecureSeal, a double-sided adhesive film.)
The typical bottom plate substrates include glass, silicon, and PCB. As for the
top plate substrate, since optical observation is usually conducted from the top,
transparent materials such as glass, polycarbonate, and PMMA are common. (For
the same reason, the ground plane is generally made of the transparent conductive
oxide ITO.) In particular, polymers and the associated manufacturing technologies
(e.g., CNC milling, laser cutting, and injection molding) are relatively accessible.
These methods enable the pipette ports, reagent reservoirs, and other chip-to-world
interfaces to be incorporated as part of the top plate, e.g., Fig. 5.5. Still, compared
with glass, the trade-offs are optical clarity, chemical inertness, and thermal stability.
Lastly, the filler medium should be electrically insulating and compatible with
the application in question. That is, it must be immiscible with the reagents, must
minimize analyte partitioning, and be thermally stable. Further, due to the small
droplet volume, it is crucial to mitigate evaporation. Thus, although air satisfies
most of the aforementioned criteria, inert oils such as dodecane and 2 ∼ 5 cS low
viscosity silicone oil are more frequently employed.
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Figure 3.7: Fluidic operations: Transport, split. #: energized electrodes.
Figure 3.8: Fluidic operations: Merge, dispense from a reservoir. #: energized
electrodes.
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3.2.3 Fluidic Operations
On an electrode array, by energizing different sets of DM electrodes in sequence, the
electromechanical force can be utilized to transport and split a microdrop. Based on
the two basic fluidic operations, steps such as merging, dispensing, and mixing can
be performed. Micrographs of these operations are shown in Fig. 3.7 and Fig. 3.8.
(Merge: Transport droplets to the same location. Dispense: Split a droplet from a
reservoir. Mix: A combination of merge, transport, and split are repeated to counter
the lack of turbulent mixing at Re ∼ 0.4.)
As an example, on the device illustrated in Fig. 5.6, the typical voltage used to
transport an aqueous droplet of 0.08% w/v Tween 20 is 35 Vrms at 1 kHz. At this
voltage, the droplet can be moved at 5 electrode/s, or 3.5 mm/s.
In turn, the five fluidic operations can be blended to execute a variety of re-
actions. For instance, Fig. 3.9 illustrates the measurement of ssDNA and dsDNA
concentrations. Importantly, since the application of the actuation voltage to the
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Figure 3.9: ssDNA, dsDNA concentration measurement performed via DM actua-
tion.
DM electrodes is computer-controlled, the two procedures in Fig. 3.9 can be con-
ducted on the same device automatically and concurrently. Hence, hands-on time
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and the chance of contamination are minimized. In this work, these advantages of
DM actuation will be used to automate and expedite the preparation of PCR reaction
mixtures (Fig. 4.1 and Fig. 4.2.)
Lastly, it should be noted that DM actuation by itself is incapable of separating
particles (such as cells, proteins, nucleic acids) from the droplet they reside in. This
crucial deficiency can be circumvented by binding the particles to, for example,
magnetic beads or a functionalized patch of the droplet-facing surface [32, 33]. After
anchoring the magnetic beads in place with an external magnet, the droplet can
be transported away from the beads. Subsequently, the process can be reversed to
resuspend the particles in a new medium.
The outlined procedure can be adapted to purify nucleic acids from a solution
of contaminants, or replenish the nutrients for an on-chip cell culture. Still, due to
the constraint on the maximum droplet volume (Sec. 3.2.2), this approach cannot
efficiently purify nucleic acids from a large-volume sample, i.e., larger than 4 µl.
Instead, alternatives such as immiscible phase filtration (Sec. 3.3) would be more
viable for this task.
3.2.4 Aspect Ratio Optimization
Using a unit droplet volume of 1 µl as an example, this section will outline an
approach for sizing the DM electrode pitch and the gasket thickness with respect to
maximizing the droplet transportation speed for temperature zone PCR purposes. In
particular, the analysis is based on the theoretical estimation of the electromechanical
droplet actuation force and the contact line friction, whereas practical limitations,
such as the difficulty of fabricating a thick gasket (> 300 µm), will not be considered.
In temperature zone PCR (Fig. 4.2), the temperature ramp rate can be improved
by increasing the average droplet transportation speed U. Thus, the goal of this
section is to facilitate the droplet transportation by selecting a suitable combination
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of DM electrode pitch L and gasket thickness H (Fig. 3.5.)
Based on the discussion in [34], the electromechanical droplet actuation force FEM
and the contact line friction FCLF might be approximated by the following equations:
FEM =
ε0εr
2d
(V − Vt)2L (3.3)
FCLF = ζU(2pi
L
2
2) (3.4)
Table 3.2: Parameters used in the estimation of FEM, FCLF.
Parameter Value
Relative permittivity of the dielectric εr 3.15 (Parylene C)
Thickness of the dielectric d 1 µm
Applied voltage V 35 V
Threshold voltage Vt 13.2 V
1
Contact line friction coefficient ζ 4×10-2 kg/(m·s)1
Average droplet speed U 5L/s
1 Adapted from [34].
According to Eq. 3.3, FEM scales with L. By intuition, for a given droplet volume,
a higher ceiling of U may be obtained by increasing L to maximize the FEM available
for pulling the droplet. However, as shown in Fig. 3.10, this intuition is only valid
up to a certain L. Specifically, this is because the primary dissipation term in the
system, FCLF, scales with U × L and hence L2 (Eq. 3.4.) Accordingly, beyond a
certain L FCLF will begin to scale faster than FEM. Then, less net force FEM - FCLF
would be available for DM droplet manipulation. (Note that the factor 2 at the end
of Eq. 3.4 is intended to account for the contact line at the two plates.)
In the case of Fig. 3.10, the maximum net force is obtained at L = 2.6 mm.
Consequently, 1 µl unit droplet volume can be achieved by having H = 190 µm
(Fig. 3.12.) As a comparison, this aspect ratio L / H = 14 falls in the middle of the
reported 4 ∼ 25 range [29, 30]. In addition, as can be seen in Fig. 3.11, it is worth
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Figure 3.10: Electromechanical force (FEM), contact line friction (FCLF) vs. DM
electrode pitch (L.) The estimation of FCLF assumes an average droplet transporta-
tion speed of 5L/s.
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gasket thickness (H) that correspond to a unit droplet volume of 1 µl. L/H is labeled.
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noting that this maximum net force is attained at the expense of wasting half of the
generated FEM to counter FCLF.
The above discussion outlines an analytical approach that uses the force balance
to determine the most suitable L and H for temperature zone PCR purposes. To
further refine the evaluation, additional terms can be incorporated to account for the
viscous dissipation effects that exist in the droplet and in the filler medium. On the
other hand, in general the droplet actuation is rarely the only factor that can affect
the selection of the aspect ratio. For instance, based on the result from ray tracing
simulations, the current integrated photodetector (Fig. 2.3) was designed to show the
optimal S/N when fitted to a fluidic device with L / H = 4.4. Therefore, in order to
reach a satisfactory balance between the two considerations (droplet transportation
speed and photodetector S/N), it might be necessary to adopt an intermediate aspect
ratio that falls between 4.4 and 14 (Fig. 3.12.)
3.3 Immiscible Phase Filtration
Nucleic acid purification is a process that isolates nucleic acids (NA) from contam-
inants. A typical magnetic bead-based assay involves three major steps: binding,
wash, and elution. Briefly, NA in a lysate is first captured by magnetic beads. Then,
the beads are washed in order to remove contaminants such as proteins, nucleases,
and cellular fragments. After washing, ionic strength is lowered to release NA from
the beads to an elution buffer. This way, NA is purified from a lysate and ready for
subsequent analyses. In addition, sample volume is reduced from milliliters of lysate
to microliters of eluent.
However, conventional magnetic bead-based purification involves repetitive pipet-
ting and centrifugation. For example, depending on the starting sample as many as
seven washes may be necessary for removing the contaminants entrapped in the bead
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pellet, adsorbed on the walls of reaction tubes, or remained in the solution after aspi-
rating the supernatant [35]. As a result, without access to costly robots the process
is labor-intensive. Furthermore, due to the dominance of interfacial tension and vis-
cosity over inertia, centrifugation is difficult to attain at microscale. Consequently,
it is not straightforward to replicate the traditional assay on microfluidic devices.
Alternatively, immiscible phase filtration (IPF) is a new variant of the conven-
tional bead-based assay. While based on the same bind-wash-elute principle, IPF
does not utilize any centrifugation. Specifically, as shown in Fig. 3.13, in IPF beads
bound with NA are first snapped out of the lysate to an immiscible phase. During
bead snapping, the aqueous/immiscible interface represents an energy barrier that
discourages the crossover of contaminants to the immiscible phase. Next, the beads
are dispersed in a wash buffer. Here, the contaminants originally entrapped in the
bead pellet are diluted away. Simultaneously, proteins adsorbed on the beads are
denatured by chaotropic salts in the wash buffer.
After washing, the beads are transported from the wash buffer through an immis-
cible phase to an elution buffer. In this process, again it is energetically unfavorable
for contaminants such as the chaotropic salts to enter the immiscible phase. As a
result, a minimum amount of contaminants is carried by the beads to the elution
buffer. Finally, the low ionic strength elution buffer promotes NA to unbind from
the beads.
Following the above procedure, NA is now purified by IPF and ready for later
analyses. For instance, genomic DNA has been purified from the PCR inhibitors
and nucleases in lysed whole blood. qPCR is then conducted off-chip to quantify the
provirus in the captured DNA. The obtained 108% amplification efficiency indicates
minimal inhibitor carryover. A separate experiment in the same study claimed 90%
sensitivity to plasma samples spiked with 800 copy/ml HIV-1 RNA [35]. Moreover,
purification time can be reduced from 15 ∼ 45 min in conventional assays to 4.1
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Figure 3.13: Schematic of an IPF device, top-down view. NA is purified from a
lysate as the magnetic beads are transported rightwards through the device.
min [36]. An IPF integrated with micromachined heaters for on-chip qPCR further
demonstrated a total assay time of 17 min [37].
Notably, the magnetic field that actuates the magnetic beads could be applied
off-chip or generated on-chip. In previous examples the transportation of beads is
controlled by permanent magnets mounted on a stepper motor or a linear actuator,
whereas an IPF has utilized the magnetic field generated on-PCB by an array of
multilayer coils [38].
Regarding the immiscible phase, compounds such as air [39], silicone oil [38, 40],
mineral oil [37], and liquid wax [35] have been used.
Fundamentally, IPF is a series of magneto-capillary valves [39]. It requires an
appropriate balance between the interfacial tension and the magnetic force acting
on the beads, particularly at the lysate/immiscible interface [41]. As an example,
Fig. 3.14 shows the beads snapping behavior under different aqueous/immiscible in-
terfacial tension conditions. Considering the goal of reducing the carryover during
bead snapping, high aqueous/immiscible interfacial tension is preferred. Yet, ex-
cessive interfacial tension would exacerbate incomplete bead snapping. Beads that
remain in the lysate or wash buffers are not transported to the elution buffer, result-
ing in the loss of NA during purification. In the extreme case, no beads would be
able to penetrate the aqueous/immiscible interface. On the other hand, insufficient
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Figure 3.14: Bead snapping under different aqueous/immiscible interfacial tension
conditions [36].
Figure 3.15: The linear correlation between bead weight and carryover volume
[35].
interfacial tension leads to increased carryover. Accordingly, during the washes more
contaminants need to be removed from the beads by digestion and dilution. In the
worst scenario, bead snapping could lead to the formation of a liquid bridge, e.g.,
between the lysate and the wash buffer in Fig. 3.13.
In addition to interfacial tension, carryover volume is shown to be linearly propor-
tional to bead load, i.e., total bead weight (Fig. 3.15, Appendix B.4.) In consequence,
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to reduce the bead load (thus, the carryover) without sacrificing the surface area for
NA binding, smaller magnetic beads are advantageous. Still, since the magnetic force
acting on a magnetic bead is proportional to its volume, it is relatively difficult for
smaller beads to overcome the interfacial tension and achieve bead snapping.
The above discussion suggests that optimal purification can only be obtained
with suitable interfacial tensions, bead load, and magnetic field. Additional concerns
include: (A) To ensure maximum NA capture, beads and lysate must be well mixed.
Further attention is required in the case of a highly viscous lysate, e.g., lysed blood
[36]. Similarly, adequate mixing of the beads with the wash buffer and elution
buffer is crucial to contamination removal and NA unbinding, respectively. (B) Bead
loss due to unsatisfactory bead snapping may be prevented by adjusting the bead
transportation speed [36] and designing the IPF geometry in accordance with the
applied magnetic field [39]. Besides, bead loss that originates from the adhesion
to the sidewalls of the fluidic device could be mitigated by applying coating [42]
and improving wash efficiency to reduce the number of wash stages. In fact, it is
demonstrated that IPF is capable of purifying NA from lysed blood without any
wash step [35], i.e., beads are snapped from a lysate to an immiscible phase, and
then directly transported to an elution buffer [36].
In conclusion, immiscible phase nucleic acid purification utilizes the energy barrier
presented by the aqueous/immiscible interfacial tension during bead snapping to
filter out the contaminants that would interfere with subsequent analyses (e.g., PCR
inhibitors) from the captured nucleic acids. Because sample volume is reduced from
milliliters of lysate to microliters of eluent, IPF could be implemented in a platform
as the upstream purification/volume reduction stage to a downstream microfluidic
analysis stage. This is feasible also because IPF does not employ centrifugation or
demand any particular device construction. Such integration is beneficial because the
manual specimen transfer from the sample preparation procedure to the bioanalytical
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instruments contributes to the hands-on time and precludes full sample-to-answer
automation. In contrast, with IPF sample preparation and microfluidic bioanalysis
located on the same device, a hands-free operation becomes more attainable. Since
the automation reduces the hands-on time and NA loss, the integration should lead
to accelerated time to result and enhanced detection limit, both of which are highly
desirable for rapid sparse cell quantification purposes.
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4Approach
After reviewing the technologies that are related to this work, this chapter will iden-
tify the advantages of combining immiscible phase filtration and digital microfluidic
droplet actuation to expedite the diagnosis of bloodstream infections. The discus-
sion also succinctly outlines the experiments that will be performed to substantiate
the feasibility of the proposed IPF - DM integration. Then, a walk-through will be
provided to illustrate the operation of the IPF - DM fluidic device.
4.1 Accelerate the Proven Strategy:
Nucleic Acid Purification Followed by qPCR
This work seeks to use fluidic techniques to accelerate the diagnosis of sepsis. Such a
fluidic device ideally should be capable of detecting multiple types of low-concentration
pathogens from a large-volume raw sample, e.g., 3 CFU/ml E. coli in 3 ml whole
blood [3]. Furthermore, the priority is to minimize sample-to-answer time and per-
haps more importantly, hands-on time. This is in response to the drawbacks of
current methods: blood culture takes one to three days [3], and SeptiFast requires
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three hours of operator time per six-hour assay [6]. Still, it should be cautioned
that performing all steps on-chip does not necessarily improve performance. Rather,
the inclusion of any step onto the device for automation purposes is only sensible
providing that detection limit and run time are not significantly impacted.
Traditionally, bloodstream infections are diagnosed by symptom classification
systems or culturing [43]. However, new methods have been commercialized, such as
biomarker detection (VIDAS BRAHMS PCT [9]) and DNA fingerprinting (SeptiFast,
Prove-it [1].) Among these methods, in terms of run time and specificity, SeptiFast
appears to offer a more reasonable balance than biomarker detection or culturing.
Briefly, SeptiFast utilizes qPCR to detect 25 of the most common infection-causing
bacterial and fungal species. Also, for some bacterial species, a follow-up qPCR can
be run to detect the mecA gene, which indicates certain antimicrobial resistance.
These qPCR-derived information are considerably more specific than what can be
provided by biomarker detection, meanwhile the run time is substantially shorter
than culturing. Accordingly, the “purification then qPCR” method could be even
more attractive if the run time and hands-on time can be further reduced.
To accelerate a SeptiFast-like “purification then qPCR” workflow, the following
might be attempted:
• Automate nucleic acid purification, and/or use a purification method that takes
less step/time to execute.
• Reduce the lag between purification and qPCR.
• Automate PCR mixture preparation.
• Reduce qPCR time by minimizing the time spent on transitioning between
60 ◦C and 95 ◦C.
Whereas lab-on-chip researches usually elect to specialize on one of the listed aspects,
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the first objective of this work is to identify a compatible set of fluidic technologies
that can enable the pursuit of acceleration on all fronts.
As will be explained in the rest of this section, a suitable solution seems to be
using immiscible phase filtration to purify the nucleic acids, followed by employing
digital microfluidic droplet actuation to prepare the PCR mixture. Furthermore, a
complete implementation might expand the two technologies to incorporate chemical
lysis and temperature zone PCR.
Yet, with two fluidic devices, each dedicated to pre- or post-purification processes,
it is still necessary to manually transfer the eluent between the two. Therefore, to
fully exploit their ease of automation to attain hands-free operation, the key is to
integrate IPF and DM onto a common platform. Thus, the second objective of this
work is to construct such a fluidic device, and then run basic purification and qPCR
tasks on the developed device to demonstrate the feasibility of IPF - DM integration.
4.2 PCR Preparation by DM Droplet Actuation
PCR mixture preparation refers to the procedure that combines purified nucleic acids,
qPCR assays, and PCR master mix into a solution for the subsequent thermocycling.
This step is extremely sensitive to contaminations, e.g., by PCR inhibitors, other
samples, and products from previous PCR runs. Also, without a dedicated robot, it
is also highly laborious and therefore prone to operator errors.
The two problems can be addressed by using DM droplet actuation to prepare the
PCR mixtures. First, the routing and mixing of the reagent droplets are performed
in an enclosed fluidic device, thereby eliminating the exposure to airborne contam-
inants. In contrast, during a conventional benchtop preparation, the solutions are
exposed and thus vulnerable to the contamination until the well plate can be sealed
by an optical adhesive film. Second, DM actuation is inherently automated, which
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minimizes hands-on time, eliminates operator error, and improves reproducibility.
Herein, the ability to use DM actuation to prepare the PCR mixture will be
demonstrated using the procedure illustrated in Fig. 4.1a. It is a simplified scenario
because the qPCR assay has been premixed with the master mix. In comparison, an
analog of the SeptiFast protocol, sketched in Fig. 4.1b, would call for six concurrent
multiplex qPCR reactions.
eluent
PCR	  mixture
(singleplex)
(a)
(b)
PCR	  mixture	  1
(mul6plex)
[ ]	  x	  6+
+
+
eluent master	  mix assays	  1
assay	  +
master	  mix
Figure 4.1: Preparation of the PCR mixture droplet. (a) Using premixed master
mix and qPCR assay. (b) Multiple multiplex qPCR reactions.
Furthermore, although not harnessed in this work, a future fully “DM-powered”
PCR stage might combine automated mixture preparation with temperature zone
PCR to drastically shorten the PCR time.
Rather than thermocycling the entire device, the method shuttles a PCR mixture
droplet between the two temperature zones (Fig. 4.2.) This expedites PCR by im-
proving the temperature ramp rate. (As a reference, for a 45-cycle qPCR conducted
on a benchtop thermocycler, ramping accounts for 67% of the 55 min run time. See
Table 5.4.) Since nanoliter-sized droplets possess minimal thermal mass, ramp rate
in this case effectively depends on the droplet transportation speed and the separa-
tion between the two zones. Using temperature zone PCR, a 40-cycle qPCR can be
completed in 18 min on a PCB-based DM device [44].
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(a) (b)
60RTdevice 95 PCR	  mixturedroplet
Figure 4.2: PCR on DM device. (a) Whole-chip thermocycling. (b) Using DM
actuation, the PCR mixture droplet is shuttled between the two temperature zones
or hot spots. In the latter case, the globally cooled device might allow other processes
(e.g., PCR preparation, non-PCR reactions) to be concurrently executed.
4.3 Nucleic Acid Purification by Immiscible Phase
Filtration
Meanwhile, since a lysate generally cannot be directly inputted to PCR due to the
presence of concentrated PCR inhibitors, it is necessary to prepend the aforemen-
tioned PCR preparation stage with a nucleic acid purification stage. Then, consid-
ering that the initial evaluation will be limited to a simplified purification scenario
yet without losing sight of the eventual sparse pathogen detection application, the
purification stage of the fluidic device should satisfy the following requirements:
• Its construction and the employed purification method should be scalable to
accept 1 µl ∼ 100s µl of lysate. As a reference, 3 ml blood is analyzed by
SeptiFast in order to deliver a statistically relevant diagnosis.
• The purification time at minimum should be comparable to typical benchtop
purification protocols.
• Amenable to low-cost automation: Ideally, no operator intervention should be
38
needed except for sample and reagent loading.
• Crucially, in order to be compatible with the downstream DM-based PCR
preparation stage, the output of the purification stage should be a static solu-
tion of concentrated nucleic acids on the order of 1 µl and with an acceptable
concentration of PCR inhibitors.
The last requirement may be interpreted from the perspective of the PCR prepa-
ration stage in two different ways. First, as DM actuation cannot efficiently ma-
nipulate liquids that are more than a few microliters in volume, it relies on the
purification stage to scale down the analyte volume from milliliter to microliter. In
this role, the purification stage might be thought of as the chip-to-world interface
of the DM-based PCR preparation stage. Second, accompanied by the volume re-
duction is the enriched pathogen nucleic acid concentration. The PCR preparation
stage depends on this preconcentration to improve the probability of having at least
one copy of the target in an eluent droplet.
The above design constraints are derived from an earlier unsuccessful attempt
to develop a purification stage that utilized size differentiation to isolate pathogens
from whole blood (deterministic lateral displacement, which is a continuous flow
technique [45].) Later on, the exploratory tests summarized in Appendix B suggested
that immiscible phase filtration, a recent variant of magnetic bead-based nucleic
acid purification, seemed to be a logical fit. In addition to satisfying the above
specifications, nucleic acids processed by IPF have been reported to be sufficiently
purified for benchtop PCR reactions [46, 47].
Herein, the IPF purification stage will be subjected to a relatively straightforward
task of purifying the nucleic acids from a highly concentrated solution of a chaotropic
salt. This uncomplicated purification scenario permits the initial development to
focus on showing the feasibility of combining IPF and DM; it does not preclude a
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more complex sample such as a cell lysate from being tested on the purification stage.
In particular, the reagents in a commercial bead-based purification kit will be
used without modification. In contrast, typical IPF studies frequently focus on ad-
justing the interfacial tension between the aqueous phase and the immiscible phase
in an attempt to reduce or completely eliminate the wash steps, e.g., [40]. The
intension here is to evaluate how well the off-the-shelf reagents would perform in
IPF-based purification. Using the reagents as-is is also expected to reduce the risk
of contamination.
Finally, it is worth noting that the IPF - temperature zone qPCR integration
has been demonstrated on a non-DM fluidic device [37]. Yet, two crucial flaws are
unaddressed in the reported implementation. First, it would be difficult to scale up
its droplet actuation mechanism to execute more than one PCR reaction at a time.
Second, magnetic beads are required to remain in the droplet that is undergoing
qPCR. However, the presence of microbeads in a PCR mixture has been observed to
reduce the amplification efficiency by 50% [48].
In contrast, since DM actuation can simultaneously manipulate multiple droplets,
the qPCR part of SeptiFast could be fully replicated on a DM device by perform-
ing six concurrent multiplex qPCR reactions (for Gram-positive and Gram-negative
bacteria, fungi, positive and negative controls.) Also, since DM does not actuate a
droplet via the magnetic beads, the beads can be removed from the eluent immedi-
ately after elution. This way, no significant amount of the magnetic silica beads will
be present in the PCR mixture droplet, and the concern about the beads interfering
with qPCR could be ruled out.
40
4.4 Interfacing IPF with DM
The interface between immiscible phase filtration and digital microfluidic droplet
actuaction is the elution buffer reservoir (Fig. 4.3, Fig. 5.4.) The EB reservoir is
the last section of the purification stage (stores the elution buffer) that doubles as
the first section of the PCR preparation stage (stores the eluent and then dispenses
the eluent droplets.) Specifically, during elution nucleic acid-bound magnetic silica
beads are transported to the EB reservoir. Then, due to the low salt condition in the
reservoir, the nucleic acid is released from the beads to the EB. Afterwards, eluent
droplets can be dispensed from the reservoir using DM actuation for the subsequent
PCR mixture preparation.
Despite the simple concept, this interface is critical to the detection limit. Under
the described implementation, the detection limit can be improved by optimizing the
ratio Vreservoir/Vdrop. In principle, by reducing Vreservoir and increasing Vdrop to make
the ratio equal to the number of qPCR reactions to be conducted, e.g., three in the
SeptiFast test, the maximum number of copies of pathogen nucleic acids could be
packed into the eluent droplets for the subsequent qPCR detection. (Vreservoir, Vdrop:
volume of the EB reservoir and the eluent droplet, respectively.)
In practice, however, Vreservoir needs to be sufficiently large to accommodate the
beads and produce high elution efficiency during elution. Also, to perform tempera-
ture zone PCR, maximum Vdrop is limited by the largest droplet volume that can be
reliably transported at the desired velocity using DM actuation. On the other hand,
whole-chip thermocycling would not be subjected to this limit.
As an example, assuming a 100µl sample with 1 copy/µl pathogen nucleic acid
concentration and no purification loss, after eluting to a 10 µl elution buffer the nu-
cleic acid is enriched to 10 copy/µl. Still, a 5 nl droplet dispensed from the EB
reservoir will contain only 0.05 copies of the pathogen nucleic acid, which cannot be
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reproducibly detected by qPCR. On the other hand, by decreasing the reservoir ca-
pacity to 1 µl and increasing the droplet volume to 333 nl (i.e., reduce Vreservoir/Vdrop),
three droplets at 33 copy/droplet can be obtained (as required by SeptiFast), which
is approximately three times the detection limit of a typical qPCR reaction.
Furthermore, a related complication is that with decreasing copies in a droplet
the packing of nucleic acids into a droplet is increasingly influenced by a Poisson dis-
tribution [49, 50]. Hence, increasingly unfavorable detection accuracy and precision
are obtained, especially because the time-sensitive nature of the application does not
permit the qPCR to be repeated. Therefore, Vreservoir and Vdrop ideally should be
sized such that even when presented with a sample that carries the lowest antici-
pated pathogen nucleic acid concentration, sufficient pathogen nucleic acids (e.g., >
20 copies) can still be packed into the eluent droplets.
Since this work represents the initial development of the IPF - DM fluidic device
(and the assays, supporting instruments needed to operate the device), an optimal
IPF - DM interface will not be the emphasis herein. (A related limitation is that, as
requested by the development of the integrated photodetector, the pitch of the DM
electrode has been fixed at 700µm. That is, only Vreservoir could be varied.) However,
the data that are to be collected, such as nucleic acid retention and qPCR detection
limit, would be valuable for optimizing future IPF - DM devices.
4.5 Advantages
The proposed approach is an enhancement to SeptiFast’s proven method of sparse
pathogen detection and paves the way for a highly automated single-chip solution
to sepsis diagnosis. The key to such a fluidic device is the integration of immiscible
phase filtration and digital microfluidic droplet actuation. Hence, as a first step,
this work aims to demonstrate the feasibility of the integration by performing basic
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purification - detection tasks on an IPF - DM fluidic device.
The fluidic device will prepare the PCR mixtures using DM actuation. Since
DM is inherently automated, it minimizes the hands-on time and reduces the chance
of contamination. Importantly, unlike other droplet manipulation techniques, DM
is not limited to actuating of a single droplet. Accordingly, the PCR preparation
stage can be scaled up to support the concurrent execution of several multiplex
qPCR reactions, which is needed to cover the detection of more than two dozens of
infection-causing pathogens. In addition to PCR preparation, DM actuation might
also be used to perform temperature zone PCR. This technique attempts to improve
the temperature ramp rate over whole-chip thermocycling to substantially trim the
PCR time.
Upstream to the PCR preparation stage, IPF will be utilized to purify the nucleic
acid. IPF is suitable because it can process a milliliter-sized sample and output the
resulting purified nucleic acid in a way that is compatible with DM. More impor-
tantly, it transforms the conventional magnetic bead-based purification scheme into
a format that is far more amenable to low-cost automation. For example, the manual
purification in this work could be fully automated using two linear actuators.
In addition to the speedup brought by the automation, a well-tuned IPF reagent
system could attain the necessary degree of purification in appreciably fewer steps
than a typical benchtop solid phase extraction procedure, thereby considerably re-
duces the purification time. This claim is supported by [35], in which the nucleic
acid is purified from whole blood for benchtop qPCR using only one bead snapping
step and without the use of any wash buffer.
Last but not least, although this work will focus on the steps that are subsequent
to the binding of the nucleic acid to the magnetic silica beads, the IPF purification
stage may be expanded to incorporate on-chip binding and on-chip chemical lysis
[38]. Such a fluidic device would be hands-free after mechanical lysis and reagent
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loading, which addresses the long hands-on time issue of the SeptiFast test.
In short, by combining IPF and DM, a “lysis-to-answer” sparse pathogen detec-
tion fluidic device seems to be achievable. In terms of the workflow and the reagents,
this approach intentionally maintains the compatibility with the sepsis diagnosis kit
SeptiFast. However, via automation and the expediting of nucleic acid purification
and qPCR, the hands-on time and the sample-to-answer time should be notably
reduced.
4.6 General Workflow and Device Operation
To illustrate how an IPF - DM fluidic device could be implemented and operated,
the following paragraphs will briefly walk through the general workflow sketched in
Fig. 4.3. To facilitate the discussion, micrographs showing the bead snapping and
the eluent droplet generation processes are shown in Fig. 4.4.
In particular, in Fig. 4.3 notice that the EB reservoir has two functions. First,
it is the last section of the purification stage (stores the elution buffer.) Second, it
is also the first section of the PCR preparation stage (stores the eluent and then
generates the eluent droplets.)
Figure 4.3: Operation of the IPF - DM fluidic device.
1. DNA binding, reagent loading:
As illustrated in Fig. 4.3, following a modified NucliSENS miniMAG protocol,
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Figure 4.4: (a) The magnetic beads were snapped from Wash Buffer 1 to the
immiscible phase. (b) An eluent droplet is dispensed from the EB reservoir with a
minimum amount of the residual beads.
DNA is bound to the magnetic silica beads. Also, the purification reagents
(wash buffers, elution buffer) and the qPCR reagents (master mix, qPCR as-
says) are loaded to the fluidic device.
2. Immiscible phase filtration, washing:
Actuated by an external magnet, the beads are snapped out of the PCR in-
hibitor solution to the immiscible phase. During the snapping, the bead pellet
is encapsulated by the carryover (Fig. 4.4a.) Because it is energetically unfa-
vorable for the aqueous PCR inhibitor solution to enter the immiscible phase,
the volume of the carryover is limited. Later, by dispersing the beads in the
wash buffers, PCR inhibitors in the carryover are digested or diluted. In the
simplified case herein, the PCR inhibitor would be the GuSCN chaotropic salt
that exists in the Lysis/Binding Buffer and Wash Buffer 1 of the miniMAG kit.
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3. Elution:
After the IPF washes, DNA-bound beads are transported to the EB reservoir.
Here, because of the low ionic strength, DNA is released from the beads to the
elution buffer. After a brief incubation, the beads are transported away from
the EB reservoir to prevent the beads from lowering the PCR amplification
efficiency.
4. PCR mixture preparation, qPCR:
Later, after DNA is released from the beads to the elution buffer, an eluent
microdrop is generated (Fig. 4.4b) and then mixed with the PCR reagents using
DM actuation. Finally, the resulting PCR mixture droplets are thermocycled,
and the copy number of the target can be correlated with the thermocycles
needed to reach a threshold fluorescence intensity.
Based on the reported durations and the empirical evidences, estimations of the
sample-to-answer time and the hands-on time are shown in Table 4.1. Assuming a
fully developed fluidic device, the total run time may be reduced from SeptiFast’s
current 6 ∼ 10 hr to 1.5 hr. More importantly, the hands-on time could be trimmed
by 90% to approximately 20 min (mechanical lysis and 5 min reagent loading.)
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Table 4.1: Estimated total run time and hands-on time.
Benchtop IPF+DM
Step Time (hr)
Mechanical lysis 0.25 0.25
Chemical lysis, purification 1.75 ∼ 2.75 0.421
qPCR preparation 1 0.05
qPCR 1.5 0.3 ∼ 0.72
Melting curve 0.5 0.5
Total / hands-on 6 / 3 1.52 / 0.33
1 Reagent loading followed by on-chip chemical lysis, pu-
rification, and elution = 5 + 10 + 5 + 5 min.
2 Temperature zone PCR ∼ whole-chip thermocycling.
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5Development of Assay, Fluidic Device and
Auxiliary System
After pinning down the approach described in Chapter 4, the reactions and the nec-
essary hardware need to be planned and developed before any on-chip validation can
be conducted. An overview of this process is the focus of this chapter. Briefly, in
Sec. 5.1 the selection of the detection target and the evaluation of the qPCR and
purification reagents are discussed. The goal is to identify the suitable reagents to
facilitate the initial testing of the fluidic device. Then, Sec. 5.2 will examine the
main workhorse in the subsequent experiments, the “Gen II” fluidic device. Com-
pared with typical DM devices, the two major differences are the inclusion of the
purification stage and the ability to perform DM droplet actuation at elevated tem-
peratures. Finally, since no commercial turn-key solutions are fully compatible with
the operation of the fluidic device, a qPCR instrument needs to be custom con-
structed. This involves the development of three components: temperature control
system, fiber optic fluorescence sensor, and device holder. Details of the in-house
qPCR instrument will be provided in Sec. 5.3.
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5.1 Assays
The demonstration of on-chip nucleic acid purification and quantification necessitates
three types of reagents: qPCR assay, PCR master mix, and the purification kit. The
purification kit purifies nucleic acids from PCR inhibitors. Then, the purified nucleic
acid is mixed with the qPCR assay and the master mix. Later, the resulting mixture
is thermocycled to perform qPCR. The selection of these reagents is surprisingly
time-consuming. Because the requirements imposed by the integrated photodetector
and the applicability to future experiments must also be contemplated. For exam-
ple, the selection of the detection target needs to account for the possibility of low
retention during the purification procedure. Also, to prepare for the later evaluation
of on-chip lysis, the target ideally should reside in readily available and easy-to-lyse
cells. As for the fluorescent tag on the probe, the fluorophore must be compatible
with an affordable laser and available from the oligomer vendors. Further, the as-
sessment of the master mix is based on the following criteria: short PCR time, high
target concentration in the reaction mix, and no premixed reference dye that may
interfere with the integrated photodetector. The next three sections will detail the
evaluation of the three reagents, and the aforementioned considerations would be
further elaborated.
5.1.1 qPCR Assay
A part of a qPCR reaction mixture is the qPCR assay. It is comprised of two primers
and a fluorophore-labelled probe. Together, the three oligonucleotides define the se-
quence to be amplified and thus detected. This section will first discuss the selection
of the fluorophore. Then, the target and its corresponding assay will be determined
for use in the subsequent on-chip qPCR experiments. Finally, the assumption un-
derlying the conversion from HeLa gDNA weight to Yb8 copy number is explained.
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Dye Selection
It is possible to focus solely on the development of fluidic devices if off-the-shelf qPCR
assays can be employed. Unfortunately, this option is currently infeasible, because
the vast majority of ready-to-use qPCR assays are supplied with the fluorophore
FAM (494/518 nm), whereas the integrated photodetector is being developed for
HEX (absorption/emission peak = 535/553 nm.) This choice is primarily attributed
to the preference of using the low-cost 532 nm laser diode as the excitation source.
In addition, the selection of the fluorophore on the qPCR probe is also influenced
by the following factors:
• SecureSeal (Grace Bio-Labs), an alternative gasket material to SU-8, is incom-
patible with red fluorophores such as Cy5 (643/667 nm.)
• The fluorophores designed to be excited with UV light generally have a much
larger Stokes shift than the aforementioned fluorophores, e.g., Alexa Fluor 350
(346/442 nm.) The large Stokes shift substantially reduces the difficulty of
suppressing the pump before it reaches the integrated photodetector (Fig. 2.3.)
Still, UV excitation might interfere with PCR. According to [51], PCR per-
formed with UV-irradiated primers and Taq polymerase is observed to reduce
the detection limit by one order of magnitude.
• The availability of a compatible 3’ quencher.
• While the integrated photodetector is being developed, on-chip qPCR is con-
ducted using the fluorescence sensor discussed in Sec. 5.3.3. Thus, a suitable
filter set (i.e., excitation filter, dichroic beamsplitter, and emission filter) needs
to be available.
• The ideal dye should feature high molar extinction coefficient, quantum yield,
and photostability. In these regards, newer dyes such as ATTO 532 are superior
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to HEX, as can be seen in Table 5.1. Still, although ATTO 532 is used in
Sec. 5.3.3 to characterize the in-house fluorescence sensor, due to cost reasons
it is not used on the qPCR probe.
Table 5.1: Comparison of two λabs ∼ 532 nm fluorophores.
Dye εmax (M
-1cm-1) Φ
HEX 9.6×104 0.7
ATTO 1.2×105 0.9
Target Selection
Since off-the-shelf qPCR assays are typically only available with FAM, in order to
replace FAM with HEX it is necessary to involve custom qPCR assays. To minimize
the time spent on developing the custom assays, a literature survey was conducted
to locate the assays that are appropriate for this work, and then the probes in the
identified assays were modified with HEX and its corresponding 3’ quencher.
Notably, during the survey the unavailability of FAM indirectly led to an ad-
ditional complication. MGB probe, a variant of the TaqMan probe, is frequently
employed in recent publications. However, MGB probe is only available from Life
Technologies with FAM as the 5’ fluorophore. As a result, MGB probes and the
sequences developed for MGB probes could not be used in this research without
modifications.
At present, two assays designed to detect multicopy/genome targets are identified
to be useful for later experiments: (1) Alu Yb8 detects a 1852 copy/genome human-
specific 176 bp sequence [52, 53]. (2) EC23S857 detects a 6 copy/genome E. coli -
specific 88 bp target [23]. As a comparison, the two targets are located within the
3.2×109 bp human genome and the 4.6×106 bp E. coli K-12 genome, respectively.
Table 5.2 shows the relevant properties of the Alu Yb8 assay. The probe has a
5’ HEX fluorophore, an internal ZEN quencher, and a 3’ Iowa Black quencher. In a
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typical 20 µl reaction that uses the Fast Advanced master mix, the final concentra-
tions of the primers and the probe are 1 and 0.25 µM, respectively. The primer/probe
ratio of 4 is based on [53].
Table 5.2: Alu Yb8 assay.
Type nmole GC (%) MP (◦C) Size (bp) Sequence 5’ → 3’
Primer 1 10 65 59 17 AGTGGCGCAATCTCGGC
Primer 2 10 55 58 22 GTCAGGAGATCGAGACC
ATCCT
Probe 2.5 64 67 25 HEX/AGCTACTCG/ZEN/
GGAGGCTGAGGCAGGA/
IBFQ
Alu Yb8 and EC23S857 were chosen for two reasons. First, multicopy/genome
targets are preferable because the detection limit is proportionally improved. Second,
it seems logical to initiate the development of the fluid device based on an “easy”
target that exists in readily available cells. (HeLa can be obtained from the Duke
Cell Culture Facility.) Subsequently, once the fluidic device is sufficiency developed,
tests can be conducted using a “difficult” but more relevant target. To clarify, an
“easy” target should have a high copy/genome ratio and exist in easy-to-lyse cells.
On the other hand, despite their significantly larger copy/cell ratio, targets in
mitochondrial DNA are thought to be unsuitable. Unlike the aforementioned targets
that feature a fixed copy/genome ratio, targets located in mtDNA have highly vari-
able copy numbers [54, 55]. As a result, the characterization of the detection limit
could be interfered.
Still, a drawback of using Alu Yb8 to model a pathogen DNA target is that back-
ground contamination would be challenging to eradicate or mitigate. Since human
cells are omnipresent and Yb8 has a high copy/genome ratio, any contamination that
exists in the reagents or introduced by the manual procedures such as the reaction
mixture preparation inevitably results in a relatively high background. This issue is
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evident in the No Template Control in Fig. 5.1 (red trace.) Further, as mentioned
on p. 18, in the case of EC23S857 the evaluation of the detection limit might be
impeded by the bacterial DNA contamination in the DNA polymerase.
Yb8 Assay Validation
After the Yb8 assay was selected and synthesized (by Integrated DNA Technologies,
Inc.), qPCR is performed to validate the design and the synthesis. Specifically, the
assay is employed to quantify the Yb8 in the nucleic acids extracted from HeLa
cells using the miniMAG purification kit. The Fast Advanced master mix is used
to prepare the reaction mixtures, and the amplification is run on the ABI 7900HT
benchtop qPCR instrument.
The obtained results are shown in Table 5.3 and Fig. 5.1. Briefly, the calibration
curve derived from the two standards (#1, 2) is utilized to estimate the amount
of Yb8 in the unknown (#3.) Also, #4 is the negative control. In the table, the
expected copy numbers are estimated from the input HeLa gDNA weight (#1, 2, 4)
or PicoGreen dsDNA measurement of the eluent (#3.)
Importantly, the successful amplification suggests that the assay is correctly de-
signed and synthesized. Further, from the aforementioned calibration curve the am-
plification efficiency can be calculated to be 81%. Lastly, although the FAM-labelled
probe is used in this evaluation in order to maintain the compatibility with 7900HT,
the HEX-labelled probe is used in all on-chip qPCR tests in Sec. 6.2.
Table 5.3: qPCR detection of Alu Yb8. Also see Fig. 5.1.
# Ct Measured/expected (copy) Sample
1 12.9 –/1.3×107 Genomic DNA
2 16.6 –/1.5×106 Genomic DNA
3 18.3 5.3×105/3.3×105 NA extracted from cells
4 33.9 5.0×101/0.0×100 No Template Control
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Figure 5.1: Amplification of a 176 bp segment in Alu Yb8. Also see Table 5.3.
Yb8 Copy Number in HeLa
The Alu Yb8 target was chosen because of the high copy/genome ratio, DNA and
cell availability, and the ease of lysing human cells. These attributes should facilitate
the initial development of on-chip lysing, purification, and qPCR.
However, rather than human somatic cells, the current source of Yb8 is HeLa
gDNA. (The exception being the experiment shown in Fig. 5.1, which involves HeLa
cells.) It is thought that the use of HeLa might better ensure the consistency between
the current gDNA-based experiments and the future cell-based experiments, e.g.,
the evaluation of on-chip lysing. This is because HeLa can be affordably obtained
from the Duke Cell Culture Facility. Furthermore, the concentration provided is
sufficiently high (3×105 cell/ml as counted by a hemocytometer) such that it can
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be directly used in on-chip lysing tests, i.e., the cells do not need to be cultured to
higher densities.
Still, the copy number of the Yb8 target in HeLa is not known to be determined.
This is likely because the sequencing of HeLa was only recently completed in March
2013, and the sequence still is not publicly accessible [56]. Consequently, when
converting from HeLa gDNA weight to Yb8 copy number, the same 3 pg/genome
and 1852 copy/genome, as in the case of human somatic cells, are assumed. Hence,
qPCR results that involve the conversion of HeLa gDNA weight to Yb8 copy number
should be interpreted with the aforementioned assumptions in mind.
To summarize, the dye on the probe is selected to be HEX, because its absorption
peak is nearly coincident with the 532 nm output of low-cost laser diodes. Also, it
is one of the stock dyes available from the major oligomer vendors.
Furthermore, the Alu Yb8 assay, which detects a 176 bp sequence that is spe-
cific to the human genome, will be employed to perform on-chip qPCR. Its high
copy/genome ratio should facilitate the initial developments, particularly in the char-
acterization of nucleic acid retention.
Lastly, the current source of Yb8 is HeLa gDNA. The decision to use HeLa gDNA
is essentially to make provision for future on-chip lysing experiments, since HeLa cells
are affordably available on-site.
However, the Yb8 copy number in HeLa is not known to be determined. As a
consequence, in the conversion from HeLa gDNA weight to Yb8 copy number HeLa
gDNA is assumed to be equivalent to human somatic cell gDNA. Thus, it is important
to analyze the subsequent qPCR-derived results with this assumption in mind.
5.1.2 PCR Master Mix
A master mix is composed of the DNA polymerase, dNTPs, and other reagents
that support the function of the polymerase. While any master mix can be used to
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demonstrate the integration of IPF nucleic acid purification and DM reaction mixture
preparation, the comparison of master mixes in this section nonetheless shows that
an appropriate choice can expedite the execution of experiments.
To facilitate the subsequent evaluation of the two master mixes, the differences
between them are summarized in Table 5.4 and Table 5.5. In the calculation of the
maximum sample volume in Table 5.4, a reaction mixture is assumed to contain
two qPCR assays in order to perform a duplex detection: the target of interest
and an exogenous internal positive control. Pre-thermocycling steps include UNG
incubation and polymerase activation. Dwell time refers to the total duration spent
at 60 ◦C and 95 ◦C. Pre-thermocycling time and dwell time are calculated from the
default protocols listed in Table 5.5. The run time is measured on the ABI 7900HT
benchtop qPCR instrument.
Table 5.4: Comparison of master mixes.
QuantiFast Fast Advanced
Max sample volume (µl) 12 (48%) 6 (30%)
Reaction volume (µl) 25 20
Pre-thermocycling steps (min) 5 2.3
Dwell (min) 34 16
Ramping (min) 31 37
Total run time, 45 cycles (min) 70 55
ROX reference dye Optional Premixed
Table 5.5: Default thermocycling profile of master mixes.
QuantiFast Fast Advanced
T (◦C) Time (s) Step
50 120 UNG incubation
95 300 20 Polymerase activation
95 15 1 Denature
60 30 20 Anneal/extend, fluorescence measurement
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QuantiFast qPCR Kit
QuantiFast (Qiagen) is a qPCR kit specifically designed for pathogen detection ap-
plications [57]. Since its master mix occupies a smaller percentage of the volume
of the reaction mixture (20%, versus 50% in the other master mix), a larger sam-
ple volume can be used (12 µl versus 6 µl, see Table 5.4.) Accordingly, at a given
pathogen concentration more copies would present in the reaction mixture, resulting
in an improved detection limit.
In addition to the master mix, the kit also includes a 160 bp synthetic DNA and
its corresponding qPCR assay. As a whole, the synthetic DNA and its qPCR assay
are intended to function as the exogenous internal positive control. By adding the
control DNA to a sample, both purification and amplification can be monitored. In
comparison with detecting Alu Yb8 in HeLa gDNA, this assay offers two advantages
in the context of characterizing the performance of a qPCR system. First, the
quantity of the synthetic DNA in a reaction mix prepared according to the default
protocol is known to be 103 copies. Second, in a measurement of the synthetic DNA,
the contamination of the reagents and the PCR apparatus by human DNA will not
be detected as the background.
Because its master mix is tuned to enhance the detection limit, and the bundled
internal control assay can be repurposed to perform a variety of tests, the QuantiFast
kit was originally selected to run the qPCR experiments. The results that are gath-
ered using the kit include: the initial hands-on experience with qPCR (Fig. 3.2), the
sensitivity of qPCR to the inhibitor GuSCN (Fig. 6.1), and the retention of nucleic
acids (Table 6.4.)
However, during the course of the above investigations, it was found that the
ROX reference dye, as shipped by the vendor, seems to be consistently below the
specified concentration or partially photobleached. To address this issue, it was
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recommended by the Duke DNA Microarray Core Facility to switch to qPCR kits
supplied by the same vendor as the 7900HT instrument, Applied Biosciences/Life
Technologies. Consequently, no further tests were conducted using the QuantiFast
kit.
An additional concern that indirectly contributed to the switch is related to the
fluorophore on the probe. Although the characterization of the fluidic device and
the workflow might rely solely on the internal control assay and the master mix in
QuantiFast, the development of the integrated photodetector demands the flexibility
to change the fluorophore if needed. Since the internal control assay is incapable of
meeting this request, one of the factors that leaded to the use of the QuantiFast kit
ceased to exist.
Fast Advanced Master Mix
To address the problem regarding the ROX concentration in QuantiFast, it was
recommended by the Duke DNA Microarray Core Facility to change to an ABI-
supplied master mix with premixed ROX. Afterwards, a suitable choice was found
to be the Fast Advanced master mix [19]. Because of the two features that will be
discussed in the following paragraphs, it is uniquely attractive to the development of
the fluidic device. Hence, this master mix is employed in conjunction with the Alu
Yb8 assay and HeLa gDNA to perform the majority of the experiments in this work.
Specifically, the first feature that makes this master mix desirable is its ability
to suppress the cross contamination between PCR experiments. This is achieved by
using the enzyme UNG to degrade the dUTP-incorporated amplicons. As can be seen
in Table 5.5, the first step in the thermocycling profile is UNG incubation. During
this step, the dUTP-incorporated amplicons generated by previous amplifications
are degraded into unamplifiable fragments. On the other hand, the DNA template
intended to be amplified in the current PCR is unaffected, since it does not contain
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dUTP. Subsequently, UNG is deactivated during the 95 ◦C polymerase activation
step. Because the replicates of a test are run back-to-back in order to preserve the
quality of the time- and temperature-sensitive reagents, this feature is necessary to
prevent the cross contamination between the replicates.
The second advantage of this master mix is the shortened PCR time. As shown in
Table 5.5, other than the extra UNG incubation time, the durations specified for the
steps are shorter than what are needed for the QuantiFast master mix. For example,
polymerase activation takes 300 s in QuantiFast, but only 20 s in Fast Advanced.
Over the course of 45 cycles, the differences amount to a reaction that is faster by
15 min, or 21%. The shortened PCR time mitigates the structural deterioration of
the fluidic device caused by thermocycling. This is particularly important because
the cast acrylic top plate and the SecureSeal gasket used in the fluidic device are not
rated for sustained exposure to 95 ◦C.
However, the Fast Advanced master mix is not without issues. First, the master
mix as supplied is premixed with the reference dye ROX. Later on, if ROX is found
to interfere with the integrated photodetector, it would be necessary to revert to the
QuantiFast master mix.
Second, test results indicate that both 7900HT and the custom-developed tem-
perature control system are incapable of fully exploiting the potential time saving
offered by the master mix. In the case of 7900HT, the 95 ◦C 1 s/60 ◦C 20 s ther-
mocycle is observed to result in considerable ringing around the two temperature
setpoints. In contrast, the 15 s/30 s thermocycle of QuantiFast produces no notable
oscillations. Consequently, as can be seen in Table 5.4, the Fast Advanced master
mix wastes more time than QuantiFast on ramping and settling to a temperature
setpoint: 6 min/19%. This behavior suggests that the temperature control system
in older qPCR systems such as the 7900HT cannot keep up with the aggressive
thermocycling profile of the Fast Advanced master mix.
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On the other hand, in the case of the custom-developed temperature control
system, conservative temperature ramp rates have to be adopted in order to reduce
the temperature difference between what is experienced by the PCR mixture droplet
and what is sensed by the thermocouple. This issue will be further discussed in
Sec. 5.3.1.
In summary, two master mixes have been evaluated. Each option is found to offer
different advantages.
First, when normalized to the volume of the reaction mixture, QuantiFast accepts
18% more sample volume than Fast Advanced. Thus, QuantiFast should have a bet-
ter detection limit to sparse pathogens. Second, the reference dye is not premixed
into the QuantiFast master mix. Therefore, the characterization of the integrated
photodetector might be done with or without the reference dye in the reaction mix-
ture.
In the case of the Fast Advanced master mix, the UNG/dUTP mechanism greatly
reduces the chance of cross contamination. Further, assuming that the temperature
can be optimally regulated, the shorter thermocycle of this master mix can lead to
substantially faster PCR. In turn, the structural integrity of the fluidic device could
be better preserved.
Although most experiments herein were conducted using Fast Advanced, in prac-
tice both 7900HT and the custom-developed temperature control system are unable
to fully adhere to the specified dwell time. Thus, PCR time is not trimmed by the
anticipated extent. Consequently, the main differences between QuantiFast and Fast
Advanced essentially boil down to the flexibility on the reference dye and the ability
to prevent cross contamination.
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5.1.3 Purification Assay
Two topics will be discussed in this section. First, the reasons behind the selection
of the miniMAG assay are explained. Second, a summary of the on-chip purification
procedure is provided, with an emphasis on outlining the adaptations made to the
default protocol.
Assay Selection
The purification assay is the ensemble of reagents used to perform cell lysis and the
subsequent purification of nucleic acids from the lysate. Here, the employed purifi-
cation assay is bioMe`rieux’s NucliSens line of Lysis Buffer and Magnetic Extraction
Reagents. Together, they are referred herein as the miniMAG assay.
After comparing six bead-based purification kits, miniMAG was selected because
it is designed to lyse and purify by the chaotrope GuSCN and the surfactant Triton
X-100, but without the help of Proteinase K [58]. In contrast to the kits that mandate
Proteinase K treatment at 56 ◦C, miniMAG makes it possible to initiate the testing
of on-chip lysis without the need to add an extra heater. (Although Proteinase K
treatment and other steps such as selective lysing are likely to be needed to optimize
the quality and quantity of the extracted nucleic acids [59, 60].)
Furthermore, it is worth noting that miniMAG, as well as Roche’s SeptiFast,
employs silica beads. Since the binding to silica is nonselective, its adoption by
SeptiFast perhaps implies that the intention is to maximize the collection of nucleic
acids. Then, the identification of pathogen DNA relies on the selectivity provided by
the qPCR assays and the follow-up verification by melting curve analysis. In addition
to SeptiFast, this “selectivity-last” approach is also employed by the newer sepsis
in vitro diagnostic kits such as Prove-it and Verigene (Mobidiag and Nanosphere,
respectively.) Hence, selective binding in a lysate, either DNA- or sequence-specific,
appears to be less preferable.
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A drawback of miniMAG is that the vendor refused to disclose any information
regarding the magnetic silica beads, e.g., diameter and concentration. Still, because
the standard protocol uses 50µl bead slurry to process 200µl whole blood, the binding
capacity might be estimated at 264 ng nucleic acid/µl bead slurry. The value is in line
with 102∼3 ng/µl specified by other bead-based kits (MO BIO UltraClean 15, Bioclone
BcMag Quick DNA, and AMS MagSi-DNA.) Accordingly, the highest concentration
used in the experiments, 1.2 ng/µl, is assumed to be within the capacity.
Summarized Procedure of On-Chip Purification
The procedure outlined below is used in the nucleic acid retention experiment in
Sec. 6.2.2. After walking through the procedure, its major differences to the vendor-
supplied default protocol are itemized and briefly discussed. (The experiment-specific
purification procedures are detailed in Appendix A.)
In the first step, HeLa gDNA is bound to the magnetic silica beads. This is
performed according to the default protocol. Initially, gDNA and then the beads are
added to the Lysis/Binding Buffer. After incubating and centrifuging, the LB Buffer
supernatant is aspirated. The DNA-bound beads are then resuspended with WB1,
i.e., 5 M GuSCN.
The second step loads the reagents to the fluidic device. Similar to what is
shown in Fig. 5.5, prior to an experiment DNA-bead/WB1 and WB3 (two locations)
are loaded to the purification stage, and EB is filled to its reservoir in the PCR
preparation stage.
The third step involves the IPF washes. To perform the first wash, the DNA-
bound beads in WB1 are actuated by an external magnet to WB3. Then, the beads
are repeatedly dispersed and pelletized in WB3. The first wash is concluded by
actuating the beads away from the WB3. Later, the beads are transported to the
second WB3 to conduct the second IPF wash.
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The last step is elution. After the two washes, the beads are transferred from the
second WB3 in the purification stage to the EB reservoir in the PCR preparation
stage. To release the DNA from the beads to EB, the beads are incubated with EB
at room temperature.
The primary differences between the default protocol and the above procedure
are:
• WB1 is designed to digest the proteins that are attached to the beads. However,
the main function of WB1 in this work is to serve as the source of the model
PCR inhibitor, GuSCN.
• WB2 in miniMAG is unused. Initially, this is because the sodium azide in
WB2 interferes with the determination of GuSCN concentration by absorption
spectroscopy (see p. 112.) Afterwards, WB2 is still avoided even for the ex-
periments that do not involve measuring the absorbance. This ensures that
the purification power derived from the absorbance measurement and on-chip
qPCR can be cross-compared.
• Following the discussion in the previous bullet point, when two washes are
needed WB2 is replaced by WB3. As can be inferred from the miniMAG
manual, WB3 and EB seem to have a similar chemical composition. Thus, two
washes in the low ionic strength WB3, rather than one in the default protocol,
is likely to affect the retention of nucleic acids.
• The volume of the reagents is rescaled to be suitable for on-chip operations.
For example, 2 µl EB is used because it is the typical capacity of the reservoirs
in digital microfluidic devices. In turn, since the volume of EB needs to be
sufficiently large to accommodate the beads without having the dispensing of
eluent droplets impeded, a suitable bead/WB1 volume is empirically deter-
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mined to be 4 µl. In addition, 8µl WB3 approaches the maximum volume that
can be reliably placed on the device without risking an accidental coalescence
of the reagents. The combination of the aforementioned volumes was tested in
the experiment in Sec. 6.1.2 before it is used to design the Gen II fluidic device.
• To promote the release of nucleic acids to a small volume of EB, it is generally
recommended to perform elution at 60 ◦C with mild agitation. However, on-
chip elution is run at room temperature. This circumvents the problem of
excessive EB evaporation due to the exposed reservoir (i.e., not sealed by the
top plate) but sacrifices the elution efficiency.
In conclusion, miniMAG is employed as the purification assay because it provides
the possibility to try basic on-chip lysis without the need of a heater. Still, the lack
of information regarding the magnetic silica beads makes certain calculations and
optimizations difficult to perform.
Lastly, it is worth pointing out that even though the optimization of interfacial
tension is crucial for the improvement of purification power, the modification of
miniMAG reagents is intentionally avoided. First, it is interesting to observe how
well the reagents in an off-the-shelf purification kit can be repurposed to perform IPF
washes. Second, the use of fresh, unmodified reagents minimizes the contamination
of nucleic acids.
5.2 Fluidic Device
In addition to identifying the suitable purification and qPCR reagents, the goal
of demonstrating a single-chip solution that combines nucleic acid purification and
detection eventually calls for new fabrication techniques to be developed and new
features to be added to the fluidic device. In essence, the application demands the
fluidic device to be single-use and capable of withstanding 95 ◦C over 1 hr without
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losing the ability to perform DM actuation. Still, although options are known to be
commercially available, it is important to understand that in this case the two re-
quirements can only be tackled with the materials and the instruments that are realis-
tically accessible. Regarding the first requirement, the increased device consumption
is countered by the substantially improved fabrication throughput. This is achieved
by reducing the footprint of the purification stage to improve the device/wafer ratio.
Also, the time-consuming fabrication steps, such as SU-8 photolithography and top
plate CNC milling, are replaced with laser patterning. As for the second require-
ment, it is temporarily addressed by adding a conductive polymer coating to the top
plate. In the next three sections, the aforementioned enhancements over typical DM
devices will be examined.
5.2.1 Layout and Structure
The layout and structure of two fluidic devices will be presented in this section. As
a starting point, the Generation I device was found to suffer from a few drawbacks.
Later on, the identified issues were addressed by the Generation II device.
Generation I Fluidic Device
The first iteration of the fluidic device is shown in Fig. 5.2 and 5.3. The design is
similar to typical DM devices in a sense that all reagents, including the wash buffers,
are enclosed in the device by the gasket and the two parallel plates. Structure-wise,
it is similar to what is illustrated in Fig. 5.6, except for the lack of the PEDOT:PSS
layer at the top plate.
The purpose of the Gen I device was to investigate which designs need to be
improved in order to reliably complete the workflow from reagent loading to thermo-
cycling. Also, it is required to verify the ability to use DM actuation to manipulate
the droplets during and after the thermocycling.
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In particular, as can be seen in Fig. 5.7, it was found that baking a Gen I device,
even at temperatures lower than 60 ◦C, would crack the ITO on the top plate. After
cracking, the ITO loses the necessary conductivity to function as the ground of the
DM actuation voltage. By implication, DM actuation would no longer be possible
after starting the PCR. This issue will be further discussed in Sec. 5.2.2.
Furthermore, the other significant drawback regarding the Gen I design is its
footprint. Since the relevant instruments in the SMIF cleanroom can only process 1
∼ 2 4-inch wafers per run, then at 6 devices/wafer the overall fabrication throughput
is somewhat insufficient relative to the rate that these single-use devices can be
consumed by the experiments. Yet, especially because of the multifaceted nature of
this research, the fabrication time must be minimized. Hence, it was the concern
about the inadequate fabrication throughput that eventually prompted the switch
to the Gen II design.
Generation II Fluidic Device
As shown in Fig. 5.4 ∼ 5.6, the Gen II device is designed based on the evaluation
of manufacturability and usability of the Gen I design. It is this device that is used
in the majority of the experiments discussed in Sec. 6.2. The Gen II device features
three major improvements over the Gen I device: reduced footprint, heat-resistant
top plate, and an on-chip resistive heater. The latter two features will be detailed
in Sec. 5.2.2 and 5.2.3, respectively. Here, the discussion will be focused on the
footprint, layout, and fabrication throughput.
As mentioned previously, the move away from the Gen I design is primarily
due to the concern about the large footprint and the corresponding low fabrication
throughput. Later on, it was realized that the footprint can be effectively trimmed
by modifying the purification stage. Specifically, since the top plate is needed by
DM but not by IPF, the top plate at the purification stage is not essential. By
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Figure 5.2: A sketch showing the layout of Generation I fluidic device. Dotted
line: The transportation of beads during the purification process.
Figure 5.3: Generation I fluidic device. The white particle around the two pipette
ports is the precipitation of GuSCN from WB1.
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Figure 5.4: A sketch showing the layout of Generation II fluidic device. It also
illustrates how the device could be configured to perform the nucleic acid retention
experiment in Sec. 6.2.2.
Figure 5.5: Generation II fluidic device.
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Figure 5.6: Structure of Generation II fluidic device.
removing the portion of the top plate that originally covered the purification stage,
the wash buffers are no longer confined by the 120 µm gasket thickness (compare
Fig. 5.3 with Fig. 5.5.) This way, the same volume of a wash buffer can now be
accommodated in a much smaller area, and the footprint occupied by the purification
stage is considerably reduced.
As part of the redesign, the number of IPF washes needed to purify the nucleic
acids from the PCR inhibitor 5 M GuSCN has been estimated to be one (refer to
Sec. 6.1.) Thus, as illustrated in Fig. 5.4, the purification stage of the Gen II device
is designed to be capable of holding three reagents: DNA-bead/WB1 and two WB3.
Moreover, the layout rearrangement resulting from the revising of the purification
stage permits the incorporation of an extra reservoir and an on-chip resistive heater
without penalizing the device area. The two additions enable more sophisticated
tests to be conducted. In particular, the heater and the DM electrodes are located
at the same 100 nm Cr layer in Fig. 5.6. Since the heater is patterned in the same
lift-off step as the DM electrodes, the inclusion of the heater does not require any
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extra fabrication step.
Still, improving the fabrication throughput of the bottom plate is inconsequential
if the throughput of the top plate is not correspondingly raised. To this end, as
part of the development of the Gen II device, the patterning of the cast acrylic top
plate is changed from CNC milling to laser cutting. This change of manufacturing
method markedly reduces the fabrication time of the top plate. Whereas CNC milling
approximately produces 6 top plates per 2 hr run, laser cutting is capable of at least
60 plates per 1 hr run. Although the rate of top plate fabrication is largely limited
by the capacity of the ITO sputtering instrument, laser cutting nonetheless brings a
significant time saving.
Overall, the number of devices that can be fabricated on a 4-inch silicon wafer is
increased from 6 to 11. The much-improved fabrication throughput is crucial because
the experiments do not permit the devices to be reused. On the down side, since
the Gen II device is not fully sealed, the chance of contaminating the reagents is
increased. This issue will be further explored in Sec. 6.3.2.
5.2.2 Heat-Resistant Plastic Top Plate
As can be seen in Fig. 5.7, baking at moderate temperatures is discovered to crack
the ITO on the top plate. This seems to be due to the mismatch of linear ther-
mal expansion coefficients between the ITO and the underlying acrylic substrate
(Table 5.6.)
Table 5.6: Coefficient of linear thermal expansion and heat distortion temperature
of the materials used at the top plate.
Material CTE (10-6/◦C) Heat distortion (◦C)
ITO 8.5 ∼ 10.2
Quartz ∼ 1
Polycarbonate 37 128
Cast acrylic 70 110
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After cracking, the ITO loses the necessary conductivity to function as the ground
of the DM actuation voltage. In other words, with the common ITO/acrylic top
plate, it becomes impossible to use DM actuation to manipulate the droplets as soon
as the PCR is initiated. This is problematic because without DM actuation holding
the PCR mixture droplet in place, it is likely to drift away from the sensing area
of the fluorescence sensor. Hence, the construction of the Gen II top plate must be
changed to make it sufficiently heat-resistant to withstand the PCR process.
Figure 5.7: Cracking of ITO after 65 ◦C bake.
Figure 5.8: Cracking of ITO in ITO/PEDOT:PSS after 95 ◦C bake. Despite the
cracking, DM actuation remains functional.
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Criteria for Selecting the Top Plate Substrate
The top plate of a DM device is preferred to be transparent in order to facilitate the
observation of droplet manipulation. Because of this reason, a commonly employed
stack involves a 0.5 ∼ 1 mm plastic substrate sputtered with 70 ∼ 140 nm of the
transparent conducting oxides ITO. (The discussion in this section will omit the
Cytop hydrophobic coating.) The plastic substrate is advantageous in two aspects.
First, it is very cost-effective. Second, it can be patterned on-site using CNC milling
or laser cutting.
Additionally, pertaining to the PCR application, the concern about ITO cracking,
and the fabrication throughput, the substrate of the top plate ideally should also meet
the following criteria:
• High operating temperature, for instance 10 ◦C higher than the typical 95 ◦C
denaturation temperature.
• Minimal CTE mismatch to ITO.
• Compatible with laser cutting, or at least CNC milling.
Regarding the second criterion, it is worth noting that having a minimal CTE
mismatch between the top plate substrate and ITO generally implies that the CTE
of the top plate substrate is also close to the CTE of the bottom plate substrate
(silicon in this case, other typical choices include quartz and Pyrex.) Under this
condition, the two plates should expand and contract by a similar amount during
thermocycling, thereby facilitating the adhesion of the SecureSeal gasket to the two
plates. In turn, the structural integrity of the fluidic device can be improved.
Considering the ultimate goal of integrating the photodetector to the top plate,
the optimum substrate for the top plate should be quartz. However, although meth-
ods that can pattern thick quartz (e.g., 0.5 mm) with the reservoir openings and the
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pipette ports (see Fig. 5.4) are known to be commercially available, none is avail-
able at the acceptable cost and turnaround. Due to this restriction, the top plate
substrate is currently limited to plastics.
Since the use of glass-like materials has been temporarily ruled out, the more
satisfactory choice among the typical transparent plastics remains to be cast acrylic.
For example, even though polycarbonate is capable of operating at higher tempera-
tures and closer to ITO in terms of CTE (Table 5.6), it is more difficult to mill and
incompatible with the laser cutter. Also, compared with cast acrylic, the relatively
common extruded acrylic has a slightly lower operating temperature. Further, it
does not tolerate acetone wash.
Lastly, it is worth mentioning that manufactures are known to be developing a
new generation of transparent and translucent high-temperature plastics. For in-
stance, Solvay Plastics’ polysulfone derivatives are rated at 204 ◦C. While these spe-
ciality/experimental polymers should be a significant improvement over cast acrylic,
their general availability at the desired film thickness is not yet guaranteed.
ITO/PEDOT:PSS/acrylic
Due to the difficulty of patterning the reservoir openings and the pipette ports on
glass-like materials, the substrate of the top plate is currently limited to cast acrylic.
As the problem of ground electrode failure cannot be solved by changing the sub-
strate, attention is shifted to finding an alternative transparent conductive coating, or
a thin-film stack, that can maintain the function as the ground electrode at elevated
temperatures.
To that end, because the use of the conductive polymer PEDOT:PSS had been
briefly attempted in our research group [61], its applicability for cast acrylic plates
was investigated. In terms of thermal stability, this material can withstand at least
170 ◦C [62]. By varying the film thickness, sequence of deposition, and fabrication
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Table 5.7: Top plate sheet resistance (Ω/) vs. baking. Substrate: cast acrylic.
Stack Pre-bake 100 ◦C bake
ITO 2.8 ∞
ITO/PEDOT:PSS 3.0 ∞
ITO/PEDOT:PSS (plasma) 3.0 2.7
method, a viable option is found to be ITO/PEDOT:PSS/acrylic (Fig. 5.6.) Al-
though the PEDOT:PSS layer does not prevent the ITO from cracking (Fig. 5.8),
after a 5 min bake at 100 ◦C the sheet resistance stays unchanged at approximately 3
Ω/ (Table 5.7.) Further, after a fully-assembled and reagent-loaded Gen II device
is thermocycled for 40 cycles, DM droplet actuation is observed to function nor-
mally (Fig. 5.9.) The result from the simulated PCR suggests that until the issue of
patterning quartz can be addressed the ITO/PEDOT:PSS/acrylic top plate should
suffice as the stopgap.
Notably, as can be seen in Table 5.7, oxygen plasma ashing of the acrylic im-
mediately prior to the spin coating of PEDOT:PSS is found to be essential to the
enhancement of temperature tolerance. The behavior might be related to the hy-
drophilicity of PEDOT:PSS.
Later on, the simpler PEDOT:PSS/acrylic top plate was also found to pass the
100 ◦C baking test. However, because it seems preferable to use ITO as a barrier to
minimize the contact of water-soluble PEDOT:PSS with the aqueous reagents, this
construction is not yet used in the on-chip qPCR experiments.
In summary, in the Gen II fluidic device the structure of the top plate is changed
from ITO/acrylic to ITO/PEDOT:PSS/acrylic. Although PEDOT:PSS does not
prevent the ITO from cracking, the conductivity is maintained after a simulated
40-cycle PCR. Interestingly, oxygen plasma ashing of the acrylic immediately prior
to the spin coating of PEDOT:PSS is found to be essential to the enhancement of
temperature tolerance.
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As a temporary solution to the ITO cracking problem, the modified top plate
structure is subsequently used in the on-chip qPCR experiments. Yet, the 80 ◦C
maximum continuous operating temperature implies that under thermocycling con-
ditions the cast acrylic may become a source of PCR inhibitors. Ultimately, a more
thermally stable construction, such as PEDOT:PSS/polysulfone and ITO/quartz,
needs to be developed.
5.2.3 On-Chip Heater
Three topics about the on-chip resistive heater will be overviewed in this section.
First, the decision to use an on-chip heater, rather than an off-the-shelf part, will be
explained. Second, the reason about positioning the heater outside the PCR mixture
Figure 5.9: Counterclockwise from (a) to (d). After 40 thermocycles, a Gen II
device with the ITO/PEDOT:PSS/acrylic top plate remains capable of dispensing
and transporting a Tween 20 droplet.
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preparation stage of the fluidic device would be discussed. Third, the properties of
the developed heater are presented.
On-Chip Heater vs. Off-the-Shelf Heater
From the perspective of demonstrating the ability to combine IPF nucleic acid pu-
rification and DM PCR mixture preparation, on-chip and off-chip heaters are equally
applicable. After a brief period of surveying and testing off-the-shelf heaters, it was
decided to equip the Gen II fluidic device with an on-chip resistive heater. The deci-
sion is based on the three factors that will be explained in the following paragraphs.
First, due to the small footprint of the fluidic device, initial evaluations found
that it is difficult for both a thermocouple and an external heater to maintain a good
thermal contact with the bottom surface of the device. (The top surface is reserved
for observation purposes.)
Second, off-the-shelf heaters with the desired power rating and temperature tol-
erance have a significantly larger thermal mass. Also, it is difficult to incorporate
off-the-shelf heaters without compromising the heat dissipation. Both issues origi-
nate from the fact that commercial heaters are designed to have a constant power
output and stay in thermal equilibrium with the operating environment. Since ef-
ficient heat dissipation is not a concern, to improve their durability these heaters
are generally encapsulated in thick plastic layers. Consequently, most commercial
heaters are unsuitable for thermocycling applications. In contrast, an on-chip re-
sistive heater would be immune from the aforementioned drawbacks because of its
negligible thermal mass.
Third, to prepare for a potential switch from full-chip thermocycling to temper-
ature zone PCR [37], a few small on-chip heaters combined with a large off-chip
thermoelectric cooler placed at the bottom surface of the fluidic device is thought to
be a feasible way to create the necessary hot spots.
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Heater Position
During the transition from 60 ◦C to 95 ◦C and the 95 ◦C dwell in a thermocycle, the
heater generally is at a higher temperature than the PCR mixture droplet. Impor-
tantly, this temperature difference should be minimized because of two reasons. First,
it is related to reducing the PCR time. Second, the less the heater needs to go above
95 ◦C, the more the polymeric materials used in the fluidic device can stay within
their temperature ratings. This matters because although DM droplet actuation is
serviceable during and after a PCR, the temperature involved nonetheless can ap-
proach or slightly exceed the short-term rating of some materials. (Long-/short-term
rating (◦C): cast acrylic 80/90, Parylene C 80/100.)
Fundamentally, the issue of exceeding the rating can only be solved by switch-
ing to the materials that are considerably more expensive and/or more difficult to
process. Thus, pertaining to the materials that are realistically available, the temper-
ature difference between the heater and the PCR mixture droplet must be decreased.
This not only improves the structural integrity of the fluidic device but also mitigates
the concern about the polymeric materials emitting PCR inhibitors.
A straightforward way to reduce the aforementioned temperature difference is
to position the heater near the DM electrode where the PCR mixture droplet is
intended to be placed. However, empirical results indicate that this layout results in
severely compromised heater lifetime, i.e., less than 10 min before failure (Fig. 5.12.)
The phenomenon can be explained by the degradation of Parylene C by the elevated
temperature nearby the heater. The thermal degradation is observed to quickly
puncture the 1.1 µm film (Fig. 5.11a.) As the puncture spreads, the electrolysis
caused by the contact of the heater and the aqueous solution further damages the
Parylene. This positive feedback soon leads to the failure of the heater and the
nearby DM electrodes.
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Since the result suggests that having the heater close to the DM electrodes and
therefore potentially in proximity to the aqueous reagents will unacceptably degrade
the heater lifetime, as a compromise in the final Gen II layout the heater is positioned
outside the PCR mixture preparation stage of the fluidic device (Fig. 5.10.) Because
the liquids cannot get in contact with the heater (Fig. 5.13), no heater at this location
is observed to fail at the relevant current density. In other words, the heater can now
comfortably outlive the typical PCR time.
Still, as in the case of the ITO/PEDOT:PSS/acrylic top plate, this layout should
be considered as a stopgap measure meant to carry the research onwards. Ultimately,
the aforementioned electrolysis problem needs to be addressed, perhaps by replacing
the Parylene C layer with a more thermally robust dielectric, e.g., Parylene HT and
ALD aluminum oxide.
Properties of the On-Chip Heater
After evaluating 48 designs, the heater shown in Fig. 5.11 is incorporated into the
Gen II design. To simplify the fabrication, the heater and the DM electrodes are
located at the same metal layer, as can be seen in Fig. 5.10. This way, no fabrication
step needs to be added to build the heater. However, this choice comes with two
downsides. First, the thickness of the heater cannot be independently tuned. Second,
it is impossible to place the heater directly underneath a DM electrode.
Table 5.8: Properties of the on-chip resistive heater.
Property Value
Dimensions (µm) 180 × 530 × 0.1
Resistance (Ω) 60 (+ 47 pad + 73 contact)
Max current density (A/cm2) 2×106
Typ. current density (A/cm2) ≤ 1.5×106
Typ. power in on-chip qPCR (W) 2 ∼ 12
Max sustainable power (W) 14
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Since the 100 nm e-beam evaporated Cr is surprisingly resistive, the main resistive
element does not need to meander as in the case of the heater pictured in Fig. 5.12.
Instead, a straight trace that is 180 µm wide and 530 µm long is able to provide
60 Ω. Also, the two contact pads are estimated to contribute 47 Ω, and the contact
resistance is unexpectedly high at an estimated total of 73 Ω. Together, the three
amount to 180 Ω, although 160 Ω ∼ 220 Ω has been measured in practice.
(In theory, the external thermocouple in Fig. 5.13 is unnecessary since the heater
itself can function as a Resistance Temperature Detector that correlates resistance
with temperature. Still, localized temperature sensing requires the main heater/sensor
element to be substantially more resistive than the contact pads and the contact re-
sistance, a condition not achieved in this work. Further, on-chip RTD has been
observed to be highly sensitive to moisture and contaminants [63].)
Regarding heater lifetime, when the current density is capped at 1.5×106 A/cm2,
the heater is known to withstand at least 10 simulated PCR tests without failure.
Even though the Mean Time Between Failures is undetermined, for this single-use
device it is sufficient to ensure that the heater can comfortably outlast the duration
of a PCR reaction.
To sum up, an on-chip heater is selected over an off-the-shelf part because of
the guaranteed thermal contact and the negligible thermal mass. Still, placing the
heater near the DM electrodes and hence close to the aqueous droplets is found to
unacceptably compromise the heater lifetime. Because of this concern, the heater
is prevented from contacting any liquids by positioning it outside the PCR mixture
preparation stage of the Gen II fluidic device. At this location, a heater operating
at the relevant current density has never been observed to fail during the course of
a PCR run.
In retrospect, the decision to use an on-chip heater is perhaps too heavily in-
fluenced by the desire to minimize the thermal mass and thus the PCR time. The
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Figure 5.10: Photomask of Gen II fluidic device showing the Cr layer and the
dimensions of the on-chip heater.
Figure 5.11: Used (a) and damaged (b) heater as observed through the top plate.
The elevated temperature around the heater punctured the Parylene, resulting in the
discoloration. To expose the contact pads, the area below the white line is masked
during Parylene deposition.
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Figure 5.12: Placing the heater in close proximity to an aqueous reagent is found to
drastically reduce its lifetime. Blue arrow: Bubble formation due to the electrolysis
of water. This happened because at the onset of the failure, the Parylene stopped to
insulate the heater from the water. Yellow arrow: Punctured Cr and Parylene.
Figure 5.13: Electrical contacts to Gen II fluidic device. To make contact with the
DM ground electrode, an alligator clip will be clamped to the top plate overhang.
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shorter the PCR time, the better the polymeric components, namely the SecureSeal
gasket and the ITO/PEDOT:PSS/acrylic top plate, can be preserved. However, it
was later learned from the tests detailed in Sec. 5.3.1 that the entire thermal “pack-
age” must be extremely well-optimized to take advantage of the reduced thermal
mass. For example, a suboptimal set of PID parameters can easily offset the benefits
that may be brought by an on-chip heater.
5.3 Auxiliary Systems
After the reagents are selected and the fluidic device is designed, the remaining miss-
ing component is the auxiliary systems that are needed to support the operation of
qPCR. As a whole, the auxiliary systems function as a qPCR instrument, which
consisted of a thermocycler, a fluorescence sensor, and a device holder. The tem-
perature control system that executes the thermocycling is designed to have a very
fine-grained control over the temperature ramping behavior at the different phases
of a thermocycle. This feature is implemented as a provision for optimizing the PCR
time. Still, to take full advantage of this feature, it is found that the ramp rate
dependent correlation between the thermocouple reading and the temperature expe-
rienced by the PCR mixture droplet must be well-characterized and repeatable from
device to device. Another auxiliary system is the fluorescence sensor. While waiting
for the integrated photodetector to be developed (Fig. 2.3), a fiber optic fluorescence
sensor has been constructed as an alternative. Other than measuring the fluores-
cence generated by qPCR, the sensor is found to have a few other interesting uses,
e.g., detecting a failing DM electrode and measuring the droplet volume. Lastly, the
device holder is unexpectedly troublesome to develop. A 3D-printed ABS holder,
softened by the elevated temperature, is found to be deformed by the pressure ap-
plied by the spring-loaded SOIC clip. On the other hand, for an aluminum holder
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to be usable, its powerful heat sinking must be suppressed. These complications will
be the subjects of the discussion in the next three sections.
5.3.1 Temperature Control
The temperature control system is responsible for modulating the on-chip heater to
perform thermocycling. At the beginning of this section, an overview of the system
will be provided. Then, a few notable details regarding the temperature measurement
aspect of the system are briefly highlighted. Lastly, the thermocycling performance
and the effects of different temperature ramp rates would be discussed.
System Overview
The temperature control system along with parts of the fluorescence sensing system
are illustrated in Fig. 5.14. The temperature control system relies on the feedback
from the temperature sensor to conduct two functions. First, the system regulates
the on-chip heater to carry out thermocycling. Second, when cooled to a preset
temperature, it will trigger the fluorescence sensing system to perform spectrum
acquisition. (The fluorescence sensing system will be discussed in Sec. 5.3.3.)
Figure 5.14: Temperature control system. The LabVIEW program is also respon-
sible for controlling the laser and the spectrometer based on the feedback from the
thermocouple. Also see Fig. 5.23.
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The LabVIEW program in Fig. 5.14 is composed of two finite state machines:
thermocycler FSM and fluorometer FSM. In particular, the thermocycler FSM con-
trols the on-chip heater using the PID algorithm. Notably, different sets of PID
parameters can be run in a thermocycle. For example, depending on the desired
balance between ramp rate and overshoot, each of the following five phases in a ther-
mocycle might employ its own set of PID parameters: < 80 ◦C → 80 ◦C, 80 ◦C →
90 ◦C, > 90 ◦C, > 70 ◦C→ 70 ◦C, < 70 ◦C. This way, a very fine-grained control over
the temperature ramping behavior can be obtained.
Temperature Measurement
Regarding the temperature sensor, a foil thermocouple is currently used. Among
the surveyed parts, the employed Omega CO1-T is found to be especially suitable
because of its 10 ∼ 20 ms short response time, 0.5 ◦C low limits of error, and the low
thermal mass. Initially, it was attempted to permanently mount the thermocouple
on the device holder. This option is thought to provide more consistent alignment
and thermal contact between the thermocouple and the fluidic device. However,
due to the reasons that will be explained in Sec. 5.3.2, this approach was eventually
abandoned. Instead, as pictured in Fig. 5.15, the thermocouple needs to be aligned
and attached to the bottom of the fluidic device prior to each experiment.
In Fig. 5.15, also note that thermal paste is indispensable to the thermal contact
between the thermocouple and the fluidic device. Without the paste, temperature
crayons indicate that towards the ceiling of the interested temperature range the
device temperature can be underestimated by as much as 55 ◦C.
Lastly, as illustrated in Fig. 5.14, before the temperature data is read into the
thermocycler FSM, the voltage signal produced by the thermocouple is first digitized
at 4 Hz by an analog-to-digital converter. Importantly, cold junction compensation
is handled by the NI USB-TC01 20-bit A/D with a thermistor near the receptacle
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Figure 5.15: Thermocouple taped to the bottom of a Gen II fluidic device. The
thermal paste is applied to enhance the contact between the device and the thermo-
couple.
of the thermocouple connector.
Thermocycling Performance
A comparison of the thermocycling performance is presented in Table 5.9. Also, the
thermocycles performed using the Fast Ramp (FR) and Slow Ramp (SR) sets of PID
parameters are shown in Fig. 5.16 and Fig. 5.17, respectively. In particular, Fig. 5.16
indicates that the on-chip heater generally outputs between 2 W to 12 W during a
thermocycle.
Table 5.9: Temperature ramp rate and PCR time of ABI 7900HT and the in-house
thermocycler at two ramp rates: Fast Ramp, Slow Ramp.
7900HT FR SR
Per cycle heating/cooling rate (◦C/s) 4.0/2.5 2.3/1.7
Overall ramp rate (◦C/s) 1.4 3.4 1.8
Cycle time (sec) 41 57
PCR time (min)/cycle 55/45 30/40 42/40
Although FR is able to complete 40 thermocycles in 30 minutes (including UNG
incubation 2 min and polymerase activation 20 s), the on-chip qPCR tests conducted
85
50
60
70
80
90
Te
m
pe
ra
tu
re
H°C
L
1180 1200 1220 1240 1260 1280
0
2
4
6
8
10
12
Time HsL
H
ea
te
rO
ut
pu
tHW
L
Figure 5.16: Three thermocycles performed with the “Fast Ramp” set of PID
parameters. The gray trace represents the temperature setpoint. The transient
temperature ramp rate can be visualized by observing the gap between two adjacent
data points.
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Figure 5.17: Three thermocycles performed with the “Slow Ramp” set of PID
parameters. The gray trace represents the temperature setpoint.
using FR were unsuccessful.
A likely explanation might be inferred from the data shown in Fig. 5.19. Briefly,
this experiment involved two thermocouples. The first thermocouple, Tbottom, is
placed at the typical position shown in Fig. 5.15. The other thermocouple, Ttop,
is sandwiched between the two plates of the fluidic device and aligned to the first
thermocouple. (A modified SecureSeal gasket is needed to accommodate Ttop.) In
other words, the two thermocouples are only separated by the 525 µm silicon bottom
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Figure 5.18: Transient temperature ramp rate derived from the data in Fig. 5.16,
5.17. Each dotted line indicates a change of the temperature setpoint.
plate and the thickness added by the thermal paste.
Using the described setup, thermocycles are run with higher and lower ramp
rates, and a thermocycle from each condition is plotted in Fig. 5.19. First, it can be
seen that the temperature difference between the two thermocouples, Ttop - Tbottom,
varies throughout the thermocycle. Second, the temperature difference is larger when
the transient ramp rate is higher. The effect is particularly noticeable by comparing
the behavior near and in the high temperature zone (1 s between the purple bars)
in the two plots.
Because of the different thermal mass, the exact temperature difference values
are not directly relevant to the typical on-chip qPCR. Still, the result suggests that:
(1) at higher ramp rates, Tbottom becomes a lesser indicator of the temperature
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Figure 5.19: In the bottom plot, the ramp rate when approaching the temperature
zones (colored bars) are lowered. Thus, ∆T during the temperature zones is reduced
(colored bars closer to ∆T = 0 ◦C.) Purple/green bars: 1/20 s in the high/low
temperature zone.
experienced by the PCR mixture droplet, Tdrop, (2) the temperature setpoints can
only be correctly set if the correlation between Tdrop and Tbottom is known and more
importantly, repeatable from device to device. The latter is difficult to achieve, in
part because the on-chip heaters are found to vary between 160 Ω to 220 Ω.
Consequently, due to the problems encountered in setting up the high ramp rate
qPCR, the slightly slower SR set of PID parameters is eventually used in the on-
chip qPCR experiments in Sec. 6.2. As demonstrated in Fig. 5.18, SR is specifically
developed to have a lower but more repeatable ramp rate. Additionally, as SR does
not throttle the on-chip heater as aggressively, it seems to be more tolerant of the
aforementioned resistance variation.
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In summary, a thermocycler is constructed in order to accommodate the electrical
and observational requirements of DM devices. A notable feature is that different
PID parameters can be run in different phases of a thermocycle. For instance, the
initial ramp up from 60 ◦C to 95 ◦C may prioritize the heating rate, but from 80 ◦C
onwards different parameters might be used to reduce the overshoot. The fine-grained
control over the temperature ramping behavior will facilitate the improvement of
PCR time.
However, the correlation between the thermocouple reading and the temperature
experienced by the PCR mixture droplet is challenging to characterize under relevant
conditions, i.e., thermocycling with an unmodified fluidic device and without extra
thermocouples attached.
Since the issue of correlation is found to be more pronounced at high ramp rate,
a more conservative set of PID parameters is currently used to leave room for the
uncertainties in temperature setpoints and heater resistance variations. Ultimately,
the obtained data suggests that with further optimizations the thermocycler would
be able to complete a 40-cycle PCR in under 30 min.
5.3.2 Device Holder
The primary purpose of the device holder is to anchor the spring-loaded SOIC clip
that makes contact with the DM electrode contact pads. In addition, as part of the
chip-to-world interface, other application-dependent functions are frequently incor-
porated into a device holder, e.g., to expedite or to improve the repeatability of the
pre-experiment procedures. In this section, the attempt to incorporate the fluidic
device - thermocouple aligner into the 3D-printed ABS device holder will be first
discussed. Then, the complications associated with aluminum device holders will be
overviewed.
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3D-Printed Holder with Fluidic Device-Thermocouple Aligner
In addition to anchoring the SOIC clip that makes contact with the DM electrode
contact pads (Fig. 5.22), 3D-printing permits more sophisticated device holders to be
designed. For instance, an aligning mechanism can be incorporated into the device
holder to ensure the alignment of the thermocouple measurement junction to the
desired position on the fluidic device, e.g., the on-chip heater (Fig. 5.20, 5.21) or a
particular DM electrode (Fig. 5.22.)
In this way, the thermocouple can be permanently mounted on the holder, thus
eliminating the step to tape it to a fluidic device prior to each experiment. The latter
not only decreases the consistency of the alignment, it is also cumbersome to manu-
ally handle the fluidic device through IPF washes with the rigid glass braided wire of
the thermocouple interfering. In addition, as it is unnecessary to align and tape the
thermocouple to the device before an experiment, the possibility of contaminating
the device is reduced.
However, these 3D-printed holders are found to become unusable after a few PCR
experiments. This is because the downward pressure applied by the spring-loaded
SOIC clip to the holder’s device-contacting surfaces would deform the ABS that is
already softened by the elevated temperature, as pictured in Fig. 5.20(d). As the
deformation gradually detaches the thermocouple from the fluidic device, it becomes
increasingly difficult for TTC to match TSP. In turn, the PID algorithm compensates
by deploying the heater at higher power and with longer duration, thereby exacer-
bating the softening of ABS. This positive feedback cycle quickly renders a holder
unusable. (TTC: thermocouple reading, TSP: temperature setpoint.)
Aluminum Device Holder
Since 3D-printed ABS holders are found to deform during thermocycling, aluminum
device holders were used instead. Although aluminum holders do not suffer from the
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Figure 5.20: (a ∼ c) As the fluidic device is mounted onto the holder, the on-chip
heater is self-aligned to the metal junction of the thermocouple. (d) The deformed
holder (arrow) ruined the thermal contact between the device and the thermocouple.
deformation issue, their adoption was not without complications.
First, because of the high thermal conductivity of aluminum, the fluidic device
cannot be directly placed on an aluminum holder. Instead, as demonstrated in
Fig. 5.22, two layers of Kapton tape needed to be applied to the device-contacting
surfaces to mitigate the overly powerful heat sinking. (Thermal conductivity in
W/m·K: 6061-T651 aluminum 167, ABS 0.19.)
The heat sinking effect of the aluminum holder is evident in Table 5.10. In
this experiment, fragments of the temperature crayons were utilized to monitor the
temperature at the PCR mixture preparation stage. For a Gen II bottom plate
mounted on an ABS holder, 8.8 W heater output is able to keep the 93 ◦C crayon
melted. On the other hand, without Kapton insulating the bottom plate from the
aluminum holder, the on-chip heater outputting at nearly its maximum sustainable
power is unable to attain more than approximately 70 ◦C.
In a subsequent evaluation, the effect of the Kapton tape was observed by placing
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Figure 5.21: Aligner (arrow) built-in to the 3D-printed device holder aligns the
on-chip heater to the metal junction of the thermocouple (inset, arrow.)
Figure 5.22: Two layers of Kapton tape are applied to the aluminum device holder
to mitigate the heat sinking. The optical fiber is part of the fluorescence sensor.
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Table 5.10: Heat sinking effect of the aluminum device holder.
Heater (W) Holder Tape (Layer) Behavior
8.8 ABS 0 Sufficient to hold at 95 ◦C.
8.8 Al 0 Sufficient to hold at 60 ◦C.
13.5 Al 0 Only reaches ∼ 70 ◦C.
a second thermocouple in the PCR mixture preparation stage of a modified Gen II
fluidic device, i.e., sandwiched between the two plates. With two thermocouples, the
temperature difference between the heater Theater and the PCR stage Tdrop can be
monitored. In Table 5.11, it can be seen that to attain Tdrop = 95
◦C, without any
tape it takes Theater = 101.5
◦C. In contrast, with two layers of Kapton tape insulating
the fluidic device from the aluminum holder the required Theater is reduced to a more
reasonable 97.5 ◦C. A third layer of Kapton does not discernibly lower Theater any
further. (This test involves a device with a different thermal mass and necessitates
a different set of PID parameters. Hence, the relationship between Theater and Tdrop
described here is not directly applicable to a typical on-chip qPCR experiment.)
Table 5.11: Theater (
◦C) needed to reach Tdrop = 95 ◦C 1 s/60 ◦C 20 s vs. layers of
Kapton tape between the fluidic device and the aluminum holder.
Tape (Layer) Tdrop,60 Tdrop,95
0 63.1 101.5
1 62.7 99.8
2 61.9 97.5
Second, although aluminum holders do not deform and thus do not distort the
alignment and the separation between the fluidic device and the thermocouple, the
approach of permanently mounting the thermocouple on the device holder remains
problematic. For example, the aluminum holder shown in Fig. 5.22 was originally
designed to align the thermocouple to the DM electrode where the PCR mixture
droplet was intended to be positioned. Yet, again because of the high thermal con-
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ductivity of aluminum, this arrangement was found to rapidly sink the heat away
via the device bottom surface - thermal paste - thermocouple - Kapton tape - alu-
minum holder path. Additionally, as a consequence of the heat sinking, the reading
from a thermocouple mounted on Kapton tape/aluminum holder would be a gross
underestimation of Tdrop.
The results suggest that even though mounting the thermocouple on the device
holder is beneficial, in practice it is difficult to implement without a holder made of
a material with a high softening temperature and a suitable thermal conductivity.
In the end, the aluminum holder pictured in Fig. 5.22 was employed in the on-chip
qPCR tests, but its thermocouple seat was unused. Instead, as shown in Fig. 5.15,
the thermocouple needed to be aligned and taped to the bottom surface of the fluidic
device before each experiment.
In summary, 3D-printed ABS device holders cannot be used. Thus is because
the pressure applied by the spring-loaded SOIC clip deforms the ABS that is already
softened by the elevated temperature. Although aluminum device holders do not
suffer from the deformation issue, the high thermal conductivity of aluminum leads
to different complications. For example, a fluidic device cannot be directly placed on
the holder. Rather, in order to mitigate the overly powerful heat sinking, layers of
Kapton tape must be applied to the device-contacting surfaces of the holder. Also,
since it is unsuitable to permanently mount the thermocouple on the aluminum
device holder, now the thermocouple must be aligned and taped to the bottom
surface of the fluidic device before each experiment.
5.3.3 Fluorescence Sensing
Since the aim of this work is to develop a single-chip solution that incorporates
the purification and the detection of nucleic acids, a sensor is needed to analyze
the fluorescence generated by on-chip qPCR. To this end, as a stepping stone to
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the integrated thin-film photodetector, a fiber optic fluorescence sensor has been
custom constructed. The first part of this section will discuss the construction, im-
plementation issues, and the performance of the sensor. Then, three other potential
applications of the sensor that are highly relevant to DM devices will be summarized
in the second part of the section.
Purpose
In parallel with the development of the integrated thin-film photodetector by the Jok-
erst group (Fig. 2.3), an off-chip fiber optic fluorescence sensor has been constructed
and characterized. An off-chip solution was needed because of roadmap-related rea-
sons. Initially, before the development of the thin-film sensor is completed, a fluo-
rescence sensor with consistent performance was necessary to debug on-chip qPCR.
Later on, reproducible on-chip qPCR will in turn serve as a stable platform for eval-
uating the integrated photodetector. Also, the on-chip sensor can be benchmarked
against the off-chip system.
Sensor Construction
Off-the-shelf fluorescence sensing solutions are found to be unsuitable or cost pro-
hibitive for our application, in part due to the complex requirements imposed by the
fluidic and thermocycling aspects of the application. Thus, a fiber optic fluorescence
sensor has been constructed in-house. As illustrated in Fig. 5.23, the sensor consisted
of five major components:
• A 4.5 mW 532 nm collimated diode laser that is directly attached to the filter
cube. Its power supply is controlled by the LabVIEW program.
• A filter cube installed with three filters (532 ± 5 nm excitation filter, 544 nm
dichroic mirror, and 555 nm long-pass emission filter) and two fiber couplers.
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• Two optical fibers: cube-to-device (0.22 NA, 550 µm core) and cube-to-spectrometer
(0.22 NA, 910µm core.)
• A CCD spectrometer that will capture the 360 ∼ 1000 nm spectrum when
triggered by the LabVIEW program.
• A LabVIEW program that, when activated by a separate LabVIEW program
that handles the PID temperature control, will turn on the laser, trigger the
spectrometer, and then turn off the laser. This process is repeated for each
thermocycle.
As an epi-illumination system, in addition to delivering the excitation light to the
PCR mixture droplet, the cube-to-device fiber is also responsible for collecting the
resulting fluorescence (Fig. 5.24.) Since the fiber and the droplet are only separated
by 0.79 mm, collection loss is reduced. (0.79 mm = 0.5 mm top plate + 0.29 mm
gap as spaced by two No. 1 cover slips. The cover slips are removed after the fiber
is positioned.)
Although adequate for the on-chip qPCR tests, the fluorescence sensor currently
suffers from two notable issues:
• No shutter between laser and filter cube: Ideally, the laser should remain on
during the course of an experiment. This way, the laser can reach the thermal
equilibrium to stabilize its optical output. However, since the in-house sensor
does not have a shutter between the laser and the filter cube, leaving the laser
on will rapidly photobleach the dyes in the PCR mixture. To circumvent this
issue, in each thermocycle the laser is only turned on when the thermocouple
is cooled to a setpoint near 60 ◦C. After warming up the laser for 300 ms, the
spectrometer integrates for 300 ms. Then, the laser is turned off 1 ms after the
integration is complete.
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Figure 5.23: Schematic of the custom-built fluorescence sensor.
Figure 5.24: Custom-built fluorescence sensor positioned on Gen II fluidic device.
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• Spectrum averaging incompatible with the needed triggering mode: A method
to improve S/N is spectrum averaging. (Still, as it prolongs the exposure of the
PCR mixture to the laser, the potential S/N improvement needs to be balanced
against the increased photobleaching of the dyes.) In the case of the in-house
sensor, because of a bug in the firmware of the CCD spectrometer, spectrum
averaging cannot be used without changing to a triggering mode that has an
unacceptable timing precision. Hence, spectrum averaging is unperformed in
the on-chip qPCR experiments.
Sensor Performance
Selected attributes of the constructed fluorescence sensor are tabulated in Table. 5.12.
Although some characterizations were performed in conditions different from the final
on-chip qPCR tests, the table nonetheless provides an overview of the sensor’s general
capability.
Table 5.12: Properties of the custom-built fluorescence sensor.
Property Value Note
Optical power 4.4 mW at laser head
4.1 mW at fiber1/top plate interface
Laser optical power stability ±3% as configured in on-chip qPCR
Spectral resolution2 28 nm FWHM as configured in on-chip qPCR
Responsivity3 204 count/nM for ATTO 532 dye4
Detection limit3 0.24 nM for ATTO 532 dye
Sensing area ∼ 700µm fiber butt-coupled to top plate
1 0.39 NA, 1000µm core.
2 Boxcar smoothing: 4 pixels.
3 40 ms integration × 20 averaging.
4 Similar spectral response to HEX, but more resistant to photobleaching.
In particular, during the evaluation of the sensing area (Fig. 5.25), in addition to
measuring the fluorescence generated by qPCR the sensor was found to be useful for
three other tasks. Given their potential significance to DM devices, these alternative
applications will be discussed in the rest of the section.
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Alternative Application 1: Droplet Detection
When the cube-to-device fiber is butt-coupled to the top plate of the fluidic device,
the data presented in Fig. 5.25 indicates that the sensing area is approximately equal
to the area of a DM electrode. Hence, the sensor can be used to detect the presence
of a fluorescent droplet on the DM electrode that is directly underneath the fiber.
Importantly, the detection will not be interfered by the fluorescent droplets at nearby
electrodes.
As can be seen in Fig. 5.25, the sensor positioned above electrode #1 correctly
detected the droplet during t = 1 ∼ 3 s and 6 ∼ 8 s. Also, there is no false positive
during 0 ∼ 1 s and 5 ∼ 6 s, when the droplet is at electrode #22 and #2, respectively.
Because the CCD spectrometer does not employ wavelength scanning, the demon-
stration suggests that droplet detection and composition measurement (i.e., fluo-
rophore type and concentration) might be simultaneously completed in a short spec-
trum acquisition step, e.g., 0.8 s = 40 ms integration × 20 averaging.
Alternative Application 2: Electrode Failure Detection
In addition, if the DM electrode that is underneath the fiber fails, the microbubbles
generated by the electrolysis of an aqueous droplet (at this point the Parylene C in
Fig. 5.6 is already broken) have been observed to cause the detected background flu-
orescence to erratically fluctuate. In other words, at least for this relatively common
failure mode, the fluorescence sensor is capable of detecting a failing DM electrode.
Consequently, it should be feasible to automatically terminate the voltage applied
to the failing DM electrode as soon as the fluctuating background fluorescence is
sensed. This way, the dielectric breakdown can be prevented from cascading to the
neighboring DM electrodes. (An example of the background fluorescence can be seen
in Fig. 5.25.)
Similarly, the presence of a water droplet in the sensing area has been measured
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Figure 5.25: A fluorescent droplet is moved in and out of the fiber sensing area.
Arrows superimposed on the photomask: The path of droplet transportation. In the
bottom plot, each dotted line indicates the start of a droplet actuation step. E.g.,
at t = 3 s the droplet is transported from electrode #1 to #2. Spectrometer: 40 ms
integration, no averaging.
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to increase the detected background fluorescence by approximately 6%. Therefore,
by monitoring the variation in background fluorescence the sensor can even detect
the presence of a non-fluorescent droplet.
Alternative Application 3: Droplet Volume Detection
Another potential use of the fluorescence sensor that is being investigated is the
measurement of droplet volume. Specifically, as long as the spectrum acquisition
time is kept short relative to the droplet velocity (i.e., a relatively low DM actuation
voltage is perhaps preferred in this application), the sensor can resolve the time it
takes for the “tail” of a fluorescent droplet to leave the sensing area (Fig. 5.26.) This
transit time is indicated by the green arrows in Fig. 5.25.
Figure 5.26: The time it takes for the tail of a droplet to leave the sensor field-of-
view (simulated as the dotted circle) may be correlated with the droplet volume.
Accordingly, if the tail of a larger droplet (e.g., a 2x droplet obtained from merging
two 1x droplets) can be shown to take a longer amount of time to leave the fiber field-
of-view, it may be feasible to correlate the transit time with the droplet volume. The
approach is highly advantageous because three types of information can be obtained
at once from a single spectrum acquisition step: droplet volume, fluorophore types,
and fluorophore concentrations.
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Furthermore, by observing the variation in background fluorescence as discussed
in Alternative Application 2, this method might be equally applicable to non-fluorescent
droplets.
In summary, as a stepping stone to the integrated thin-film photodetector, a fiber
optic fluorescence sensor has been constructed. Although hampered by the lack of
a shutter between the laser and the filter cube and a firmware bug that prevents
the use of spectrum averaging, the sensor in its current incarnation is adequate for
on-chip qPCR experiments. In addition to measuring the fluorescence generated
by qPCR, the in-house sensor is able to detect fluorescent droplets, non-fluorescent
droplets, and the microbubbles that are indicative of a failing DM electrode. Also,
droplet volume measurement appears to be feasible. In other words, with further
optimizations applied to the sensor, a single short spectrum acquisition step could
identify the dye types, dye concentrations, and droplet volume - a capability useful
for a wide range of applications.
5.4 Chapter Summary
The progress described in this chapter represents the groundwork for the on-chip
verifications in Ch. 6. These tasks are divided into three categories: assay, fluidic
device, and auxiliary system. The three categories need to work in unison in order to
demonstrate the feasibility of combining IPF nucleic acid purification and DM PCR
mixture preparation on one fluidic device.
A qPCR assay found to be suitable for the on-chip tests is the Alu Yb8 assay. It
detects a human-specific target that has a very high copy/genome ratio, which would
facilitate the debugging of the on-chip protocols in the events of low nucleic acid yield
from on-chip lysis or suboptimal retention throughout the on-chip purification. Later
on, the evaluation of on-chip lysis may take advantage of the on-campus availability
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of HeLa cells. Thus, for the sake of consistency HeLa gDNA is currently used as
the source of Yb8. Still, since the copy number of Yb8 in HeLa in unknown, in the
conversion from HeLa gDNA weight to Yb8 copy number HeLa gDNA is assumed
to be equivalent to human somatic cell gDNA.
The Alu Yb8 assay will be combined with the Fast Advanced master mix to
perform the majority of the qPCR reactions in Ch. 6. This master mix uses the
UNG/dUTP mechanism to prevent the amplicons from contaminating later PCR
reactions. The feature is desirable because the fluidic device is not fully sealed.
Also, its short 95 ◦C 1 s/60 ◦C 20 s dwell times when combined with an optimized
thermal system might substantially reduce a 40-cycle PCR time to approximately 30
min. In turn, the structural integrity of the fluidic device could be better preserved.
Regarding the fluidic device, purification and PCR each presents an issue that
needs to be solved.
First, the design of the purification stage needs to be scalable in terms of the
volume of the purification reagents that can be accommodated. This is overlooked
in the Gen I device, which stores the purification reagents in upsized DM reservoirs
(Fig. 5.2, 5.3.) The resulting large device footprint would necessitate an impractical
amount of fabrication time to meet the consumption of these single-use devices.
Afterwards, recognizing that the purification reagents need not be confined by the
parallel plates, the purification stage of the Gen II device is not covered by the top
plate (Fig. 5.4, 5.5.) No longer squeezed by the 120µm gasket thickness, the reagents
can regain a droplet form. Hence, for a given reagent volume the occupied area is
considerably smaller. Conversely, this “coverless” implementation of the purification
stage could be scaled up more efficiently. With the improvement, the Gen II layout
trims the footprint of the purification stage by 84% and improves the fabrication
throughput by 83%. Importantly, the thermal mass is correspondingly reduced.
This is despite the addition of the third reservoir and the on-chip resistive heater.
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The second issue is related to the ability to perform DM droplet actuation at
elevated temperatures. Without DM actuation to hold the droplet in place during
thermocycling, the slight deformation of the top plate and the gasket will cause the
droplet to drift away from the sensing area of the optical fiber. Yet, because of
the CTE mismatch between the ITO electrode and its polymeric substrate, when
heated the ITO will crack and lose the necessary conductivity to function as the
ground of the DM actuation voltage. This is temporarily addressed by changing the
structure of the top plate from ITO/acrylic to ITO/PEDOT:PSS/acrylic. Although
PEDOT:PSS does not prevent the ITO from cracking, the conductivity is maintained
after a simulated 40-cycle PCR. Notably, oxygen plasma ashing of the acrylic im-
mediately prior to the spin coating of PEDOT:PSS is found to be essential to the
enhancement of temperature tolerance. In the long run, however, a more thermally
stable construction, such as PEDOT:PSS/polysulfone and ITO/quartz, should be
employed.
Other than the two application-oriented improvements that are summarized above,
the usefulness of the techniques developed to reduce the fabrication time of DM de-
vices should not be neglected. Conventionally, the gasket is fabricated using SU-8
photolithography, and the top plate is CNC milled. Both steps are highly time con-
suming and do not necessarily yield the optimal results. For example, thick SU-8 is
prone to cracking during fabrication, and the stiff SU-8 gasket does not adequately
seal the gap between the two plates. To address these concerns, the Gen II fluidic
device uses a SecureSeal gasket and Clarex cast acrylic top plate. With the material
change, laser patterning can now be used to rapidly fabricate the gasket and the
top plate in large quantities. Also, mask-less manufacturing permits the designs to
be modified on-demand. Perhaps more importantly, the SecureSeal gasket, which is
essentially a double-sided adhesive film, was demonstrated to provide a far superior
sealing than the SU-8 counterpart.
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With the reagents selected and the fluidic device designed, the auxiliary systems
still need to be built before on-chip evaluations can be conducted. This is unavoidable
due to the lack of compatible off-the-shelf solutions. As a whole, the auxiliary systems
function as a qPCR instrument, which consists of a thermocycler, a fluorescence
sensor, and a device holder.
At the moment, the thermocycling performance is hindered by the difficulty of
characterizing the ramp rate-dependent correlation between the thermocouple read-
ing and the temperature experienced by the PCR mixture droplet under relevant
conditions, i.e., thermocycling with an unmodified fluidic device and without extra
thermocouples attached. Therefore, a more conservative set of PID parameters is
being used to leave room for the uncertainties in temperature setpoints and heater
resistance variations.
Interestingly, other than measuring the fluorescence generated by qPCR, it seems
feasible to adapt the fiber optic fluorescence sensor for applications such as detecting
a failing DM electrode and measuring the droplet volume. The latter would be a
particularly useful capability for DM systems.
Lastly, it is worth noting that frequently more robust solutions to the encoun-
tered problems are known to exist yet are inaccessible in practice due to budgetary
or turnaround constraints. Therefore, the challenge here is to develop a reasonable
combination of wetware, hardware, and software with the obtainable resources. Al-
though there is certainly room for improvement, as will be demonstrated by the
results presented in Ch. 6, this goal is indeed attained.
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6Experimental Results
This chapter will present the results from the wet experiments. Based on the ex-
perimental method, the chapter is divided into three parts. First, in Sec. 6.1, the
effectiveness of on-chip purification is assessed by off-chip absorbance measurements.
In contrast, in Sec. 6.2, on-chip purification is followed by on-chip qPCR. This is
used to verify the previous estimation of the purification power, and to measure the
retention of nucleic acids throughout the workflow. Importantly, these two experi-
ments demonstrated the feasibility of the proposed IPF - DM integration. Lastly,
the performance of on-chip qPCR is discussed in Sec. 6.3.
Note that each section generally contains an overview of the employed experi-
mental method. Separately, the experimental methods are detailed in Appendix A.
6.1 Estimation of Purification Power
As discussed in Appendix B, PDMS-on-glass devices were initially employed as a
low-cost stand-in to obtain the initial experience with immiscible phase filtration.
PDMS molding, however, is difficult to integrate into the fabrication process of digital
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microfluidic devices. For this reason, the fluidic device detailed in Sec. 5.2 and
other devices of similar construction were developed and used in all subsequent tests.
The IPF- and DM-compatible, high fabrication throughput design provides a stable
platform for more sophisticated experiments. As a first step, Sec. 6.1 will begin to
evaluate the effectiveness of IPF-based on-chip purification.
First, the GuSCN concentration range in the PCR mixture that starts to inhibit
qPCR is determined in Sec. 6.1.1. This is done by gradually increasing the amount
of GuSCN added to the reaction mixture and then observing the resulting variation
of the threshold cycle. In later experiments, a sufficient number of IPF washes has
to be performed in order to lower the inhibitor concentration in the PCR mixture
droplet to below the determined concentration range.
Second, in Sec. 6.1.2, on-chip purification is conducted with a varying number of
IPF washes. Then, by correlating the UV absorption with GuSCN concentration,
the extent of contamination in the simulated eluent can be determined. Here, the
absorbance method is preferred because the data it provides is independent of the
custom-developed on-chip qPCR. Further, by taking advantage of the NanoDrop in-
strument, the absorbance of the microliter-sized eluent generated by the purification
stage of the fluidic device can be directly measured without any dilution.
Combining the results obtained in Sec. 6.1.1 and 6.1.2, the minimum number of
IPF washes needed to attain uninhibited qPCR can be estimated. Afterwards, this
estimation will be tested in Sec. 6.2 with on-chip qPCR.
6.1.1 Effect of GuSCN on PCR
Although convenient for initial evaluations such as Appendix B, food dyes are not
the contaminants typically encountered in qPCR-based diagnosis. Therefore, in the
following studies it was necessary to replace Red 40 with an applicable PCR inhibitor.
To this end, after assessing candidates such as hemoglobin, human serum albumin,
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and fluorescent protein [64, 65], the chaotropic agent guanidine thiocyanate (GuSCN)
was eventually selected.
Primarily, GuSCN is chosen because it is directly relevant to the current workflow:
it exists in Lysis Buffer and Wash Buffer 1 of the miniMAG purification kit (LB
and WB1, respectively.) Between the two buffers, WB1 contains more concentrated
GuSCN at 5 M. Also, WB1 is encountered relatively downstream in the purification
process. Hence, subsequent calculations assume Cinhibitor,in = 5 M.
On the other hand, because reference values are unavailable in the literature, the
PCR inhibiting concentration of GuSCN needs to be determined. This concentration
can be found by raising the GuSCN concentration in the reaction mix until benchtop
qPCR shows a delayed threshold cycle Ct.
Following the experimental method detailed in Appendix A.1, the resulting am-
plification plot is shown in Fig. 6.1, and the Ct - GuSCN relationship is summarized
in Table 6.1. The data indicates that GuSCN starts to impede PCR at 25 ∼ 50 mM
in a reaction mix. In other words, under the relatively ideal benchtop PCR condi-
tions, a purification power of at least 5 M / 25 mM = 200 is needed. Furthermore,
since the initial on-chip PCR will be less optimized than benchtop PCR (for instance,
the polymerase activation step might be too cold or too short to activate all DNA
polymerase), it is expected to be more sensitive to inhibitors. Thus, on-chip PCR
may require a purification power that is somewhat higher than 200. (The 25 ∼ 50
mM range was later found to be in line with the 20 ∼ 40 mM range shown in [66].)
Table 6.1: PCR inhibition by GuSCN.
GuSCN(mM) PCR behavior
≥ 158 No amplification
50 Ct delayed by 3 cycles
≤ 25 Normal
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Figure 6.1: PCR inhibition by GuSCN. Blue: No GuSCN Control (NGC.)
6.1.2 GuSCN Concentration vs. Number of Washes
After selecting the model PCR inhibitor and determining the target purification
power, the next step is estimating the number of on-chip washes needed to attain the
target purification power. However, a method to measure the GuSCN concentration
first needs to be established.
Correlate GuSCN Concentration with UV Absorbance
To evaluate the purification power achieved by on-chip washes, UV absorbance mea-
surement is used to determine the GuSCN concentration. In particular, rather than a
traditional spectrometer, a NanoDrop spectrometer is employed. The key difference
between the two is sample volume. For the former, it is generally required to fill a 1
ml cuvette. In the latter case, a measurement is performed on a 1 ∼ 2 µl droplet.
Since the purification stage of the fluidic device is designed to generate a few mi-
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Figure 6.2: Absorbance spectrum of 1.5 mM GuSCN.
croliters of eluent, on a traditional spectrometer the eluent needs to be diluted by 500
∼ 1000 fold. With such dilution, GuSCN absorbance might become undetectable. In
contrast, the absorbance of the eluent can be directly measured by NanoDrop with-
out any dilution. Consequently, relative to cuvette-based spectrometers NanoDrop
can obtain better GuSCN detection limit and dynamic range.
Shown in Fig. 6.2 is the absorbance spectrum of 1.5 mM GuSCN. Although
the spectrum indicates that the absorbance peaks at approximately 230 nm, in Ta-
ble 6.2 it can be seen that as GuSCN concentration increases the peak absorption
wavelength is red-shifted. This behavior may be related to the shift of chemical
equilibrium towards the left of Eq. 6.1, which in turn causes the apparent molar ab-
sorption coefficient at a given wavelength to become concentration dependent. This
explanation is one of the reasons why the Beer-Lambert law is only valid at “low”
concentrations.
GuSCN −−⇀↽− Gu+ + SCN− (6.1)
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Table 6.2: Peak absorption wavelength vs. GuSCN concentration.
GuSCN (mM) Absorption peak (nm)
0.5 230
5 230
50 241
500 249
5000 262
Figure 6.3: Absorbance - GuSCN standard curve for low and high concentration
range (left and right, respectively.) Each concentration n = 3. Both plots R2 > 0.99.
To overcome this issue, two standard curves are established: a low range curve
that correlates 230 nm absorbance with GuSCN concentration 0.5 ∼ 5 mM, and a
high range curve that correlates 260 nm absorbance with GuSCN concentration 10
∼ 500 mM. The low and high range standard curve are shown in the left and right
of Fig. 6.3, respectively.
GuSCN Concentration vs. Number of Washes
In the above paragraphs, GuSCN concentration is demonstrated to be correlated with
the UV absorbance. Further, the GuSCN concentration in a microliter-sized droplet
can be directly determined, without any dilution, by measuring its absorbance on a
NanoDrop spectrometer.
This is a convenient technique that enables the quantitative comparison of the
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model inhibitor concentration before and after an on-chip wash, i.e., purification
power. Combined with the knowledge about how GuSCN affects qPCR (Table 6.1),
at least in this simplified scenario it becomes possible to estimate the number of
washes needed to obtain uninhibited on-chip qPCR.
Still, since absorbance is not chemical-specific, to use the method to monitor the
GuSCN concentration after a wash it is necessary to ensure that GuSCN is the only
UV absorber that changes its concentration between the washes. Because of this
limitation, in the experiments discussed in Sec. 6.1.2 no nucleic acid is added to
the input. Accordingly, the purification power result presented later in this section
neglects any impact that may be incurred by the presence of nucleic acids, for instance
by making the beads more difficult to disperse in a wash buffer. Thus, the purification
power derived from this set of experiments should be considered as an overestimation.
Similarly, because the sodium azide in Wash Buffer 2 (WB2) of the miniMAG
purification kit is a UV absorber, WB2 is unused. Instead, in addition to WB1 (the
source of 5 M GuSCN) the on-chip purification process involves only Wash Buffer
3 and Elution Buffer. WB3, EB, and 5 cS silicone oil have been tested to show
negligible UV absorbance.
With the purification protocol modified to be compatible with the measurement
of GuSCN concentration, it is then proceeded to evaluate the effectiveness of on-chip
IPF washes.
Briefly, as detailed in Appendix A.2, the experiment consists of three major steps.
First, the magnetic beads suspended in WB1 are actuated by an external magnet
either directly to EB (no wash) or to WB3 (1 ∼ 2 washes.) Secondly, the beads
along with the GuSCN carryover are brought into contact with EB. Third, with the
magnet holding the beads in place, the eluent (i.e., EB contaminated with GuSCN)
is aspirated from the device and subsequently analyzed on NanoDrop.
Following the outlined procedure, absorbance measurements indicate that after 0,
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Figure 6.4: Purification power and GuSCN concentration in eluent vs. number
of washes. Mean and 95% CI (t-distribution) calculated from n = 5, 6, 5 (0, 1, 2
washes, respectively) are labelled.
1, 2 washes the average GuSCN concentrations in the eluent are 131.6, 28.4, 0.8 mM,
respectively. As plotted in Fig. 6.4, the concentrations correspond to purification
power 38, 176, and 6124.
Among the results, there are three aspects that are particularly worth examining.
First, the purification power of the no wash case will be discussed. Second, the
effectiveness of each wash step is assessed. Third, with the addition of these data the
number of washes needed to obtain uninhibited on-chip qPCR can now be estimated.
1. Purification power of the no wash case:
After on-chip washes, as part of the elution process GuSCN is further diluted by
the elution buffer. Hence, even with no on-chip wash GuSCN is still lowered from
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5 M to 131.6 mM.
Although it appears that dilution can be increased to eliminate the need for IPF
washes, the approach is impractical for two reasons. First, with more dilution
less extracted DNA can be packed into the droplets. In turn, the detection limit
(in terms of E. coli per volume of sample, for instance) is impacted. Second,
purification is not only dilution. For instance, when purifying nucleic acids from
blood, the wash buffers are also responsible for digesting the proteins that might
interfere with the downstream PCR.
2. Purification power gained by each wash step:
With one wash, the purification power obtained is 176, which results from
4.6 × 38 (1st wash × dilution.)
With two washes, the purification power obtained is 6124, which results from
4.6 × 35 × 38 (1st wash × 2nd wash × dilution.)
Interestingly, although both washes are performed with the same volume of WB3,
the second wash is significantly more effective than the first (PP2nd = 35, PP1st
= 4.6.) Still, it is unclear if a third wash would be able to provide a higher pu-
rification power than the second wash. This is because the absorbance method is
limited to approximately 0.25 mM GuSCN. As a result, it is incapable of detecting
the GuSCN in the eluent from a three-wash test.
In addition, it is important to note that even though the purification power gained
from the second wash is similar to the purification power resulted from the dilution
of inhibitors during elution (PP2nd = 35, PPelu = 38), as discussed in the previous
bullet point the former does not penalize the nucleic acid concentration in eluent
droplets, which in this approach is the factor that ultimately determines the overall
detection limit.
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3. Number of washes needed to obtain uninhibited on-chip qPCR:
In this section, two important results are presented. Initially, it is shown that
GuSCN must be lowered from 5 M to less than 25 ∼ 50 mM in order not to
inhibit a downstream qPCR reaction. In other words, the purification power
needed is at least 200.
Next, it is demonstrated that one- and two-wash purification respectively generate
176 and 6124 in purification power. On top of this purification power acquired
from the purification process, on-chip PCR mixture preparation should further
generate a purification power of 2. Consequently, the total purification powers
are doubled to 352 and 12248.
(In Sec. 6.2.2, a 1x eluent droplet is merged with a 1x master mix/qPCR assay
droplet to form a qPCR-ready 2x-volume droplet. Correspondingly, GuSCN is
diluted by two fold. In an optimized implementation, however, the purification
power gained from digital microfluidic PCR mixture preparation would be 3. This
is because normally a PCR mixture should be assembled from three droplets:
eluent, assay, and master mix.)
Combining the two data, the subsequent “purification then qPCR” full on-chip
demonstration can be predicted to require only one wash. Still, it is essential to
recall that the estimation might be somewhat optimistic. Because the experiment
it is partially based on neglects the effects of nucleic acids on purification power.
Therefore, it remains to be seen if the margin of purification power, 352 minus
the needed 200, is sufficient to counter the inefficiency factors that have not been
revealed by the investigations so far.
In contrast, two-wash purification seems likely to provide enough margin to safe-
guard against the above concern. Later on, these observations will be validated
in Sec. 6.2.1 by varying the number of washes and then monitoring the changes
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in the threshold cycle of on-chip qPCR.
6.2 Demonstration of IPF - DM Integration
In the previous section, it was estimated that one-wash purification would be suffi-
cient for uninhibited PCR. This estimation will be tested in Sec. 6.2.1 by varying the
number of washes and then observing the corresponding effect on the amplification
curves generated by on-chip qPCR.
After confirming the needed number of IPF washes, the next step is to demon-
strate the feasibility of the IPF - DM integration. This is achieved in Sec. 6.2.2 with
an experiment that involves on-chip purification of the gDNA from the inhibitor so-
lution, PCR mixture preparation via DM actuation, and the quantification of the
retained Yb8 using on-chip qPCR. Further, by utilizing the copy number - threshold
cycle relationship that will be detailed in Sec. 6.3, this experiment also reveals the
percentage of the nucleic acid target that is retained throughout the workflow.
6.2.1 Threshold Cycle vs. Number of Washes
In Sec. 6.1, the PCR inhibiting concentration of GuSCN and the purification power
gained by the IPF washes were determined. Also, by combining the two information,
the number of washes needed to obtain uninhibited on-chip qPCR was estimated.
To recap, one wash was projected to be adequate. However, the estimation is
partly based on the results from benchtop qPCR. Since on-chip qPCR is not yet
optimized, compared with benchtop qPCR it may be less tolerant of GuSCN. Hence,
in practice more purification power than the estimated value might be required.
The goal of this section, therefore, is to verify if one wash is indeed sufficient for
on-chip qPCR. Later on, the number of washes confirmed to be necessary will be
used in the “purification then qPCR” full on-chip demonstration in Sec. 6.2.2.
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Summary of Experimental Method
To facilitate the discussion on the obtained results, the experimental method is sum-
marized in the following paragraphs. A thorough description of the experimental
method is provided in Appendix A.3.
To confirm if one wash is indeed sufficient, the number of washes is varied in order
to observe its effect on the threshold cycle of on-chip qPCR. To this end, all other
variables are fixed. For example, to ensure the purification power obtained here is
in line with the previously measured values, in the purification stage the bead load,
buffer volume, and wash procedure are identical to what were used in Sec. 6.1.2.
Furthermore, the concentrations of reagents and the thermocycling profile are kept
the same in all experiments.
Importantly, in addition to the above parameters, the amount of DNA in the
PCR mixture also has to be consistent across the tests. This is because threshold
cycle is a function of copy number and amplification efficiency. Accordingly, when
monitoring the threshold cycle to detect the change in amplification efficiency (which
is lowered by GuSCN), it is necessary to fix the copy number.
However, since each additional wash inevitably reduces the nucleic acid retention,
if the experiment was started with DNA-bound beads the downstream qPCR would
see the copy number and the amplification efficiency both varying. Then, the change
in threshold cycle cannot be solely attributed to the GuSCN concentration in the
PCR mixture. Therefore, instead of subjecting DNA-bound beads to a varying
number of washes, the copy number here is fixed by adding the DNA directly to
the master mix/qPCR assay solution. This method is viable because the DNA
polymerase is inactive prior to the hot-start step of qPCR.
Other than the tests outlined above, there are two control experiments: no
GuSCN control and no template control (NGC and NTC, respectively.) NGC pro-
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vides a reference threshold cycle that is uninfluenced by GuSCN. In NGC, beads are
not used. Instead, Elution Buffer is directly dispensed as the eluent droplet. On the
other hand, the threshold cycle of NTC indicates the extent of background human
DNA contamination. Therefore, in NTC no DNA is added to the master mix/qPCR
assay solution. Also, similar to NGC, Elution Buffer is directly dispensed as the
eluent droplet.
Ideally, at least three qPCR reactions (excluding replicates) should be concur-
rently performed on a fluidic device: NGC, NTC, and one for the wash test. This
way, the robustness of each threshold cycle datum would be guaranteed by its ac-
companying on-chip positive and negative controls. However, despite the benefits,
this experimental method was not adopted. This is because the current fluidic device
and the fluorescence sensing strategy are somewhat ill-equipped to handle multiple
concurrent qPCR reactions.
As a compromise, each control is run on a separate fluidic device. Also, NGC
and NTC are always run when a new master mix/assay/DNA solution is prepared.
Lastly, it is worth noting that the presence of DNA on the beads may reduce the
actual purification power to below the previously estimated value, for example by
making the beads more difficult to disperse in a wash buffer. However, this influence
is not straightforward to quantify, because the methodological limitation discussed
on p. 112 prevents the purification power measurement and the on-chip qPCR from
being performed simultaneously.
Result and Discussion
Following the experimental method outlined above, on-chip qPCR is performed with
the eluent resulting from 0, 1, and 2 IPF washes. Along with the NGC and NTC,
each of the five types of tests is replicated three times. The obtained amplification
plot is shown in Fig. 6.5, and the threshold cycle data are tabulated in Table 6.3.
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Figure 6.5: Threshold cycle vs. number of washes.
Table 6.3: Threshold cycle vs. number of washes.
Type Average Ct Note
Wash × 0 - No exponential phase.
Wash × 1 22 Ct delayed by 3 cycles.
Wash × 2 19 Ct = NGC.
No GuSCN Control 19 Reference Ct.
No Template Control 24 Background Yb8.
The following observations can be made from the amplification plot:
1. Two-wash purification
It produces effectively the same amplification curve as NGC. In other words, as
estimated, two-wash purification is able to generate enough purification power to
achieve uninhibited on-chip qPCR.
2. One-wash purification
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Compared with NGC, its threshold cycle is delayed by 3 cycles.
Previously, one wash was predicted to provide sufficient purification power, albeit
with a small margin over the needed value: 352 versus 200. However, the estima-
tions done in Sec. 6.1.2 are based on the data gathered using benchtop qPCR, not
on-chip qPCR. Therefore, the reason why one wash performed unsatisfactorily
perhaps can be explained by the consequences of this difference.
First, on-chip qPCR might have a less-than-estimated tolerance for the inhibitors
coming from the purification process. This follows since parts of the overall in-
hibitor tolerance could be consumed by the additional inhibitors introduced by the
PCR stage of the fluidic device. Secondly, a lesser overall inhibitor tolerance itself
is a likely consequence of the unoptimized on-chip qPCR. For instance, inaccurate
temperature setpoints will exacerbate the degradation of DNA polymerases. In
turn, even less DNA polymerases would be able to survive the denaturing effect
of GuSCN.
Thus, as both effects push the demanded purification power to above 200, one
wash quickly becomes inadequate. Meanwhile, two washes, with a purification
power estimated at 12248, appear to have enough leeway to counter the two
effects.
3. No purification
A very weak amplification was detected. Unlike the PCR behavior of other curves,
this trace seems to skip the exponential phase and directly enter a plateau-like
phase. Thus, although the generated fluorescence surpassed the threshold inten-
sity, it did not occur when the reaction was in the exponential phase. As a result,
this test did not yield any valid threshold cycle value.
4. No template control
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Significant amplification is detected in NTC. The result was not unanticipated,
because positive NTC was previously obtained on benchtop qPCR, as can be seen
in Fig. 5.1.
Since the qPCR is intended to detect a 1852 copy/genome target in the human
genome, positive NTC is somewhat unavoidable. Potential sources of the contam-
ination include the reagents, assembling of the fluidic device, and the experiment
setup process. In particular, the steps thought to contribute the most to the
background are reagent loading and IPF purification, during which the reagents
are exposed and in close proximity to the operator.
Currently, the floor of the dynamic range is not limited by the qPCR chemistry or
the fluorescence sensor. Rather, it is determined by the high background human
DNA contamination. Further discussions about the dynamic range can be found
in Sec. 6.3.2.
In sum, to purify the DNA from 5 M GuSCN, one wash is found to result in a
delayed threshold cycle, and two washes are in fact necessary for uninhibited qPCR.
Since each on-chip wash takes approximately twenty seconds, the extra wash
does not significantly penalize the sample-to-answer time. Instead, the most affected
aspects are the floor plan and footprint of the fluidic device, and perhaps more
importantly, nucleic acid retention.
Also, one-wash purification’s deviation from the estimation could be attributed to
the on-chip qPCR having a less-than-estimated tolerance for the inhibitors inherited
from the purification process. This may be due to the extra inhibitors introduced by
the PCR stage taking up the inhibitor budget, and/or the overall inhibitor budget
itself might become smaller because of the suboptimal on-chip qPCR. Either of the
two mechanisms will compromise the amplification efficiency.
Hence, the amplification efficiency of on-chip qPCR will be measured in Sec. 6.3.1.
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Its value would be useful for confirming the reasons why one-wash purification fails
to lead to uninhibited qPCR.
6.2.2 Nucleic Acid Retention
The second IPF - DM experiment has two purposes. First, after confirming the
needed number of IPF washes in Sec. 6.2.1, this experiment will fully demonstrate
the feasibility of the proposed IPF - DM integration. To that end, all steps from the
purification of gDNA from the inhibitor solution to the detection of the nucleic acid
target by qPCR are performed on-chip.
Secondly, by combining the threshold cycle data from this experiment and the
copy number - threshold cycle relationship that will be detailed in Sec. 6.3, the
retention of the nucleic acid target throughout the workflow can be estimated. This
parameter is important because a better retention corresponds to a higher probability
of having more copies of the targets in an eluent droplet, thereby improving the
detection limit.
Summary of Experimental Method
The experiment begins with the off-chip binding of the gDNA to the magnetic sil-
ica beads. In the case of 100% retention, the amount of the gDNA added to the
Lysis/Binding Buffer would lead to 30x/8550 copies of Alu Yb8 in the final PCR
mixture droplet. Next, as part of a suspension with Wash Buffer 1 (WB1), the
beads are transferred via pipetting to the purification stage of the fluidic device.
The amount of the beads loaded to the device is identical to what was used in the
experiment in Sec. 6.2.1. Beyond this step, all procedures are on-chip.
At this point, the goal is to purify the gDNA from WB1, which is essentially a
solution of 5 M GuSCN - a potent PCR inhibitor at high concentration. To attain
the necessary degree of purification (that is, lower the GuSCN concentration in the
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Figure 6.6: NA retention experiment: (a) floor plan and (b) workflow. Dotted
line: During purification, DNA-bound beads are transported by an external magnet.
Dashed line: Microdrops are generated and then transported by DM actuation.
final PCR mixture to a level that can be tolerated by PCR), as suggested by the
result in Sec. 6.2.1 two IPF washes in WB3 are performed. Afterwards, the beads are
transported to the Elution Buffer reservoir (EB.) After a brief incubation, the gDNA
is released from the beads. At the same time, the aqueous carryover that travels
with the beads brings a certain amount of GuSCN to the EB. However, the inhibitor
concentration becomes inconsequential after two IPF washes and two dilutions: with
EB and later with the master mix/qPCR assay droplet.
Subsequently, an eluent droplet and a master mix/qPCR assay droplet are dis-
pensed from their respective reservoir and then mixed together. The dispensing,
transportation, and merging of the two microdrops are achieved using digital mi-
crofluidic actuation. Finally, the auxiliary system is started to thermocycle the PCR
mixture droplet and to monitor the resulting fluorescence.
Fig. 6.6 illustrates the movement of the magnetic beads during the purification
process and the actuation of the two droplets during PCR mixture preparation.
Additional details about the experimental method can be found in Appendix A.5.
Lastly, after summarizing the workflow, it is perhaps worth noting that the rel-
atively high 30x copy number is used primarily because of the concern about the
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ability to confidently discern the retained target from the background in the case of
very low retention. Specifically, with a maximum starting concentration of 30x the
present 0.06x ∼ 30x dynamic range of the on-chip qPCR would correspond to 0.2% ∼
100% retention. Thus, even after provisioning for a ten-fold margin over the floor in
order to confidently differentiate a low retention case from the Yb8 background, the
range of nucleic acid retention that can be measured by the on-chip qPCR remains
rather usable at 2% ∼ 100%. Furthermore, the other reason for using 30x is because
Assumption 1 in Sec. 6.3.2 does not need to be invoked if the retention is within or
close to 3.3% ∼ 100%.
Estimation of Nucleic Acid Retention
Following the outlined procedure, the obtained amplification plot is shown in Fig. 6.7.
Compared with the amplification plot in Fig. 6.5, the spread among the three repli-
cates in Fig. 6.7 appears to be relatively wide. The phenomenon perhaps can be
explained by the different procedures that the gDNA needs to go through before
qPCR. In the Fig. 6.5 case, the gDNA that contains the Yb8 target is premixed with
the master mix and the qPCR assay, loaded to the reservoir, and then dispensed.
As a result, the initial Yb8 copy number in the PCR mixture droplet should be rela-
tively consistent. In contrast, the gDNA here needs to go through binding, washing,
and elution in addition to droplet dispensing. Because these steps are not yet auto-
mated, they are likely to introduce variations to the initial Yb8 copy number, and
thus affecting the amplification curves.
Via the copy number - threshold cycle relationship given in Eq. 6.4, the threshold
cycles in Fig. 6.7 correspond to an average nucleic acid retention of 36%. As the
experiment is structured, the obtained estimation on the retention encompasses all
of the losses occurred throughout the workflow from off-chip binding to on-chip PCR
mixture preparation. The major factors that are suspected to be responsible for
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Figure 6.7: Threshold cycle vs. nucleic acid retention.
lowering the nucleic acid retention are itemized below:
• Binding
– Not all added gDNA are captured by the magnetic silica beads.
• Purification
– Some analytes are left in WB1 and WB3 and thus not transported to the
Elution Buffer reservoir. For example, when the beads are snapped away
from WB3 after an IPF wash, a somewhat small portion of the beads is
observed to remain trapped in WB3.
– DNA detach from the beads during an IPF wash.
– During elution, the release of the DNA from the beads to EB is incomplete.
• PCR mixture preparation
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– An eluent droplet may have a different nucleic acid concentration than
the eluent in the reservoir.
– Nucleic acids might adhere to the surfaces of the fluidic device, for instance
when transporting the eluent droplet to the location designated for the
subsequent thermocycling.
Challenges in Achieving Effective Elution
In particular, optimal retention greatly depends on effective elution. Yet, because
elution is the step that bridges IPF nucleic acid purification with DM PCR mix-
ture preparation, the optimization of the elution protocol and the EB reservoir is
challenging due to the sometimes conflicting requirements. For instance:
• EB volume
– Less improves the detection limit, more improves elution/retention.
– The proposed approach calls for eluting to a small volume of EB to im-
prove the probability of having at least one copy of the target in the eluent
droplets. On the downside, the preference of nucleic acids to unbind from
the silica during elution to certain extent decreases with an increasing
nucleic acid concentration in the eluent.
• Bead volume (pertaining to the current range of EB volume)
– Less improves retention by facilitating mixing during elution, more im-
proves retention in a different way by enhancing the capture of targets.
– Elution is promoted by having an adequate degree of mixing between the
beads and the EB. However, mixing is difficult in the current implementa-
tion because during elution the beads would take up a substantial volume
of the EB reservoir. Although the issue could be addressed by employing
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less beads, this solution limits the ability to use more beads to improve the
probability of capturing the targets and to adjust the binding capacity.
In addition to what are outlined above, elution efficiency is also influenced by
temperature. In the present protocol, elution is conducted at room temperature,
rather than the 60 ◦C generally recommended for eluting to a small volume of EB.
This circumvents the problem of excessive EB evaporation due to the exposed reser-
voir (i.e., not sealed by the top plate, refer to Fig. 5.5) but sacrifices the elution
efficiency and hence, nucleic acid retention.
Lastly, independent of the experiment described in this section, a previous at-
tempt at characterizing the retention of 160 bp DNA indicates that the loss due to
elution is 3.4x relative to the loss due to IPF washes (Table 6.4.) Although the exact
ratio might not be directly applicable to the experiment here, it nonetheless suggests
that the optimization of elution should be a top priority in the effort to improve the
retention.
Table 6.4: Loss of nucleic acid retention due to unoptimized on-chip processes. The
steps labelled with “b” are performed off-chip according to vendor-supplied protocols.
Bind Wash Elute qPCR Relative NA retention
b b b b 1
b on-chip b b 0.88
b on-chip on-chip b 0.47
Demonstration of Feasibility
The overall goal of this work is to demonstrate the feasibility of integrating IPF
nucleic acid purification with DM PCR mixture preparation. Such integration is
important in the context of speeding up the common “lyse, purify, quantify” workflow
because both IPF and DM are inherently amenable to automation.
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Previously, this integration is partially showcased in Sec. 6.2.1 with the “empty”
beads went through a different number of IPF washes and the gDNA essentially
directly added to the PCR mixture droplet. To assess the number of washes needed
to attain uninhibited qPCR, the fixed initial Yb8 copy number ensured that the
on-chip qPCR is only influenced by the GuSCN concentration.
In contrast, in the experiment discussed in this section, the gDNA is purified from
the inhibitor using IPF washes, and then Yb8 in the gDNA is quantified by thermo-
cycling the PCR mixture droplet prepared using DM actuation. While the protocols
and the fluidic device are shown to have room for improvements, the successful am-
plifications nevertheless fully uphold the viability of the proposed integration.
Finally, it should be stressed that although the demonstration is basic, the po-
tentials unlocked by the integration of IPF and DM should not be overlooked. For
instance, lysis and binding implementations already known to be compatible with
IPF purification could be incorporated [35]. Such a system would allow the operator
to walk away after reagent loading. Another possibility is to replace (or augment)
qPCR with other potentially faster multiplex sequence detection methods, such as
the amplification-free, microarray-based approach commercialized by Nanosphere,
Inc. [67].
6.3 Performance of On-Chip qPCR
In this section the focus is shifted to gaining a basic understanding about the present
performance of on-chip qPCR, e.g., the amplification efficiency, the level of back-
ground contamination, and the dynamic range of Alu Yb8 quantification. In par-
ticular, the suboptimal amplification efficiency and the deviation from the predicted
number of IPF washes in Sec. 6.2.1 might be attributed to the same causes. Ad-
ditionally, the implicit assumptions when using the current data for quantification
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purposes are clarified.
6.3.1 Amplification Efficiency
The focus of this section is to determine the amplification efficiency of on-chip qPCR.
At this stage, knowing the amplification efficiency is useful for three reasons. First,
it indicates how well a qPCR reaction is optimized. Second, it is helpful in un-
derstanding why one-wash purification does not comply with the purification power
estimation (Sec. 6.2.1.) Third, it is part of the data that correlates the threshold
cycle with the Alu Yb8 copy number (Sec. 6.3.2.)
As a brief overview, amplification efficiency is defined as:
Cn = Ci(1 + E)
n (6.2)
(Ci, Cn: initial copy number and copy number at cycle n, E: amplification efficiency.)
According to the equation, low efficiency reduces the quantity of amplicons generated
per thermocycle. In turn, more thermocycles would be needed to reach the threshold
fluorescence intensity, resulting in a delayed threshold cycle.
However, in general amplification efficiency is not directly calculated from the
above equation, since this would require an independent method to measure Cn.
Rather, in practice it is determined from the slope of the threshold cycle - initial
copy number standard curve.
To determine the amplification efficiency, on-chip qPCR is initiated after an Elu-
tion Buffer droplet is mixed with a master mix/assay/gDNA droplet. Three final
DNA concentrations are tested: 0x, 1x, and 30x (refer to Appendix A.4 for details.)
For each concentration there are three replicates. In reality, only the 30x experiment
needs to be run. This is because the 0x and the 1x conditions are identical to the
No Template Control and the No GuSCN Control in Sec. 6.2.1, respectively.
In particular, since the goal is to evaluate the on-chip qPCR, on-chip purification
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Figure 6.8: On-chip qPCR amplification efficiency and Yb8 background.
is not involved. Still, for comparison purposes the on-chip qPCR here is configured
in the same way as Sec. 6.2.1. Because of this reason, the DNA is premixed with the
master mix/assay solution, instead of dissolved in the Elution Buffer by itself.
Following the procedure described above, the obtained threshold cycle - initial
copy number data is plotted in Fig. 6.8.
It can be seen that relative to a hypothetical case with 100% amplification effi-
ciency (gray line), on-chip qPCR (black solid line) generates a lower threshold cycle
when the starting copy number is high, and it generates a higher threshold cycle
when the starting copy number is low. This behavior is a symptom of low amplifi-
cation efficiency. The actual efficiency value can be calculated from the slope of the
solid line:
10−1/slope − 1 = 10−1/−4.06 − 1 = 76% (6.3)
That is, on average 1.76 amplicons are generated per template per thermocycle,
rather than the theoretical value of 2. Although the difference seems to be small,
relative to a 100% efficient amplification there will be 98% less amplicons after 30
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thermocycles.
Since 90% ∼ 110% is considered to be typical, the low efficiency suggests that on-
chip qPCR remains to be further fine-tuned. (As a comparison, 81% is obtained on
the benchtop qPCR, see Sec. 5.1.1.) Moreover, the two reasons previously hypothe-
sized in Sec. 6.2.1 to explain why one-wash purification failed to lead to uninhibited
on-chip qPCR can also explain the potential causes of the low amplification efficiency.
Firstly, the low efficiency could be due to the PCR stage introducing its own PCR
inhibitors. These additional inhibitors are not considered in the purification power
estimation, but along with the GuSCN inherited from the purification process the
total amount of inhibitors in a PCR mixture droplet becomes enough to partially
impede the amplification.
Second, the low efficiency seen here might be a result of a substandard thermocy-
cling profile. As an example, if the denaturation step is slightly too long or too hot
(since there is a difference between the setpoints and the temperature experienced by
a PCR mixture droplet), the degradation of the DNA polymerase will be greatly ac-
celerated. This not only directly affects the amplification efficiency, it also facilitates
the inhibitors’ effort to inactivate or denature the DNA polymerase. Accordingly,
the inhibitor tolerance would appear to be weaker.
Notice that the first explanation relates only to the consequences of on-chip pro-
cesses, whereas the root of the second mechanism originates from factors that are
off-chip, e.g., the duration and the temperature setpoint of the denaturation step.
Independent of the two factors that are discussed above, amplification efficiency is
also influenced by the composition of the reaction mixture. For instance, the master
mix and the assay occupy 50% and 5% of the volume of the reaction mixture prepared
according to the standard protocol. In contrast, due to the dilution incurred by the
merging of two droplets, in the reaction mixture prepared on-chip the percentages
and hence the concentrations of the associated reagents (e.g., DNA polymerase,
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dNTPs, primers, probe) are halved. Therefore, the more diluted reagents could be
one of the reasons for the low on-chip amplification efficiency. Fundamentally, this
issue is perhaps best addressed by increasing the concentrations of the chemicals in
the stock solutions. This is feasible for the assay since it is shipped from the vendor
in a lyophilized form. However, it might require switching away from off-the-shelf
master mixes.
Still, amplification efficiency alone cannot pinpoint the primary cause of a sub-
optimal qPCR. Rather, low efficiency merely indicates the presence of issues in the
qPCR chemistry, the thermocycling profile, or both. To improve the efficiency, how-
ever, there are many variables between the two that need to be systematically ex-
amined.
Lastly, it should be noted that in a rigorous investigation of amplification effi-
ciency, the range of template concentration tested should span at least five logs, and
each concentration should have at minimum three replicates. This is recommended
because in Eq. 6.3 a small change in the slope will greatly affect the corresponding
amplification efficiency. However, this level of stringency was not targeted herein,
because the priorities of the fluidic device development are placed on demonstrating
the feasibility of the proposed approach and qualitatively understanding the principal
challenges of implementing the fluidic device and the auxiliary system. For the same
reason, it was opted not to further venture into the investigation of the amplification
efficiency when on-chip purification and on-chip qPCR are both involved, as this will
(among other things) require the binding capacity of the magnetic silica beads to be
first characterized. This obstacle will be further discussed on p. 136.
In sum, in this section the amplification efficiency of on-chip qPCR is estimated
to be 76%. As a comparison, 81% is obtained on the benchtop qPCR, and 90% ∼
110% is considered to be the ideal range. Furthermore, the likely culprits of the
low amplification efficiency can also explain the inability of one-wash purification to
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lead to uninhibited on-chip qPCR. By implication, one wash may become sufficient
if the on-chip amplification efficiency can be improved to the benchtop level. Finally,
the low amplification efficiency could be due to issues with the qPCR chemistry, the
thermocycling profile, or a combination of both. To better pinpoint its cause, in
retrospect it is necessary to vary the number of on-chip washes and then check the
resulting threshold cycle on benchtop qPCR. This way, the estimation of purification
power can be verified independent of the on-chip qPCR.
6.3.2 Limitations of Nucleic Acid Quantification
In the previous section, the threshold cycle - initial copy number relationship was es-
tablished. Other than using its slope to estimate the on-chip amplification efficiency,
the standard curve can also be used to derive the copy number from an obtained
threshold cycle. This method was employed in Sec. 6.2.2 to determine the retention
of the nucleic acid target throughout the workflow. This section, however, will come
back to clarify the assumptions and the limitations when the results gathered so far
are being used for copy number quantification purposes.
Assumptions
To recap, the standard curve obtained in Sec. 6.3.1 is:
Ct = 29− 4.06× log(Yb8 copy) (6.4)
In Sec. 6.2.2, the standard curve was used to quantify the nucleic acid targets that
are retained throughout the workflow and then detected by the on-chip qPCR, i.e.,
nucleic acid retention (see Method C below.) However, because the characterization
of amplification efficiency is preliminary, the use of Eq. 6.4 requires the following
assumptions to be in place:
1. In Method B, the amplification efficiency is constant for copy numbers up to
30x in the PCR mixture droplet.
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2. Method B and C have the same amplification efficiency.
For the ease of comparison, Experimental Method B, C are summarized below:
• Method B: Used in Sec. 6.3.1 to characterize the on-chip amplification efficiency.
Droplet 1: Master mix, assay, gDNA – 1x (B1), 30x (B2), 0x (B3).
Droplet 2: Elution Buffer.
• Method C: Used in Sec. 6.2.2 to characterize the nucleic acid retention.
Droplet 1: Master mix, assay.
Droplet 2: Beads with gDNA suspended in GuSCN→ 2 IPF washes→ elution
→ dispense eluent as Droplet 2 (30x × retention%).
• “1x” refers to 285 copies of Alu Yb8. 1x in the PCR mixture is equivalent to
3.1 copy/nl.
In both cases, Droplet 1 and Droplet 2 are merged to form the reaction mixture, and
then the thermocycling is started. (Further details of the experimental methods are
supplied in Appendix A.4 and A.5.)
Next, the two assumptions are explained and justified.
– Assumption 1
Recall that the amplification efficiency was derived from the threshold cycles of on-
chip qPCR experiments with 1x and 30x starting template concentrations. While
no subsequent tests employ concentrations higher than 30x, later discussions as-
sume the same 76% amplification efficiency for initial template concentrations
lower than 1x. The extrapolation to initial concentrations higher than what are
involved in the standard curve is likely to become problematic approaching 103x,
because PCR can be impeded by template overload, e.g., > 100 ng for a 20µl re-
action using the ABI Fast Advanced Master Mix. In contrast, no similar issue will
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affect the extrapolation to lower template concentrations. Thus, this assumption
is perhaps not unreasonable.
– Assumption 2
Method C is used in Sec. 6.2.2 in the assessment of analyte retention. In Method
C, the gDNA is purified from GuSCN via IPF washes, eluted from magnetic beads,
packed into a microdrop, mixed with qPCR reagents via DM actuation, and then
finally thermocycled.
Essentially, this assumption anticipates that after the two IPF washes in Method
C, the resulting PCR mixture droplet would be sufficiently clear of GuSCN (as in
Method B), and the subsequent on-chip qPCR would not be inhibited.
The assumption is considered to be sensible because of two previously gathered
results. First, it is shown in Sec. 6.2.1 that after two IPF washes, the amount
of GuSCN brought by the (DNA-less) magnetic beads to the Elution Buffer and
in turn to the PCR mixture droplet is insufficient to impede the on-chip qPCR.
Second, two-wash purification is shown in Sec. 6.1.2 to generate significantly more
purification power than what is needed to attain uninhibited qPCR: 12248 ver-
sus 200. On the other hand, it is known that under Method C conditions the
obtained purification power is decreased, while the required purification power
is increased. Nevertheless, given the considerable excess purification power that
could be afforded by two-wash purification, it seems plausible for it to remain
adequate under Method C conditions.
In particular, Assumption 2 is related to the amplification efficiency when on-chip
purification and on-chip qPCR are both involved. In a thorough 5-log evaluation,
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the highest initial copy number that needs to be tested will approach
background×margin over background×max of 100∼4
= 17× 10× 104 = 1.7× 106 copies (= 6× 103x) (6.5)
According to the Eq. 6.4 standard curve, this corresponds to an impractical threshold
cycle of 4. Furthermore, this copy number might require significantly more magnetic
beads than what can be accommodated on the current fluidic device. Because of these
obstacles, this amplification efficiency is challenging to measure at the moment.
After the discussion about the two assumptions, it should be understood that
they are put in place to temporarily plug the gaps in the existing data. In this
function, they enable the calculations of a few performance indicators later in this
section that will allow one to gain some basic knowledge about the approximate
performance of the current system, and more importantly, to identify the issues that
should be addressed with priority in subsequent efforts. Invoking these assumptions
is not ideal. Still, since this work is structured to demonstrate the viability of a
new approach rather than characterize a mature qPCR instrument, it is perhaps
permissible providing that the derived results are analyzed with the two assumptions
in mind.
Yb8 Background
With the assumptions in place and the reasonings behind them clarified, it is now
appropriate to initiate a quantitative discussion about the performance of the current
on-chip qPCR.
First, the background Alu Yb8 level can be determined by using the Eq. 6.4
calibration curve to estimate the Yb8 copy number that corresponds to the threshold
cycle of the No Template Control in Sec. 6.2.1:
23 = 29− 4.06 log Yb8chip
Yb8chip = 17 copies (per 46× 2 nl PCR)→ 184 copy/µl (6.6)
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As a comparison, on the benchtop qPCR the No Template Control shows:
33.9 = 40.5− 3.88 log Yb8bench
Yb8bench = 50 copies (per 20µl PCR)→ 2.5 copy/µl (6.7)
These values include only the contamination incurred by the experiment setup pro-
cess, PCR mixture preparation, and thermocycling. In other words, they do not
include the contamination introduced during nucleic acid purification.
In the case of benchtop qPCR, because the well plate is sealed by an optical
adhesive film, during thermocycling the PCR mixture is protected from further con-
tamination. Thus, the primary source of contamination is the manual PCR mixture
preparation process.
In contrast, because the reservoirs on the fluidic device are exposed, human DNA
that falls into a reservoir during the experiment setup procedure could be subse-
quently packed into the dispensed droplets during on-chip PCR mixture preparation.
In particular, certain steps in the experiment setup procedure, such as thermocouple
attachment, reagent loading, and optical fiber alignment to the PCR mixture droplet,
require the operator to be in close proximity with the reagents and the fluidic device.
Hence, these steps might considerably exacerbate the extent of the contamination.
Furthermore, as shown in Fig. 6.9, dust particles have been observed to enter
the fluidic device through a reservoir and then contact a dispensed droplet during
thermocycling. Accordingly, unlike the sealed wall plate in the case of benchtop
qPCR, a PCR mixture droplet may be further polluted during thermocycling, even
when the droplet is surrounded by the silicone oil medium and has been actuated
away from the potential conduits of nucleic acid contaminants, i.e., the reservoir
openings and the pipette ports. Due to the duration of qPCR, a significant amount
of undesired Yb8 could enter the fluidic device during this period.
As can be expected from the difference in their susceptibility to contamination,
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Figure 6.9: In this sequence of micrographs, a dust particle can be seen to enter
the fluidic device from the reservoir and then contact the microdrop during thermo-
cycling.
in terms of the Yb8 concentration in the final PCR mixture shown in Eq. 6.6 and
6.7, on-chip qPCR indeed has a 74x higher background than benchtop qPCR. On
top of this background, additional Yb8 contamination can also be introduced during
on-chip nucleic acid purification. For instance, since the purification stage of the
fluidic device is also exposed to the operator, unintended sources of Yb8 can be
captured by the magnetic silica beads during the IPF washes and then detected by
the downstream on-chip qPCR. Still, because of the short duration, the amount of
contaminating Yb8 that can be inflicted during the purification process is perhaps
relatively limited.
Off-the-shelf qPCR instruments typically have a detection limit that approaches
sub-ten copies. In comparison, the Yb8 background here is three to five times higher.
The high background would be difficult to eradicate or mitigate, however. Recall that
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the Alu Yb8 target was chosen because HeLa cells and HeLa gDNA are commercially
available. Also, a target with a very high copy/genome ratio was intentionally se-
lected in order to ensure that the demonstration of integrated on-chip purification
and qPCR would not be stalled by substandard lysis or low nucleic acid retention.
On the other hand, the tradeoff is that an elevated Yb8 background can be caused
by, for example, a seemingly trivial number of human cells inadvertently fall into
the Elution Buffer. In fact, at the concentration given by Eq. 6.6, the current back-
ground is equivalent to having only 0.2 somatic human cell in a 2µl reservoir. Due
to this tradeoff, the detection limit is currently constrained by the high background
and not by the qPCR chemistry.
Dynamic Range
The current dynamic range of on-chip qPCR, based on the available data and the
associated assumptions, will be briefly discussed in the following paragraphs and
then compared with that of a typical qPCR reaction. The purpose of this discussion
is to gain a basic understanding about the current state of the on-chip qPCR and
accordingly, identify what need to be improved in future implementations.
The floor of the dynamic range in this case is determined by the threshold cycle
of the No Template Control, i.e., the background human DNA contamination. On
the other hand, one of the factors that limits the ceiling of the dynamic range is the
inhibition of PCR by overly concentrated nucleic acids. However, without making
additional assumptions about the amplification efficiency at higher Yb8 concentra-
tions, the ceiling in this case is constrained by the highest tested concentration.
Following the above discussion, the dynamic range is approximately 5×102, which
ranges from 17 ∼ 8.6 × 103 initial copies in the 92 nl PCR mixture droplet. From
another point of view, after factoring in the 36% retention of DNA (from off-chip
binding to on-chip purification and qPCR, as determined in Sec. 6.2.2), prior to the
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binding step this range would correspond to 2.1 × 103 ∼ 1.0 × 106 copies per ml of
Lysis/Binding Buffer. In turn, 2.1 × 103 copies of Yb8 could be extracted from 0.6
somatic human cells, or in the case of a single copy per genome target amplifying at
the same efficiency, 1.0× 103 cells.
In contrast, most qPCR reactions feature a dynamic range of 105∼7, which ranges
from 10 ∼ 106∼8 copies in a 10 ∼ 25 µl reaction volume. Hence, the dynamic range
of on-chip qPCR at present lags by at least 200 folds. Fundamentally, this is a direct
consequence of the low amplification efficiency.
Furthermore, a potential concern that is related to the dynamic range can be
uncovered by switching the point of view from the initial copy number of the target
to the initial total gDNA concentration.
Specifically, using the aforementioned values as an example, 8.6 × 103 copies of
Yb8 is part of the 14 pg gDNA. In a 92 nl PCR mixture, this equates to 0.2 ng/µl.
Yet, for a 1 copy/genome target, the same number of copies has to come from 26
ng gDNA, which corresponds to 3 and 279 ng/µl for 10µl and 92 nl PCR reactions,
respectively. The latter concentration is substantially higher than the maximum 10
ng/µl recommended by the employed master mix. As a result, when the current
system is used to detect a single copy target, the ceiling of the dynamic range may
be further compressed by the total DNA loading in the PCR mixture.
6.4 Chapter Summary
Chapter 6 begins by determining the PCR inhibiting concentration of GuSCN. This
is done by gradually increasing the amount of GuSCN added to the reaction mixture
and then observing the resulting variation of the threshold cycle. It is found that
GuSCN must be lowered from 5 M to less than 25 ∼ 50 mM. In other words, the
purification power needed is at least 200.
140
Then, the purification power gained by the IPF washes is measured. This is
achieved by correlating GuSCN concentration with the UV absorbance of the elu-
ent generated by the purification stage of the fluidic device. After factoring in the
purification power resulting from the preparation of the PCR mixture droplet, it is
estimated that one- and two-wash purifications generate 352 and 12248 in purification
power, respectively.
Although based on the above purification power estimations it was predicted that
one wash would suffice, on-chip qPCR reveals that in fact two IPF washes are needed.
This may be due to the extra inhibitors introduced by the PCR stage taking up the
inhibitor budget, and/or the overall inhibitor budget itself might become smaller
because of the suboptimal thermocycling profile. Either of the two mechanisms will
compromise the amplification efficiency.
Later, in the characterization of on-chip qPCR the amplification efficiency is
found to be 76%. The value is indeed lower than the 81% obtained with the bench-
top qPCR instrument and the 90% ∼ 110% range that is typically considered to
be optimal, thereby supporting the aforementioned explanations. Additionally, the
dynamic range of on-chip qPCR is shown to be approximately 17 ∼ 8.6× 103 copies
of Yb8 in a 92 nl PCR mixture droplet.
Finally, the average percentage of the nucleic acid target that is retained through-
out the workflow is 36%. The experiment involves off-chip binding, on-chip purifi-
cation of the gDNA from the inhibitor solution, PCR mixture preparation via DM
actuation, and the quantification of the retained Yb8 using on-chip qPCR. There-
fore, the experiment fully demonstrated the feasibility of the proposed IPF - DM
integration.
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7Future Work and Conclusions
7.1 Future Work
After demonstrating the feasibility of IPF - DM integration, there are several imple-
mentation issues that remain to be addressed before more sophisticated experiments
can be reliably conducted.
For instance, due to accessibility reasons, the polymeric materials currently used
on the fluidic device have temperature tolerances comparable to or lower than 95 ◦C,
i.e., Parylene C and the cast acrylic top plate. However, in subsequent revisions
these materials must be replaced with materials that have the appropriate ratings,
e.g., Parylene HT and a glass top plate. Further, all materials should be checked for
the tendency to emit PCR inhibitors under thermocycling conditions.
Another area in need of a major revamping is the thermal aspect of the imple-
mentation. For example, the correlation between the temperature experienced by
the PCR mixture droplet and the temperature sensed by the thermocouple during
a thermocycle is not well characterized. Also, the position of the on-chip heater did
not take into account the heat sinking of the aluminum device holder. These issues
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in turn exacerbate the difficulty of finding a suitable set of PID parameters. Ulti-
mately, to fully optimize the thermal behavior of the system, a predictive thermal
model needs to be established, and thermal imaging would be an indispensable tool
in the development of the model.
In addition, two topics that are unexplored in this work will be discussed below.
First, enhancing the bead - buffer mixing is essential for improving the detection
limit. Second, the possibility of combining IPF with other sequence detection meth-
ods would be considered.
Mixing Enhancement
Thorough mixing of NA-bound beads with the buffers is essential to effective washing
and elution. Yet, all but one [35] of the surveyed publications on IPF conduct washes
and elution when the beads are pelletized. This approach seems to be suboptimal,
because the beads buried inside an agglomerate are only exposed to a limited flux of
reactants [68]. From the integration point of view, ideally a magnetic field gradient
created by on-chip coils [38] or serpentines [69] can be modulated to propel the beads
off the substrate to promote mixing. Still, while such structures can be incorporated
into the bottom plate of the fluidic device, the added fabrication complexity might
be somewhat undesirable.
Instead, as a way to unpack the pellet and agitate the beads without additional
moving parts, an ultrasonic transducer could be positioned at a location deemed to
be effective by finite element modeling. However, low intensity is required to avoid
NA shearing and polymerase denaturation, e.g., 1 W/cm2 [70]. As an alternative,
an extra linear actuator mounted with magnets can be placed on top of the fluidic
device. To agitate the beads, the magnetic field can be manipulated by varying the
relative position of the magnets [35]. Ultimately, improved bead - buffer mixing
would lead to refined purification power and detection limit.
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Alternative Sequence Detection Method
Although qPCR is one of the most mature sequence detection methods, the direct
detection techniques (i.e., amplification-free) in principle could have the advantage in
assay time and system complexity. This is because qPCR is typically time-consuming
and requires sophisticated temperature control and fluorescence sensing systems.
Another issue of qPCR is that the bacterial DNA contamination intrinsic to the
manufacture of the polymerase inevitably interferes with the detection of pathogen
DNA (Sec. 3.1.4.)
Figure 7.1: Variants of Nanosphere’s nanoparticle-based sequence detection
method [71, 72].
As an example, Fig. 7.1a illustrates a direct detection method that utilizes 13 nm
gold nanoparticles (GNP) conjugated with ∼ 200 sequence-specific oligonucleotides
and consists of two main steps. Initially, two GNP - DNA probes (GNP - A and GNP
- B) are hybridized to the DNA target (A’ - target - B’), thus forming the GNP - A -
A’ - target - B’ - B - GNP complex. (A’ is part of the target that is complementary
to A.) Later, the solution is spotted onto a glass slide and illuminated. A positive
detection of the target, in the form of the complexed probes, can then be sensed by
the red shift in the spectrum of the evanescent-induced scatter [71]. An updated
version of this technique, sketched in Fig. 7.1b, eliminated the need for GNP - B by
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pre-binding the slide with the B probe. After washing away the unbound compounds,
the GNP is stained with sliver. As the particle size grows from 13 nm to 0.5 ∼ 1 µm,
the scatter intensity is improved by 103x [73].
The technology outlined above has been commercialized as Nanosphere’s Veri-
gene line of bloodstream infection tests [67]. Even though Verigene is not strictly
amplification-free (since it analyzes the lysate of 350 µl positive blood culture broth),
the example nevertheless shows how direct detection might function.
In this work, the maturity of qPCR is leveraged to provide a relatively predictable
path of development. In the long term, however, the potentials of having IPF working
in conjunction with a (truly) amplification-free sequence detection method must not
be overlooked.
7.2 Conclusions
In the last section of this document, the main objectives of this work and their
corresponding results will be summarized.
Challenges of Sepsis Diagnosis
Septic shock is a severe form of bloodstream infection. Its diagnosis is challenging in
part for two reasons. First, the infection can be caused by more than 50 species of
pathogens. Second, the pathogens might exist in the bloodstream in very low con-
centrations, e.g., less than 1 colony-forming unit/ml blood. Consequently, depending
on the method it might be necessary to analyze 3 ∼ 20 ml of blood. In turn, these
difficulties of identifying the pathogens translate to inadequate and delayed treat-
ments. The median time to receive an effective antimicrobial therapy is 6 hr after
hypotension onset. By then, the survival rate has dropped at an average of 7.6%/hr
to 42%.
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Identification of Suitable Microfluidic Technologies
To address this issue, this work aims to take advantage of the advances in microfluidic
technologies to expedite and automate the detection of sparse pathogens in a large-
volume biofluid. In particular, the diagnostic method evaluated to be most amenable
to the enhancements is magnetic bead-based nucleic acid purification followed by
sequence detection via multiplex qPCR.
Subsequently, the solution is identified to be a fluidic device that integrates immis-
cible phase filtration (IPF) and digital microfluidic droplet actuation (DM, Fig. 4.3.)
IPF utilizes the high interfacial tension at the aqueous/immiscible interface to min-
imize the carryover of PCR inhibitors when the nucleic acid-bound beads are trans-
ported away from the lysate (Fig. 4.4.) Relative to a typical benchtop solid phase
extraction procedure, a well-tuned IPF reagent system could attain the necessary
degree of purification in appreciably fewer wash steps, thereby considerably reducing
the purification time. Also, IPF is far more compatible with low-cost automation.
In addition to purifying the nucleic acids, IPF also scales down the volume to
what can be efficiently manipulated by DM. Thus, after elution DM could be used to
automatically prepare the PCR reaction mixtures (Fig. 4.1), which further reduces
the hands-on time and the chance of contamination. Afterwards, either whole-chip
thermocycling or temperature zone PCR can be employed (Fig. 4.2.) The latter
in particular might substantially trim the PCR time. Notably, unlike the methods
that rely on the magnetic beads to transport the droplets, DM can be scaled up to
concurrently execute multiple multiplex qPCR reactions.
IPF - DM Integration: Demonstration and Characterization
As the first step towards such a sample-to-answer sparse pathogen detection device,
the key result of this work is showing the feasibility of the IPF - DM integration.
As can be seen in Fig. 6.6, the demonstration involves all three steps that are at the
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core of the proposed scheme: (1) Purify the DNA from an inhibitor solution with
two IPF washes. (2) Prepare the PCR mixture droplet using DM actuation. (3)
Perform qPCR to quantify the target.
Further, as summarized in Sec. 6.4, the performance of the current system has
been characterized, including the purification power, amplification efficiency, nucleic
acid retention, and the level of background contamination. The evaluation involved
UV absorbance measurement (Fig. 6.4) and on-chip qPCR (Fig. 6.5, 6.7.) These
results would facilitate the revising of the device design and the protocols. For
instance, the data suggest that future iterations of the fluidic device should employ
the materials with higher temperature ratings that do not emit PCR inhibitors under
thermocycling conditions. Also, to improve the nucleic acid retention, bead - buffer
mixing needs to be enhanced, especially during elution. A system updated with
these improvements would be better suited to validate the qualitative design rules
outlined on p. 41.
Improvements on Device Fabrication
The developed fluidic device features two notable improvements. Importantly, both
are application-agnostic and applicable to the fabrication of other DM devices.
First, the ability to perform DM droplet actuation at elevated temperatures is
obtained with the adoption the ITO/PEDOT:PSS/acrylic top plate (Fig. 5.6.) This
is utilized to maintain the droplet - sensor alignment during thermocycling. Interest-
ingly, oxygen plasma ashing of the acrylic immediately prior to the spin coating of
PEDOT:PSS is found to be essential to the enhancement of temperature tolerance
(Table 5.7.)
Second, the fabrication time is markedly reduced by laser patterning the Clarex
cast acrylic top plate and the SecureSeal gasket (Fig. 5.5.) The mask-less manufactur-
ing also permits the designs to be modified on-demand. In contrast, the conventional
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thick SU-8 gasket is time-consuming to fabricate, crack-prone, and provides lesser
sealing.
Construction of Auxiliary Systems
Temperature control and fluorescence sensing systems are needed to support the ex-
ecution of qPCR. However, because off-the-shelf solutions are either incompatible or
unaffordable, significant effort was spent on constructing the auxiliary systems that
are uniquely suited for the operation of the custom fluidic device. Briefly, the temper-
ature control system permits different PID parameters to be run in different phases
of a thermocycle (Fig. 5.14.) This fine-grained control over the balance between fast
ramping and reduced overshoot is a provision for refining the PCR time and ampli-
fication efficiency. Additionally, other than measuring the fluorescence generated by
qPCR, it seems feasible to adapt the fiber optic fluorescence sensor to estimate the
droplet volume (Fig. 5.23 ∼ 5.26.) This method might replace lens - camera-based
droplet observation in an application that demands a tight package.
Estimation of Sample-to-Answer Time
Finally, to reiterate the main advantage of the selected approach, an assessment of
the sample-to-answer time is provided in Table 7.1. With a fully evolved IPF - DM
fluidic device, current evidences indicate that the total run time might be reduced
from the present 6 ∼ 10 hr to 1.5 hr. More importantly, the hands-on time could be
trimmed by 90% to approximately 20 min (mechanical lysis and reagent loading.)
These differences may ultimately improve the survival rate of septic shock from 42%
to 70%.
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Table 7.1: Estimated total run time and hands-on time.
Benchtop IPF+DM
Step Time (hr)
Mechanical lysis 0.25 0.25
Chemical lysis, purification 1.75 ∼ 2.75 0.421
qPCR preparation 1 0.05
qPCR 1.5 0.3 ∼ 0.72
Melting curve 0.5 0.5
Total / hands-on 6 / 3 1.52 / 0.33
1 Reagent loading followed by on-chip chemical lysis, pu-
rification, and elution = 5 + 10 + 5 + 5 min.
2 Temperature zone PCR ∼ whole-chip thermocycling.
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Appendix A
Experimental Methods
A.1 Effect of GuSCN on PCR
In Sec. 6.1.1 the following procedure is used to determine the PCR inhibiting con-
centration of GuSCN.
The experiment takes advantage of the synthetic internal control (IC) DNA and
its corresponding assay that are included in the Qiagen QuantiFast PCR + IC kit.
Following the vendor-recommended protocol, each 25 µl PCR reaction mixture con-
sists of 5 µl master mix, 2.5 µl IC assay, 2.5 µl IC DNA (103 initial copies), 0.5 µl ref-
erence dye ROX, 12 µl nuclease-free water, and 2.5 µl GuSCN solution. The GuSCN
solutions are separately prepared by diluting Wash Buffer 1 in the miniMAG purifi-
cation kit with nuclease-free water to the desired GuSCN concentration. The final
GuSCN concentrations tested are 0.05, 5, 15.8, 25, 50, 158, 250, and 500 mM. In ad-
dition, there are two controls: the positive control that does not contain GuSCN, and
the No Template Control that does not contain the IC DNA and GuSCN. Nuclease-
free water is added to the controls to maintain the 25 µl reaction volume. For each
condition there were three replicates.
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After the reaction mixtures are loaded to a 96-well plate, the plate is sealed
with an optical adhesive film, centrifuged briefly at 1500 RPM, and inserted into the
benchtop qPCR instrument ABI 7900HT. Throughout the preparation, the exposure
of the reagents to light is minimized. Further, before pipetting the reagents are always
vortexed to ensure homogeneity. Finally, qPCR is initiated with the thermocycling
profile: polymerase activation 95 ◦C 5 min, and then 95 ◦C 15 s/60 ◦C 30 s for 45
cycles.
A.2 GuSCN Concentration vs. Number of Washes
In Sec. 6.1.2 the device and the procedure described below are used to generate the
eluent for the subsequent absorbance measurement on the NanoDrop spectropho-
tometer.
Device: The device used in this test is an interim implementation of what is later
developed into the purification stage of the fluidic device discussed in Sec. 5.2. As
shown in Fig. A.1, it consists of a laser-patterned double-sided adhesive film (120 µm-
thick SecureSeal) placed on a glass slide. This structure is then spin-coated with
Cytop in order to render the liquid-facing surfaces hydrophobic.
Preparation of bead/WB1 suspension: The preparation of the bead/WB1 suspension
involves three major steps. First, 50 µl Magnetic Extraction Reagent (that is, the
magnetic beads) is added to 1 ml Lysis Buffer. Next, after incubating and centrifug-
ing the bead/LB suspension, the LB supernatant is aspirated. Lastly, the beads are
resuspended with 400 µl WB1 (i.e., 5 M GuSCN.) To ensure the same amount of
beads is used in each test, the suspension is thoroughly vortexed before it is pipetted
to the device.
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Figure A.1: The device employed to measure the purification power. In this variant
up to six tests can be performed on a device.
Reagent loading: Prior to an experiment, a device is loaded with three types of
reagents: 4 µl magnetic silica beads suspended in WB1, 8µl WB3, and 2 µl EB. (WB,
EB: Wash Buffer and Elution Buffer in the miniMAG purification kit, respectively.)
Depending on the number of IPF washes that is being tested, 0 ∼ 2 droplets of WB3
are loaded. 2 µl EB is used because it is the typical capacity of the reservoirs in
digital microfluidic devices. In turn, since the volume of EB needs to be sufficiently
large to accommodate the beads without having the dispensing of eluent droplets
impeded, a suitable bead/WB1 volume is empirically determined to be 4 µl.
IPF washes and absorbance measurement: The procedure involves three major steps.
First, the magnetic beads in WB1 are actuated by an external magnet either directly
to EB (no wash) or to WB3 (1 ∼ 2 washes.) During a wash step, the beads are re-
peatedly dispersed and pelletized in WB3 for five times. Second, the beads along
with the GuSCN carryover are brought into contact with EB. Third, with the magnet
holding the beads in place, 1.5 µl of the eluent (i.e., EB contaminated with GuSCN)
is aspirated from the device and then analyzed on the NanoDrop 1000 spectropho-
tometer. EB is used to blank the spectrophotometer prior to the measurements.
152
A.3 Threshold Cycle vs. Number of Washes
The experiment in Sec. 6.2.1 involves two phases. The first phase is identical to the
on-chip purification procedure performed in Sec. 6.1.2. The goal is to transport the
beads from 5 M GuSCN to the EB without having the GuSCN concentration in the
EB rising above 25 mM. To this end, a different number of IPF washes is tested in
order to estimate the minimum number needed. Unlike Sec. 6.1.2, however, in the
second phase absorbance measurement is replaced by on-chip qPCR as the method
for assessing the amount of GuSCN in the eluent. Overall, the experiment can be
summarized as:
• Method A: Used in Sec. 6.2.1 to verify the estimation of purification power.
Droplet 1: Master mix, assay, gDNA 1x.
Droplet 2: Beads suspended in GuSCN → 0 ∼ 2 IPF washes → elution →
dispense eluent as Droplet 2.
Fluidic device: The fluidic device described in Sec. 5.2 is first used in this experiment.
In particular, the thermocouple is attached to the bottom of the device before loading
the reagents, i.e., the stack from top to down is device/thermal paste/TC/Kapton
tape. Furthermore, with the help of the alignment guides, the TC is always placed
at the same position relative to the edges of the fluidic device. This is necessary for
improving the repeatability of temperature measurements.
Preparation of master mix/Yb8 assay/gDNA solution: The Fast Advanced master mix
is used in all on-chip qPCR experiments. Following the vendor-provided protocol, a
20 µl reaction mixture consists of 10µl master mix, 1µl Yb8 assay, 7 µl nuclease-free
water, and 2µl 0.1 ng/µl gDNA. In the No Template Control, gDNA is replaced by
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water. A fresh 20µl stock is prepared for each test case, and the same stock is used
in all three replicates of a test case. The resulting PCR mixture droplet would have
5 pg/µl gDNA, which is equivalent to 285 copies of Yb8 in the 92 nl mixture. In
later discussions 285 copies is generally referred as “1x.”
On-chip purification: The purification procedure is identical to what is performed
in the experiment in Sec. 6.1.2 (refer to p. 151 for the procedures of bead/WB1
preparation, reagent loading, and IPF washes) with the exception of two differences.
First, instead of the purification stage, EB is loaded to its designated reservoir in the
PCR preparation stage of the fluidic device. Second, in this case by the end of the
purification procedure the contaminated EB is not aspirated off the device. Rather,
it remains in the reservoir as the source of the eluent droplets.
After purification, the remaining WB1 and WB3 are removed from the purifi-
cation stage, and the PCR preparation stage is filled with 5 cS silicone oil. Sub-
sequently, the device is mounted onto a translational stage, and the electrical con-
nection to the DM electrodes is established. An enclosure is employed to shield the
reagents on the device and the device-side optical fiber from unwanted light.
On-chip PCR mixture preparation: The PCR mixture preparation process involves
three major steps. First, using DM actuation an eluent droplet is dispensed from the
EB reservoir. Second, the other reservoir is loaded with the master mix/assay/DNA
solution, and a droplet is dispensed from this reservoir. Note that the master
mix/assay/DNA solution is only pipetted to the device after the eluent droplet is
generated. This is done in order to mitigate DNA contamination and the photo-
bleaching of the qPCR probe. Third, the two droplets are merged together, resulting
in a PCR mixture droplet that is ready to be thermocycled. This PCR mixture
droplet is held in place by DM actuation during thermocycling to prevent it from
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drifting away from the sensing area of the optical fiber.
In the above PCR mixture preparation process, droplet actuation is guided by
visual observation via a long working distance zoom lens coupled to a CCD camera.
Illumination is kept to minimum intensity to reduce photobleaching. Additionally,
in the two dispensing steps, a droplet is only accepted if its diameter is comparable
to the pitch of the DM electrodes.
On-chip qPCR: Upon completing the preparation of the reaction mixture droplet,
the device-side optical fiber of the fluorescence sensor is brought into gentle contact
with the top plate and aligned to the droplet. Then, thermocycling is started with
the following setpoints: UNG incubation 53 ◦C 2 min, polymerase activation 98 ◦C 40
s, 98 ◦C 1 s/62 ◦C 20 s for the first 10 cycles, and 95 ◦C 1 s/62 ◦C 20 s for the remaining
30 cycles. Note that the temperature experienced by the droplet is different from
the setpoints.
The measurement of 559 nm intensity is initiated every time the thermocouple
is cooled to the anneal/extend temperature setpoint. At this moment, the laser is
turned on and given 300 ms to stabilize its power. Then, the CCD spectrometer
integrates for 300 ms, after which the laser is turned off. This process is repeated in
each thermocycle.
A.4 Amplification Efficiency
Sec. 6.3.1 focuses on evaluating the on-chip amplification efficiency. The experiment
involves two phases: PCR mixture preparation and thermocycling. The first phase
is outlined below. It can be seen that two template concentrations are tested (1x,
30x) in order to estimate the amplification efficiency.
• Method B: Used in Sec. 6.3.1 to characterize the on-chip amplification efficiency.
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Droplet 1: Master mix, assay, gDNA – 1x (B1), 30x (B2), 0x (B3).
Droplet 2: Elution Buffer.
Preparation of master mix/Yb8 assay/gDNA solution: A fresh 20 µl stock of the master
mix/assay/DNA solution is prepared for each test case, and the same stock is used
in all three replicates of a test case. All three stocks contain 10µl Fast Advanced
master mix and 1µl Yb8 assay. In addition, B1 contains 7 µl nuclease-free water and
2 µl 0.1 ng/µl gDNA; B2 contains 3 µl water and 6 µl 1 ng/µl gDNA; B3 contains 9 µl
water but no gDNA, which serves as the No Template Control. As an example, in
B1 the PCR mixture droplet has 5 pg/µl gDNA, which equates to 1x/285 copies of
Yb8 in the 92 nl mixture.
On-chip PCR mixture preparation: The fluidic device described in Sec. 5.2 is used.
Initially, the thermocouple is aligned and attached to the device. Next, the device
is mounted onto a translational stage, and the electrical connection to the DM elec-
trodes is established. An enclosure is employed to protect the reagents on the device
and the device-side optical fiber from unwanted light.
After loading the two reagents and the silicone oil to the device, DM actuation
is used to dispense the EB droplet and the master mix/assay/DNA droplet from
their respective reservoirs. Subsequently, the two droplets are merged to form the
PCR mixture droplet. In the PCR mixture preparation process, droplet actuation
is guided by visual observation via a long working distance zoom lens coupled to a
CCD camera. Illumination is kept to minimum intensity to reduce photobleaching.
Additionally, in the two dispensing steps, a droplet is only accepted if its diameter
is comparable to the pitch of the DM electrodes.
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On-chip qPCR: Prior to thermocycling, the zoom lens is moved away from the trans-
lational stage to prevent it from blocking the access of the device-side optical fiber to
the fluidic device. In turn, the fiber is brought into gentle contact with the top plate
and aligned to the droplet. At this point, the reaction mixture droplet is held in
place by DM actuation to prevent it from drifting away during thermocycling from
the sensing area of the optical fiber. Finally, qPCR is performed in the same way as
discussed on p. 155.
A.5 Nucleic Acid Retention
Sec. 6.2.2 attempts to estimate the retention of Yb8 throughout the workflow. As
outlined below, the experiment involves off-chip binding and on-chip purification,
PCR mixture preparation, qPCR.
• Method C: Used in Sec. 6.2.2 to characterize the nucleic acid retention.
Droplet 1: Master mix, assay.
Droplet 2: Beads with gDNA suspended in GuSCN→ 2 IPF washes→ elution
→ dispense eluent as Droplet 2 (30x × retention%).
Preparation of gDNA-bead/WB1 suspension: The preparation of the gDNA-bead/WB1
suspension involves three major steps. First, 60µl 1 ng/µl gDNA (∼ 1.3×105x copies
of Yb8) and then 50 µl Magnetic Extraction Reagent (that is, the magnetic beads) are
added to 1 ml Lysis Buffer. Next, after incubating and centrifuging, the LB super-
natant is aspirated. Lastly, the DNA-bound beads are resuspended with 400µl WB1
(i.e., 5 M GuSCN.) To ensure the amount of Yb8 is consistent across the replicates,
the suspension is briefly vortexed before 4µl (∼ 1.3 × 103x copies) is transferred to
the device. Assuming all Yb8 is retained, a reaction mixture droplet would possess
30x copies.
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Although the binding capacity of the beads in the miniMAG purification kit
is unspecified by the vendor, the maximum values recommended by the surveyed
silica particle-based kits all fall in 102∼3 ng DNA per µl bead slurry (e.g., MO BIO
UltraClean 15, Bioclone BcMag Quick DNA, and AMS MagSi-DNA.) Therefore, the
employed 1.2 ng/µl is assumed to be within the capacity.
Preparation of master mix/Yb8 assay solution: A 40µl stock was prepared from 20µl
Fast Advanced master mix, 2 µl Yb8 assay, and 18 µl nuclease-free water. The water
is added to keep the final master mix and assay concentrations identical to what are
used in the previous experiments. The same stock is used in all three replicates.
On-chip purification: The fluidic device described in Sec. 5.2 is used. Prior to an
experiment, 4 µl DNA-bead/WB1 and 8 µl WB3 (two locations) are loaded to the
purification stage, and 2µl EB is filled to its reservoir in the PCR preparation stage.
Since the gDNA has been previously bound to the magnetic beads, there are two
steps remain in the purification process: IPF wash and elution. To perform the first
IPF wash, the DNA-bound beads in WB1 are actuated by an external magnet to
WB3. Then, the beads are repeatedly dispersed and pelletized in WB3 five times.
The first wash is concluded by actuating the beads away from the WB3. Later, the
beads are transported to the second WB3 to conduct the second IPF wash. After
the two washes, the beads are transferred from the second WB3 in the purification
stage to the EB reservoir in the PCR preparation stage. To release the DNA from
the beads to EB, the beads are incubated with the EB at room temperature for 5
min.
Afterwards, to ready the device for the subsequent steps, the remaining WB1
and WB3 are removed from the purification stage. Also, the PCR preparation stage
is filled with 5 cS silicone oil.
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On-chip PCR mixture preparation, qPCR: The procedures for the mixture preparation
and qPCR are the same as outlined on p. 154.
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Appendix B
Dye-Based Initial Evaluation of
Immiscible Phase Filtration
B.1 Experimental Methods
As illustrated in Fig. B.1a, the prototype IPF is assembled by mounting a molded
PDMS block on a glass slide. It therefore represents a primitive approximation of
the proposed Fig 5.5 structure. In particular, the 50 µl input is a solution of Red 40
dye (Kroger), DI water, and 5 µm silica-coated iron oxide superparamagnetic beads
(FF-103, Bioclone.) Here, Red 40 serves as the simulated contaminant. To assess
the impact of input viscosity on purification power, glycerol (G2025, Sigma-Aldrich)
is added in some experiments to achieve up to 38 cP input viscosity. Moreover, to
investigate the effect of bead load on purification power, bead load is varied from
0.4 to 1.6 mg. Otherwise, the typical bead load is 1.6 mg. The beads are manually
actuated by a 0.64 T NdFeB magnet (B666-N52, K&J Magnetics.) Depending on the
tests, one to three washes are conducted. To facilitate the removal of contaminates
that might be entrapped in a bead pellet, during a wash step the beads are vigorously
agitated. With three washes, IPF is generally completed in three minutes. After IPF,
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Figure B.1: An early PDMS-based IPF. (a) An illustration of the device structure
and the bead snapping process. Side view. (b) As evident from the decreasing color
intensity in successive wash chambers, the concentration of the simulated contami-
nant Red Dye 40 carried by the beads decreases as the beads are transported from
input to wash 3. Top-down view.
input and wash solutions are monitored by a spectrophotometer (Genesis 20, Thermo
Electron) for the absorbance at 502 nm. Lastly, purification power is calculated by
normalizing the absorbance of wash solutions to the absorbance of the input. It is
recognized that the complexities of nucleic acid purification and amplification are
not fully modeled by the described setup. For instance, Red 40 and DNA fragments
are different in electrostatic and hydrodynamic properties. Nevertheless, the proof-
of-concept setup is perhaps sufficient for understanding the basics of IPF.
B.2 Selection of the Immiscible Phase
To simplify device operation, ideally the same chemical should be used as the immis-
cible phase in IPF and DM. For this reason, immiscible phases frequently employed
in DM are evaluated as the immiscible phase in IPF, e.g. air [74] and low viscosity
oils such as dodecane [75] and 2 cS silicone oil [31]. In the case of air, beads can only
be snapped out of the input solution after surfactants such as Triton X-100 (TX1568,
EMD Millipore) are added to the input. That is, the unmodified input/air interfacial
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tension, 72 mN/m, is too high for bead snapping on a PDMS surface. On the other
hand, in the case of 2 cS silicone oil (Gelest) the 40 mN/m input/oil interfacial ten-
sion seems to be adequate for bead snapping. Additionally, bead transportation in
the immiscible phase appears to be smoother in silicone oil than in air. Based on the
observation by Dulk et al. [39], this may be attributed to the reduced bead-PDMS
friction in oil. However, over the course of tens of minutes the soak in silicone oil
is observed to cause severe PDMS swelling. With the device geometry and surface
properties altered, bead snapping on reused devices is found to generate excessive
contamination carryover. In the case of dodecane (Alfa Aesar), the swelling is some-
what more pronounced. Therefore, all subsequent experiments in Appendix B were
conducted on fresh devices with 2 cS silicone oil as the immiscible phase.
B.3 Effect of Input Viscosity and Interfacial Ten-
sion
In the project it is expected to encounter a wide range of input viscosities: from
fragmented DNA or lysed cells suspended in a buffer, to the viscous suspension
aspirated from lysed blood. Thus, the impact of input viscosity on purification
power is investigated. Still, adding glycerol to increase the input viscosity has a
side effect of lowering the input/oil interfacial tension. In turn, the bead pellet
snapped out of the input is usually accompanied by an unsatisfactory carryover
volume. In the worst case, this could result in the formation of a liquid bridge
between the input and the wash solution. To overcome the issue, it is discovered
that a device could be slightly tilted (counterclockwise in Fig. B.1a) to promote
the pullback of the input solution during bead snapping. The finding implies that
when the input/oil interfacial tension is slightly below the optimum range, an IPF
device with a characteristic length comparable to the capillary length of the input
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solution might utilize the tilt to improve the purification power without involving
extra surfactants. Using the tilt technique, in 1 ∼ 38 cP the purification power
appears to be unaffected by the increase in input viscosity. (As a comparison, the
viscosity of whole blood at 37 ◦C and 0.7 s-1 shear rate is 33 cP [76].) However,
at higher input viscosity the actuation of beads during bead snapping needs to be
slowed down, e.g. 1 mm/s. Afterwards, faster bead transportation could be resumed
once most of the viscous contaminants are removed by the first wash.
B.4 Effect of Bead Load on Purification Power
The obtained purification power is typically on the order of 102 to 103 per wash, which
is similar to [39]. In other words, after two washes the amount of Red 40 carried by
the bead pellet can be reduced by six orders of magnitude. In addition, purification
power is determined to be linearly impacted by an increasing bead load. As an
example, increasing the bead load from 0.4 mg to 1.6 mg lowers the purification power
from 167 to 24. Since the finding suggests a linear correlation between pellet volume
and carryover volume (as reported in [35]), it is therefore important to minimize the
bead load for instance by improving the capture of nucleic acids during the binding
step.
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